


THE NEW JOURNAL OF UROLOGY



Coban G, Toluk O, Ilktac A. A Review of Metastatic Tumours of the Kidney with Literature: A Single Centre Experience. *New J Urol.* 2024;19(3):110-114.

Assessing the Effectiveness of Intravesical Botulinum Toxin Therapy in Improving Quality of Life for Overactive Bladder Patients with Moderate Functional Impairment

Necmi Bayraktar, Sadrettin Tuğcu

A Review of Metastatic Tumours of the Kidney with Literature: A Single Centre Experience

Ganime Çoban, Özlem Toluk, Abdullah İlktac

Microscopic Testicular Sperm Extraction in Patients with Klinefelter Syndrome: Long-Term Outcomes from a Single Center

Eyyup Sabri Pelit, Bülent Kati

Evaluation of the Impact of Body Mass Index on the Outcomes of Supine Percutaneous Nephrolithotomy

Ender Cem Bulut, Burak Elmas, Bora Küpeli

Effect of Atomoxetine on Mouse Isolated Vas Deferens Contractility
Seçkin Engin, Mehmet Kağan Altınbaş

Factors Affecting Biochemical Recurrence After Radical Prostatectomy and Validity of CAPRA Score in Predicting Biochemical Recurrence

Yusuf Arıkan, Berat Aydın, Enes Dumanlı, Deniz Noyan Özlü, Buşra Emir, Mehmet Zeynel Keskin

Outcomes of Emergency Surgical Treatment for Penile Fractures: A Study on Suture Materials, Delayed Repair, and Postoperative Results

Süleyman Sağır, Ferhat Çelikkaleli, Müslüm Ergün, Cüneyt Özden, Mustafa Güler, İzzettin Toktaş

Artificial Intelligence in Prostate Cancer Diagnosis

Adem Alçın, Asif Yıldırım

THE
NEW JOURNAL
OF UROLOGY

• Volume **19** • Number **3** • October **2024**

THE
NEW JOURNAL
OF UROLOGY

New J Urol
eISSN 3023-6940

Volume 19 / Number 3 / October 2024

Grant Holder

Ali İhsan Taşçı

Editor-in-Chief

Ali İhsan Taşçı

Editor

Yavuz Onur Danacıoğlu

Deputy Editor-in-Chief

Mithat Ekşi

Managing Editor

Fatma Taşçı

Biostatistical Editor

Salih Polat

Büşra Emir

Language Editor

Serda Güzel

Copy Editors

Murat Şahan

Samet Şenel

Digital Media Editor

Mustafa Soytaş

Publishing Service

Pera Publishing Services

🌐 <https://www.perayayincilik.com/>

Publishing Coordinator

Seda Karlıdağ

Contact

Istanbul St. Yenimahalle Mah. Kosk Apt.

N:113/A Bakırköy / Istanbul

☎ 0533 726 72 55

🌐 www.newjournalurology.com

The New Journal of Urology is an international peer-reviewed journal, published triannually (in February, June, October). Publication languages is English. All responsibility for the submitted and published content rests solely with the author(s).

Published content can be cited provided that appropriate reference is given.

Indexed by

TÜBİTAK-ULAKBİM TR-Dizin, EBSCO, Index Copernicus, SCILIT, Google Scholar, Türk Medline Pleksus, Türkiye Atıf Dizini, SOBIAD, OAJI, İdeal Online, EuroPub, J-GATE

OPEN ACCESS



Dear Colleagues,

We are pleased to have published the third issue of The New Journal of Urology for 2024. This issue includes seven (7) original articles and one (1) review. We believe that all the current articles will be read with interest and these articles are expected to contribute to the literature and serve as a reference for future studies. The New Urology Journal has been indexed in the TÜBİTAK-ULAKBİM TR Index since the first issue of 2011. Our journal is indexed in Google Scholar, Turkish Medline, Turkish Citation Index, SOBIAD, OAJI, İdeal Online Database, EuroPub, J-GATE, and DOAJ databases, EBSCO and InfoBase Index. In addition, the New Journal of Urology is in collaboration with the Orcid and CrossRef DOI systems. The process of our journal being included in the ESCI, PubMed, and EMBASE indexes is ongoing. The editorial team is very grateful to all the authors and reviewers who have contributed to this issue. We are aware that this is a painstaking effort, and we cannot thank you enough for it. I would also like to welcome Dr. Büşra Emir, who has recently joined our team and will serve as our second statistics editor. We request that you submit your articles to The New Journal of Urology, take timely and rigorous action as a referee, and read the articles published in the journal and cite them where appropriate.

Respectfully yours,

Ali İhsan Taşçı
Editor-in-Chief

Yavuz Onur Danacıoğlu
Editor

EDITORIAL BOARD

Editor-in-Chief

Ali Ihsan TASCI
Department of Urology, Dr.Sadi Konuk
Training and Research Hospital, Istanbul/
Türkiye
E-mail: alihasantasci@hotmail.com
ORCID ID: 0000-0002-6943-6676

Editor

Yavuz Onur DANACIOGLU
Department of Urology, Dr.Sadi Konuk
Training and Research Hospital, Istanbul/
Türkiye
E-mail: dr_vonur@hotmail.com
ORCID ID: 0000-0002-3170-062X

Deputy Editor-in-Chief

Mithat EKSI
Department of Urology, Dr.Sadi Konuk
Training and Research Hospital, Istanbul/
Türkiye
E-mail: mithat_eksi@hotmail.com
ORCID ID: 0000-0003-1490-3756

Biostatistical Editors

Salih POLAT
Department of Urology, Amasya
University Sabuncuoglu Serefeddin
Training and Research Hospital, Amasya/
Türkiye
E-mail: salihpolat@gmail.com
ORCID ID: 0000-0002-7580-6872

Busra EMIR

Izmir Katip Celebi University Faculty of
Medicine Department of Biostatistics
Izmir/Türkiye
E-mail: busra.emir@ikcu.edu.tr
ORCID ID: 0000-0003-4694-1319

Language Editor

Serda GUZEL
Department of Translation and
Interpreting, Istanbul Arel University,
Istanbul/Türkiye
E-mail: serdaguzel@arel.edu.tr
ORCID ID: 0000-0001-5212-9891

Copy Editors

Murat SAHAN
Department of Urology, İzmir Bozyaka
Training and Research Hospital, İzmir/
Türkiye
E-mail: dr.msahan@gmail.com
ORCID ID: 0000-0002-0065-4245

Samet SENEL

Department of Urology, Ankara City
Hospital, Ankara/Türkiye
E-mail: samet_senel_omt@hotmail.com
ORCID ID: 0000-0003-2280-4192

Digital Media Editor

Mustafa SOYTAS
Clinical Fellow of Urooncology
Division of Urology and Uro-oncology,
McGill University
Montreal, QC, Canada
E-mail: drmustafasoytas@gmail.com
ORCID ID: 0000-0002-3474-3510

BOARD MEMBERS

Abdullah Erdem CANDA
Department of Urology, Faculty of
Medicine, Koc University, Istanbul/Türkiye
E-mail: erdemcanda@yahoo.com
ORCID ID: 0000-0002-5196-653X

Ahmad MOTAWI

Department of Andrology Faculty of
Medicine, Cairo University/Egypt
E-Mail: a7madmotaw3@gmail.com
ORCID ID: 0000-0003-0962-0604

Ahmet Rahmi ONUR

Department of Urology, Faculty of
Medicine, Firat University, Elazig/Türkiye
E-mail: rahmionur@yahoo.com
ORCID ID: 0000-0001-6235-0389

Ahmet Yaser MUSLUMANOGLU

Department of Urology, Bağcilar Training
and Research Hospital, Istanbul/Türkiye
E-mail: ymuslumanoglu56@hotmail.com
ORCID ID: 0000-0002-8691-0886

Ali Serdar GOZEN

Department of Urology, SLK Klinikum
Heilbronn, Am Gesundbrunnen 20,
Heilbronn, GERMANY
E-mail: asgozen@yahoo.com
ORCID ID: 0000-0002-2205-5876

Asif YILDIRIM

Department of Urology, Goztepe
Medeniyet University, Istanbul/Türkiye
E-mail: asifyildirim@yahoo.com
ORCID ID: 0000-0002-3386-971X

Archil CHKHOTUA

L. Managadze National Center of Urology,
Tbilisi, GEORGIA
E-mail: achkhotua@gmail.com
ORCID ID: 0000-0002-0384-8619

Arunas ZELVYS

European Association of Urology,
European Board of Urology, Vilnius
University Hospital Santariskiu Klinikos
Vilnius, Lithuania
E-mail: arunas.zelvys@santa.lt
ORCID ID: 0000 0002 9778 9372

Ates KADIOGLU

Department of Urology, Faculty of
Medicine, Istanbul University,
Istanbul/Türkiye
E-mail: kadiogluates@ttnet.net.tr
ORCID ID: 0000-0002-5767-4837

Badrinath KONETY

Allina Health Cancer Institute -
Minneapolis, USA
E-mail: badrinath.konety@allina.com
ORCID ID: 0000-0002-1088-3981

Fatih YANARAL

Department of Urology, Memorial Şişli
Hospital, Istanbul/Türkiye
E-mail: fatihyanaral@gmail.com
ORCID ID: 0000-0002-7395-541X

Hashim HASHIM

Bristol Urological Institute, Southmead
Hospital, Bristol, Somerset, UK
E-mail: h.hashim@gmail.com
ORCID ID: 0000-0003-2467-407X

Ihsan KARAMAN

Department of Urology, Medistate
Kavacik Hospital, Istanbul/Türkiye
E-mail: mikaraman@hotmail.com
ORCID ID: 0000-0003-3275-3202

Imad ZIOUZIOU

Department of Urology, College of
Medicine and Pharmacy, Ibn Zohr
University, Agadir, MOROCCO

E-mail: imadzouziou@hotmail.com
ORCID ID: 0000-0002-9844-6080

Jean De La ROSETTA

Department of Urology, Istanbul Medipol
University, Istanbul/Türkiye
E-mail: jdelarosette@medipol.edu.tr
ORCID ID: 0000-0002-6308-1763

Jeremy Y. C. TEOH

Prince of Wales Hospital, Shatin,
Hong Kong.
E-mail: jeremyteoh@surgery.cuhk.edu.hk
ORCID ID: 0000-0002-9361-2342

Joyce BAARD

Amsterdam UMC, University of
Amsterdam, Amsterdam, the Netherlands
E-mail: j.baard@amsterdamumc.nl
ORCID ID: 0000-0002-5509-0213

Kemal SARICA

Department of Urology, Kafkas University,
Kars/Türkiye
E-mail: kemalsarica@superonline.com
ORCID ID: 0000-0001-7277-3764

M. Derya BALBAY

Department of Urology, Şişli Memorial
Hospital, Istanbul/Türkiye
E-mail: derya.balbay@memorial.com.tr
ORCID ID: 0000-0003-0060-5491

Mahmut GUMUS

Department of Medical Oncology, Faculty
of Medicine, Medeniyet University,
Istanbul/Türkiye
E-mail: mahmut.gumus@medeniyet.edu.tr
ORCID ID: 0000-0003-3550-9993

Mesrur Selcuk SILAY

Department of Urology, Bahcelievler
Memorial Hospital, Istanbul/Türkiye
E-mail: selcuksilay@gmail.com
ORCID ID: 0000-0001-5091-9654

Murat BOZLU

Department of Urology, Faculty of
Medicine, Mersin University,
Mersin/Türkiye
E-mail: muratbozlu@yahoo.com
ORCID ID: 0000-0002-8624-0149

Mohammed SAID SULAIMAN

Department of Surgery, St. Paul's Hospital
Millennium Medical College, ETHIOPIA
E-mail: bensulaimani@gmail.com

Oner SANLI

Department of Urology, Faculty of
Medicine, Istanbul University,
Istanbul/Türkiye
E-mail: onersanli@hotmail.com
ORCID ID: 0000-0001-5801-6898

Osama Kamal ZAKI SHAEEER

Faculty of Medicine, Cairo University,
Egypt
Email: dr.osama@alrijal.com
ORCID ID: 0000-0002-3811-9969

Paolo GONTERO

Urology Unit, Department of Surgical
Sciences, University of Turin, Italy
E-mail: paolo.gontero@unito.it
ORCID ID: 0000-0002-9714-6596

Pilar LAGUNA

Department of Urology, Istanbul Medipol

University, Istanbul/Türkiye
E-mail: plaguna@medipol.edu.tr
ORCID ID: 0000-0003-0906-4417

Raed AZHAR

Urology Department of King Abdulaziz
University Saudi Arabia Kingdom
E-mail: raedazhar@gmail.com
ORCID ID: 0000-0001-5233-1352

Rajveer PUROHIT

Department of Urology, Mount Sinai
Hospital, New York/USA
E-mail: rajveer.purohit@mountsinai.org
ORCID ID: 0000-0002-5912-8354

Ramazan Gökhan ATIS

Department of Urology, Memorial Şişli
Hospital, Istanbul/Türkiye
E-mail: gokhanatis@hotmail.com
ORCID ID: 0000-0002-9065-6104

Saad ALDOUSARI

Department of Surgery of Kuwait
University, KUWAIT
E-mail: saad.aldousari@gmail.com
ORCID ID: 0000-0003-1670-9287

Selami ALBAYRAK

Department of Urology, Faculty of
Medicine, Medipol University,
Istanbul/Türkiye
E-mail: salbayrak@medipol.edu.tr
ORCID ID: 0000-0002-4245-7506

Shahid KHAN

Department of Urology, East Surrey
Hospital, London/United Kingdom
E-mail: shahidkhan1@nhs.net
ORCID ID: 0009-0002-3072-1514

Sudhir KUMAR RAWAL

Oncology Services
Rajiv Gandhi Cancer Institute,
New Delhi, INDIA
E-mail: sunil.kumar@amo.bbott.com
ORCID ID: 0000-0002-3331-2372

Simon TANGUAY

FRCS Professor and Chair Division of
Urology Mostafa Elhilali/David Azrieli
Chair in Urologic Sciences McGill
University, Montreal, QUEBEC
E-mail: simon.tanguay@mcgill.ca
ORCID ID: 0000-0001-6947-304X

Turhan ÇAŞKURLU

Department of Urology, Memorial
Ataşehir Hospital Istanbul/Türkiye
E-mail: tcaskurlu@hotmail.com
ORCID ID: 0000-0002-4471-2670

Volkan TUGCU

Department of Urology, Liv Hospital,
Istanbul/Türkiye
E-mail: volantugcu@yahoo.com
ORCID ID: 0000-0002-4136-7584

Widi Atmoko

Department of Urology, Cipto
Mangunkusumo General Hospital,
Universitas, INDONESIA
E-mail: dr.widiatmoko@yahoo.com
ORCID ID: 0000-0002-7793-7083

Yodgorov Ibrokhim FAHHRIDDINOVICH

Bukhara State Medical University
Bukhara, UZBEKISTAN
E-mail: ibroxim_yodgorov@mail.ru
ORCID ID: 0000-0001-9563-0686



CONTENTS

Original Research

- Assessing the Effectiveness of Intravesical Botulinum Toxin Therapy in Improving Quality of Life for Overactive Bladder Patients with Moderate Functional Impairment** 103-109
Necmi Bayraktar, Sadrettin Tuğcu
- A Review of Metastatic Tumours of the Kidney with Literature: A Single Centre Experience** 110-114
Ganime Çoban, Özlem Toluk, Abdullah İlktaç
- Microscopic Testicular Sperm Extraction in Patients with Klinefelter Syndrome: Long-Term Outcomes from a Single Center** 115-120
Eyyup Sabri Pelit, Bülent Katı
- Evaluation of the Impact of Body Mass Index on the Outcomes of Supine Percutaneous Nephrolithotomy** 121-128
Ender Cem Bulut, Burak Elmas, Bora Küpeli
- Effect of Atomoxetine on Mouse Isolated Vas Deferens Contractility** 129-135
Seçkin Engin, Mehmet Kağan Altınbaş
- Factors Affecting Biochemical Recurrence After Radical Prostatectomy and Validity of CAPRA Score in Predicting Biochemical Recurrence** 136-144
Yusuf Arıkan, Berat Aydın, Enes Dumanlı, Deniz Noyan Özlü, Buşra Emir, Mehmet Zeynel Keskin
- Outcomes of Emergency Surgical Treatment for Penile Fractures: A Study on Suture Materials, Delayed Repair, and Postoperative Results** 145-150
Süleyman Sağır, Ferhat Çelikkaleli, Müslüm Ergün, Cüneyt Özden, Mustafa Güler, İzzettin Toktaş

Review

- Artificial Intelligence in Prostate Cancer Diagnosis** 151-156
Adem Alçın, Asif Yıldırım

Correction

- Correction: Evaluation of Perioperative Clinical Parameters and Quality of Life in Patients Undergoing Radical Perineal or Retropubic Prostatectomy: A Prospective Randomized Study** 157-158
Utku Can, Alper Coskun

Evaluating the Efficacy of Intravesical Botulinum Toxin Treatment in Enhancing Quality of Life for Patients with Overactive Bladder and Moderate Functional Impairment

Necmi Bayraktar^{1,2}, Sadrettin Tuğcu¹

¹Department of Urology, Burhan Nalbantoğlu State Hospital, Nicosia, Turkish Republic of Northern Cyprus

²Cyprus International University

Submitted: 2024-04-04

Accepted: 2024-09-02

Corresponding Author;

Necmi Bayraktar, MD

Burhan Nalbantoğlu State Hospital,
Nicosia, Turkish Republic of
Northern Cyprus

E-mail: necmi.bayraktar@neu.edu.tr

ORCID

N.B. [0000-0001-6449-9216](https://orcid.org/0000-0001-6449-9216)

S.T. [0009-0007-6137-3977](https://orcid.org/0009-0007-6137-3977)

Abstract

Objective: Overactive bladder (OAB) significantly impacts the quality of life, affecting individuals across various age groups irrespective of gender. While conventional treatments exist, they often fall short for patients with moderate functional impairment, marked by an Eastern Cooperative Oncology Group Performance Score (ECOG PS3). Intravesical botulinum toxin therapy has emerged as a promising alternative, especially for those unresponsive to traditional pharmacotherapy.

Material and Methods: In this retrospective study from 2020 to 2023, we analyzed data from patients treated with botulinum toxin therapy for OAB. ECOG PS3 patients with a bladder capacity of at least 200 milliliters were included. Data collected included medical histories, voiding diary, and quality of life scores (ICIQ-SF and I-QOL).

Results: The research featured 46 individuals and demonstrated a statistically substantial advancement in quality-of-life following treatment. The parameters of incontinence episodes and voiding diary scores exhibited statistically significant enhancements. Notably, there was no observable increase in residual urine or urinary tract infections subsequent to treatment.

Conclusion: Intravesical botulinum toxin therapy has demonstrated a marked improvement in the quality of life for patients suffering from OAB and exhibiting moderate functional impairment. Nevertheless, further research is required in multicenter randomized trials to substantiate the findings and maintain their credibility.

Keywords: botulinum toxins, type A, overactive bladder, quality of life, urinary incontinence, urinary retention

Cite; Bayraktar N, Tuğcu S. Assessing the Effectiveness of Intravesical Botulinum Toxin Therapy in Improving Quality of Life for Overactive Bladder Patients with Moderate Functional Impairment. *New J Urol.* 2024;19(3):103-109. doi: <https://doi.org/10.33719/nju1461979>

INTRODUCTION

Overactive bladder is a condition defined by dysfunction in bladder storage capacity, leading to a substantial decline in the quality of life of those affected (1, 2). This condition can affect individuals of all ages, regardless of sex, and can be effectively managed with lifestyle modifications, medications, and pelvic floor exercises. Patients with OAB who exhibit anticholinergic resistance may not experience the desired treatment outcomes. Patients presenting with a moderate impairment in functional capacity (ECOG PS3) may experience OAB symptoms resulting from either idiopathic or neurogenic causes. Notably, the decrease in quality of life experienced by this particular cohort of individuals may prove to be more pronounced than others (3).

Although the Eastern Cooperative Oncology Group Performance Scale (ECOG PS) was developed to assess cancer patients, it can also be employed for non-cancer patients(4, 5). The ECOG Performance Status Scale assesses the influence on patients' daily activities, rating them from 0 to 5, with 0 signifying complete functionality and 5 denoting passing away. The ECOG PS3 classification indicates that the patient can perform limited self-care activities but mainly depends on a bed or chair for support. This indicates that patients spend more than half of their time in bed or seated(6). Individuals with moderate functional impairment are severely negatively affected in terms of quality of life when conditions such as OAB occur. It may be more difficult for these patients to access health services regularly parallel to their illness. More curative treatment modalities need to be energetically prioritized.

Urinary incontinence and other complications such as sleep disorders, psychological disorders, fractures, and injuries resulting from falls are among the potential complications associated with Overactive Bladder (OAB) syndrome(7-9). Restricting fluid intake, decreased mobility, and constipation are common issues faced by patients, which can exacerbate their existing problems. Undoubtedly, patients often resort to social isolation and seek remedies such as increased reliance on diapers, limitation of physical activity, and spending extended periods in bed as a means of alleviating their symptoms. Moreover, these difficulties can give rise to social problems that exacerbate caregivers' burdens. Alternative treatment methods should be considered to change the negative processes in both patients and caregivers (10, 11).

Intravesical BTxA injections have gained prominence as a novel approach for treating OAB. The efficacy and safety of intravesical Botulinum Toxin therapy in the treatment of OAB are well known, especially in anticholinergic refractory patients (12). Intravesical botulinum toxin therapy with minimally invasive methods can be used safely and effectively in the elderly and those with neurologic deficits(11).

BTxA injections have been recognized as a valid therapeutic approach for patients with OAB syndrome, including those with either non-neurogenic or neurogenic conditions. It is usually considered in patients unresponsive to anticholinergic treatments followed by behavioral and physiotherapies. Unsuccessful treatment attempts in patients with restricted mobility negatively affect the quality of life and create a feeling of helplessness and loneliness in patients. Thus, restriction of fluid intake leads to undesirable conditions such as increased dependence on the bed or chair, which worsens the patient's general condition.

This study investigated the impact of intravesical injection of botulinum toxin in patients with ECOG PS3. It had two objectives: first, to assess the effectiveness and safety of intravesical botulinum toxin, and second, to report any observations regarding improved quality of life in this group of patients.

MATERIAL AND METHOD

Data Collection

This study included patients with moderately functional performance and OAB syndrome who underwent intravesical botulinum toxin treatment between 2020 and 2023. The study was conducted retrospectively, and data were generated through a retrospective review of patient files. The validated Turkish versions of the quality-of-life scale were used. Since urodynamic studies are not routinely performed in every patient, urodynamic results and data were not evaluated in this study. Figure 1 shows the flow chart.

Eligibility Criteria

All individuals in the study were part of the ECOG PS3 group, and their gender and age were not considered as selection criteria. The primary inclusion criterion was an ultrasonographic bladder capacity > 200 ml. Additionally, patients were required to have failed previous treatments with anticholinergic medications and/or beta-3 agonists.

A history of neurological disease or diabetes mellitus was not used as an exclusion criterion. However, patients with ongoing urinary tract infections or other acute urological conditions were excluded from the study. Those with mental or psychotic disorders who were likely to face difficulties during the follow-up were not included in the study. Furthermore, those whose residual urine volume after voiding, as determined by ultrasound, exceeded 100 cc were excluded from the study.




Figure 1. Flow Chart of Study

Data Analysis

The dependent samples t-test was used to compare the dependent variables across groups. Statistical significance was set at $p < 0.05$. The sample size was verified using G-Power software, with a power of 99.8 and an effect size of 0.8, as determined by Cohen's *d*. The tables provide a summary of the descriptive statistics. Categorical data are expressed as numbers (*n*) and percentages, while quantitative data are presented as mean \pm standard deviation (SD). Regression and correlation tests were conducted to determine the factors influencing the treatment outcomes. Data analysis was performed using SPSS version 28.0 software.

Ethical Considerations

Before performing the procedure, informed consent was obtained from all patients, emphasizing the potential

complications that may arise both during and after the intervention. This study followed the ethical guidelines established by the Declaration of Helsinki and was approved by the Ethics Committee of TRNC Burhan Nalbantoğlu State Hospital (project code 19/24).

Treatment and follow-up protocol

The surgical procedure was performed with sedation in the lithotomy position for all patients. The administration of third-generation cephalosporins serves as a prophylactic measure against infection. Patients diagnosed with idiopathic OAB received 100 IU of BTxA neurogenic component received 200 IU (13). Twenty bladder sites were injected using a rigid cystoscope. Following the procedure, an 18 Fr Foley catheter was inserted in all patients, and the urethral catheters were withdrawn three days after insertion. Voiding residual micturition controls, including ultrasound and urine analyses, were carried out one week after removal. After 12 weeks, the volume frequency charts, and quality of life questionnaires were assessed. Patients with pre-procedural or recurrent urinary tract infections were administered low-dose daily antibiotic therapy (trimethoprim) for three months as part of their treatment. Continuation rates for BTxA treatment sessions were tracked annually. After the initial BTxA application, patients were monitored to determine if they returned for second or third sessions as the effects of the initial treatment waned. The data on continuation rates was collected, enabling us to assess patient compliance and treatment effectiveness at various times.

RESULTS

A total of 46 individuals (16 men and 30 women) were evaluated in the study. The average age of participants was 69 years, with a standard deviation of 6.8 years. The participant's body mass index (BMI) ranged from 10.33 to 45.9, with a mean of 23.89 and a standard deviation of 6.25. The cause of OAB was idiopathic in 36 participants, while neurogenic bladder was the cause in 10 individuals. All patients with a neurogenic OAB had a history of intracranial embolism. Prior to administering BTxA injections into the bladder, the urine of 39 patients was found to be sterile, while infection was detected in 7 patients. Additionally, 12 patients reported experiencing constipation before treatment, whereas 34 did not. Among the study participants, 23 had hypertension, 8 had diabetes, 5 had COPD, and 13 had coronary disease. The patient characteristics are shown in Table 1.

Table 1. Characteristics of the Patients

Characteristic	Value
Total number of participants	n = 46
Gender	
- Males	16
- Females	30
Mean age (years) ± SD	69 ± 6.8
Mean BMI (kg/m ²) ± SD	23.89 ± 6.25
BMI range (kg/m ²)	10.33 - 45.9
Cause of OAB	
- Idiopathic	n = 36
- Neurogenic*	n = 10
Other health conditions	
- Hypertension	n = 23
- Diabetes	n = 8
- COPD	n = 5
- Coronary disease	n = 13

Note: BMI = Body Mass Index, SD = Standard Deviation, COPD = Chronic Obstructive Pulmonary Disease

The statistical analysis results indicated a substantial variation in the assessed parameters before and after treatment. The Wilcoxon Signed-Rank Test was used for data analysis due to the non-normal distribution of our post-treatment measurements, as confirmed by conducting the preliminary Shapiro-Wilk test. This decision was further supported by the paired nature of our pre- and post-treatment data comprising a total sample size of 46 participants.

Several key metrics exhibited statistically significant changes following treatment, as revealed by the Wilcoxon Signed-Rank Test: post-treatment voiding diary (VD) scores ($Z = -5.933$, $p < .001$), leakage incidents ($Z = -5.763$, $p < .001$), Incontinence Quality of Life questionnaire (I-QOL) scores ($Z = -5.842$, $p < .001$), and Post-void Residual (PVR) measurements ($Z = -3.874$, $p < .001$). The parameters evaluated before and after BTxA injection are summarized in Table 2.

The Spearman correlation test evaluated the relationship between various parameters given the non-normally distributed data. A strong positive correlation was identified between baseline and post-treatment ICIQ scores (pre-treatment ICIQ and post-treatment ICIQ) ($\rho = .673$, $p < .001$), indicating a close relationship between quality-of-life measures before and after treatment. A significant positive correlation was also found between the pre- and post-I-QOL scores ($\rho = .576$, $p < .001$).

A linear regression test was performed to determine the effects of the pre-treatment dependent and independent variables on post-treatment ICIQ and IQOL scores. Age, sex, body mass index (BMI), presence of urinary tract infection or constipation before treatment, pre-treatment post-voiding residual (PVR) amount, and number of urinary incontinence episodes demonstrated no impact on treatment outcomes.

Table 3. Shows annual retention rates for patients receiving BTxA treatments. The data indicate a decline in retention rates following the first session, suggesting a decrease in treatment adherence as the effects of the first BTxA session wane over time.

Table 2. Comparison of Parameters Before and After BTxA Injection

Parameter	Before Btx-A Injection (Mean ± SD)	After Btx-A Injection (Mean ± SD)	P-value
Incontinence Episodes	3±1.6	1±0.8	<0.01
Voiding Diary	15±1.29	10±1.28	<0.01
ICIQ-SF Score	16±3.16	6±5.17	<0.01
I-QOL Score	46±12.3	86±14.8	<0.01
PVR (% and n)			
<50ml	100% (46/46)	60.9% (28/46)	<0.01
50-100ml	Nil	26.1% (12/46)	
>100ml	Nil	13.0% (6/46)	

Note: ICIQ: International Consultation on Incontinence Questionnaire, I-QOL: Incontinence Quality of Life, PVR: Post-voiding Residual Urine, SD: Standard Deviation, Min: Minimum, Max: Maximum, BTxA: Botulinum Toxin A

Table 3. Annual Continuation Rates for Patients Undergoing Sequential Intravesical BTxA Treatment Sessions

Year	Initial BTxA Application n (%)	Second BTxA Session n (%)	Third BTxA Session n (%)
2020	8(100%)	7(87.5%)	5(62.5%)
2021	12(100%)	10(83.3%)	6(50%)
2022	17(100%)	11(64.7%)	nil
2023	9(100%)	2(22.2%)	nil

BTxA; Botulinum Toxin A, n; Number

DISCUSSION

OAB syndrome, as defined by the International Continence Society, is a symptom complex comprising urinary urgency, usually accompanied by increased daytime frequency and/or nocturia, with or without urinary incontinence, in the absence of urinary tract infection (UTI) or other detectable diseases (13). Previous research has demonstrated the efficacy of BTxA in treating various medical conditions, although its impact on patients with an ECOG PS of 3 remains insufficiently documented. Our study supports using intravesical BTxA as an effective option for treating OAB in patients with ECOG PS 3 with empirical evidence.

Our findings align with the current literature, which suggests that botulinum toxin, particularly in patients resistant to or benefiting little from anticholinergics, can effectively alleviate overactive muscle symptoms(14). Nevertheless, concentrating on this particular patient group helps bridge the knowledge gap in this area. To evaluate the success rate of treatment for OAB, assessing the condition's impact on the patient's quality of life is essential, as it is a critical factor that influences treatment outcomes. Consequently, measuring the patient's quality of life using scales before and after treatment is a crucial component in determining the success rate of the treatment. As such, it should be considered an independent factor evaluated separately from other variables.

OAB has been shown to significantly negatively impact quality of life (2, 15). Our study indicates that OAB adversely influences quality of life during pre-treatment assessment; however, following treatment with intravesical botulinum therapy, quality of life scores improved.

One of the primary limitations of this study is its retrospective design, the absence of a control group, and the relatively small sample size. The retrospective nature inherently limits the ability to establish causal relationships, as the study relies on pre-existing data that may be subject to selection bias and lacks the randomization present in prospective studies. Additionally, without a control group, it is challenging to directly attribute the observed improvements in quality of life and symptom reduction solely to the intravesical Botulinum Toxin A therapy. These factors collectively limit the generalizability of our findings to the broader population of patients with overactive bladder (OAB).

Moreover, the small sample size may have limited our ability to detect less common complications or more nuanced

treatment effects. The limited number of participants makes it difficult to generalize the findings to a larger population and may obscure the identification of rare adverse events. Therefore, while our results are promising, they should be interpreted with caution. Future studies with larger, multicenter prospective designs are necessary to validate our findings and to explore the full spectrum of treatment effects and potential complications. Such studies would provide a more robust understanding of the efficacy and safety of Botulinum Toxin A therapy in OAB patients.

We observed no significant increase in residual urine or the incidence of urinary tract infections (UTIs) following treatment with BTxA. However, it is crucial to recognize that the modest size of the study population may influence these findings. Smaller sample sizes can make it difficult to identify infrequent side effects or unique treatment effects in subgroups (16,17). Therefore, caution should be exercised when generalizing the results. Previous studies in larger patient groups have reported increased UTI frequency after BTxA treatment(18). Consequently, the inconsistency between our findings and those of previous studies might be attributed to the limitations of our sample size.

In addition, Botulinum Toxin A injections are not limited to patients resistant to anticholinergics but also have therapeutic effects on those who do not respond to beta-3 agonists or combination therapies. This broader applicability may indicate the need for further research to explore the potential of Botulinum Toxin A in the management of OAB in different patient subgroups.

Moreover, the lack of a control group precludes a comparison with other treatment modalities or with a placebo, which could have provided a more robust assessment of the therapy's efficacy. As such, while our findings are promising, they should be interpreted with caution, and there is a need for future studies with prospective designs and appropriate control groups to validate our results. These additional studies would help confirm the effectiveness of Botulinum Toxin A in improving the quality of life for OAB patients and better understand the potential placebo effects and other confounding variables that may have influenced our outcomes.

Increased post-voiding residual urine volume is a well-known complication in patients with intravesical BTx Administration and sometimes requires additional treatment modalities,

such as clean intermittent catheterization. However, although residual urine increased after voiding was observed in our study, no patients required additional treatment. Criteria, such as sample size or patient selection in the patient group, may be effective for these results.

The primary limitation of this study is that despite utilizing a statistically appropriate sample size, the small number of participants may have influenced the results and findings, particularly considering the scarcity of long-term and comprehensive follow-up data. The absence of long-term follow-up data precludes a thorough understanding of the sustainability of treatment benefits and potential delayed adverse effects. Future studies with extended follow-up periods are necessary to evaluate the durability of BTxA's therapeutic effects and to monitor for any long-term complications. Furthermore, the retrospective nature of the data collection, the absence of a control group, and the single-center conduct of the study were identified as significant weaknesses. Effective treatment protocols require a comprehensive assessment of the consequences of overactivity on quality of life.

Future research endeavors should explore comprehensive treatment methods integrating botulinum toxin therapy with other therapeutic interventions, such as behavioral modifications and physical therapy(9).

CONCLUSION

Intravesical BTxA therapy has been demonstrated to be both safe and effective in treating individuals with overactive bladder syndrome who experience moderate functional impairment. This treatment has been shown to enhance patients' quality of life. Nevertheless, our study suggests that further research is necessary in the form of controlled, multicenter studies with larger sample sizes to validate and extend the results obtained.

Abbreviations

OAB: overactive bladder syndrome, ECOG PS: Eastern Cooperative Oncology Group Performance Scale, ICIQ: International Consultation on Incontinence Questionnaire, I-QOL: Incontinence Quality of Life

Conflict of Interest: The author declares that they have no conflicts of interest.

Funding: This research received no specific grant from any

funding agency in the public, commercial, or not-for-profit sectors.

Ethic Committee: KKTC Burhan Nalbatoğlu Site Hospital Ethic Committee: 03.04.2024 EK:19/24.

REFERENCES

1. Yi Q-T, Gong M, Chen C-H, Hu W, Zhu R-J. Epidemic investigation of benign prostatic obstruction with coexisting overactive bladder in Shanghai Pudong New Area and its impact on the health-related quality of life. *BMC Urology*. 2019;19(1):82. <https://doi.org/10.1186/s12894-019-0513-1>
2. Kim S-K, Kim S-H. The impact of overactive bladder on health-related quality of life in Korea: based on the results of a Korean Community Health Survey. *Quality of Life Research*. 2021;30(4):1017-24. <https://doi.org/10.1007/s11136-020-02710-3>
3. Pyo H, Kim BR, Park M, Hong JH, Kim EJ. Effects of overactive bladder symptoms in stroke patients' health related quality of life and their performance scale. *Annals of Rehabilitation Medicine*. 2017;41(6):935-43. <https://doi.org/10.5535%2Farm.2017.41.6.935>
4. Simcock R, Wright J. Beyond Performance Status. *Clin Oncol (R Coll Radiol)*. 2020;32(9):553-61. <https://doi.org/10.1016/j.clon.2020.06.016>
5. Jang H, Lee K, Kim S, Kim S. Unmet needs in palliative care for patients with common non-cancer diseases: a cross-sectional study. *BMC Palliative Care*. 2022;21(1):151. <https://doi.org/10.1186/s12904-022-01040-0>
6. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *American journal of clinical oncology*. 1982;5(6):649-56. <https://doi.org/10.1097/00000421-198212000-00014>
7. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. *Am J Manag Care*. 2000;6(11 Suppl):S574-9.
8. Lepor H. Challenges in the detection and diagnosis of bladder dysfunction: optimal strategies for the primary care physician. *Reviews in Urology*. 2004;6(Suppl 1):S1.
9. Enemchukwu E, Cameron A. Management of complex

- OAB patients: A call to action. *Neurourol Urodyn*. 2022;41(8):1938-9. <https://doi.org/10.1002/nau.25048>
10. Park WH. Urinary incontinence and physician's attitude. *J Korean Med Sci*. 2013;28(11):1559-60. <https://doi.org/10.3346/jkms.2013.28.11.1559>
 11. Schnelle JF, Smith RL. Quality indicators for the management of urinary incontinence in vulnerable community-dwelling elders. *Ann Intern Med*. 2001;135(8 Pt 2):752-8. https://doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00015
 12. Truzzi JC, Lapitan MC, Truzzi NC, Iacovelli V, Averbeck MA. Botulinum toxin for treating overactive bladder in men: A systematic review. *Neurourol Urodyn*. 2022;41(3):710-23. <https://doi.org/10.1002/nau.24879>
 13. D'Ancona C, Haylen B, Oelke M, Abranches-Monteiro L, Arnold E, Goldman H, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. *Neurourology and urodynamics*. 2019;38(2):433-77. <https://doi.org/10.1002/nau.23897>
 14. Ginsberg D, Jen R, Nseyo U. Botulinum Toxin Treatment of Neurogenic Detrusor Overactivity and Overactive Bladder. *Textbook of Female Urology and Urogynecology*: CRC Press; 2023. p. 490-500. rita-jen-unwanaobong-nseyo. <https://doi.org/10.1201/9781003144236-51>
 15. Yi Q-T, Gong M, Chen C-H, Hu W, Zhu R-J. Epidemic investigation of benign prostatic obstruction with coexisting overactive bladder in Shanghai Pudong New Area and its impact on the health-related quality of life. *BMC urology*. 2019;19:1-8. <https://doi.org/10.1186/s12894-019-0513-1>
 16. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. RESEARCH METHODS & REPORTING- Prognosis and prognostic research: what, why, and how?-Doctors have little specific research to draw on when predicting outcome. This first article in a series explains why research into prognosis is important and how to design such research. *BMJ (CR)-print*. 2009;338(7706):1317. <https://doi.org/10.1136/bmj.b375>
 17. Shaban AM, Drake MJ. Botulinum toxin treatment for overactive bladder: risk of urinary retention. *Curr Urol Rep*. 2008;9(6):445-51. <https://doi.org/10.1007/s11934-008-0077-1>
 18. Shapiro K, Anger J, Cameron AP, Chung D, Daignault-Newton S, Ippolito GM, et al. Antibiotic use, best practice statement adherence, and UTI rate for intradetrusor onabotulinumtoxin-A injection for overactive bladder: A multi-institutional collaboration from the SUFU Research Network (SURN). *Neurourol Urodyn*. 2024;43(2):407-14. <https://doi.org/10.1002/nau.25334>

A Review of Metastatic Tumours of the Kidney with Literature: A Single Centre Experience

Ganime Çoban¹, Özlem Toluk², Abdullah İlktac³

¹Department of Pathology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Türkiye

²Department of Biostatistics and Medical Informatics, Bezmialem Vakif University Faculty of Medicine, Istanbul, Türkiye

³Department of Urology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Türkiye

Submitted: 2024-07-19

Accepted: 2024-10-21

Corresponding Author;

Ganime Çoban, MD

Department of Pathology, Faculty of Medicine, Bezmialem Vakif University,
Adnan Menderes Blv., Vatan Street,
34093, Fatih, Istanbul, Türkiye

E-mail: dr'gcoban@hotmail.com

ORCID

G.Ç. [0000-0002-5779-6797](https://orcid.org/0000-0002-5779-6797)

Ö.T. [0000-0001-6495-0839](https://orcid.org/0000-0001-6495-0839)

A.İ. [0000-0002-0599-5436](https://orcid.org/0000-0002-0599-5436)

Abstract

Objective: Metastatic tumors of the kidney are quite rare. In this study, we aimed to increase awareness by discussing the clinicopathological data of our cases in the context of the literature.

Material and Methods: A total of 760 cases, subjected to trucut biopsy or resection, were examined. The primary diagnoses, clinical, and histopathological features of the cases were investigated.

Results: The study included 60 trucut and 700 partial/radical nephrectomy cases, with metastasis to the kidney detected in 24 cases. The most common primary organ was the lung, with less frequent cases from lymph nodes, skin, breast, nasal sinus, gall bladder, pleura, prostate, colon, esophagus, stomach, and ovary. Most tumors were of epithelial origin. The majority of the cases were solitary and endophytic in appearance. Kidney metastasis occurred at a median of 36 (2-123) months after the primary diagnosis. The median survival time after kidney metastasis was 8 (1-90) months.

Conclusion: In this study, detailed demographic and pathological data of cases metastasizing to the kidney were documented. Although the rate of metastatic tumors in the kidney is low, even in solitary and endophytic appearances, the possibility of metastasis should be considered, especially in elderly patients, and confirmed with histopathological findings.

Keywords: metastasis, kidney, prognosis, lung, solitary, nephrectomy

INTRODUCTION

Metastatic tumors of the kidney are quite rare, ranking 12th among organs that can be metastasized. In autopsy series, the incidence of tumors metastasizing to the kidney varies, reaching up to 12.6% (1,2,3). Increased imaging techniques and the distinction between primary and secondary tumors

radiologically have also increased the detection rate of metastasis not only in autopsy series but also routinely. In more than half of the cases, kidney metastasis is not detected at the time of primary tumor diagnosis. While kidney metastasis may be seen years after the treatment of the primary tumor, rarely, kidney metastasis diagnosis can be made before the

primary diagnosis (4). When kidney metastasis is detected, metastases are often present in other organs as well (5). Clinical signs include flank pain and hematuria, but most cases are incidentally detected during imaging (5). Compared to the primary tumor, metastases are more likely to be bilateral, multifocal, solitary, and endophytic.

Metastatic tumors in the kidney include lung, colon, breast, soft tissue, and thyroid metastases (5). Cases are generally asymptomatic and detected incidentally through imaging (6).

In this study, we aimed to highlight and increase awareness of these rare tumors by comparing the histopathological diagnoses of tumors metastasizing to the kidney in patients who underwent needle biopsy or surgery (partial/radical nephrectomy) due to a kidney mass with radiological and clinical findings.

MATERIALS AND METHODS

This retrospective study was approved by Bezmialem Vakif University Rectorate Technology Transfer Office Ethics Committees Unit. (Decision No: 333, Date: 22.11.2023). A total of 760 biopsies performed due to kidney masses (tru-cut or partial/radical nephrectomy) between January 2012 and January 2024 at Bezmialem Vakif University were evaluated. Archive materials and hospital information systems were scanned to record the diagnoses of primary and metastatic tumors. Cases with histopathologically and immunohistochemical confirmed metastasis were included in the study, while tumors directly invading the kidney were excluded. The frequency, bilaterality, endophytic/exophytic nature, multifocality, locations of metastatic tumors, presence of metastases in other organs at the time of kidney metastasis, the time between primary diagnosis and metastasis, and average survival time after kidney metastasis were recorded. The available data were discussed in light of current literature findings.

RESULTS

The study included 760 cases, 700 of which underwent partial/radical nephrectomy and 60 trucut biopsy. Metastasis was detected in 19 (76%) of the trucut biopsies and 6 (24%) of the resection materials. In total, 25 cases of kidney metastasis were present. The average age of metastatic cases was 62.2 (21-84) years. The most common symptom was abdominal/flank pain, followed by hematuria, with multiple symptoms present in other cases. In one case, adenocarcinoma of lung origin was detected by trucut biopsy due to acute kidney failure without a kidney mass. Metastases were located in the left kidney in 14

(56%) cases, the right kidney in 5 (20%) cases, and bilaterally in 6 (24%) cases. Nineteen (76%) cases were endophytic, and 6 (24%) were exophytic (Table 1). Eighteen (72%) cases had unifocal, and 7 (28%) had multifocal tumors.

Table 1. Demographic and clinical findings of the cases

	Number (n, %)
Case number	25
Age (mean ±Std. Deviation)	62.2(±16.78)
Gender	
Female	9(36)
Male	16(64)
Biopsy type	
Trucut	19(76)
Partial/radical nephrectomy	6(24)
Localization	
Right	5(20)
Left	14(56)
Bilateral	6(24)
Number of tumors	
Unifocal	18(72)
Multifocal	7(28)

In 21 (84%) cases with kidney metastasis, the primary site of the tumor was known, while in 1 (4%) case, it was unknown, and in 3 (12%) cases, the diagnosis was made simultaneously with kidney metastasis. After the diagnosis in one case, a systemic search found the primary focus. The most common primary organ was the lung (8 cases, 32%), followed by lymph nodes (5 cases, 20%) and skin (2 cases, 8%), with one case each in the breast, nasal sinus, gall bladder, pleura, prostate, colon, esophagus, stomach, and ovary. Twelve (48%) tumors were adenocarcinomas, 7 (28%) were lymphomas, 2 (8%) were small cell carcinomas, 2 (8%) were sarcomas, 1 (4%) was melanoma, and 1 (4%) was squamous cell carcinoma. Six (85.7%) of the seven lymphoma cases were B-cell, and one (14.3%) was T-cell lymphoma. Of the lung metastases, seven (87.5%) were adenocarcinomas, and one (12.5%) was small cell carcinoma (Figure 1). In 8 (32%) cases, metastasis was only to the kidney, while in 17 (68%), there were metastases to other organs as well.

The median survival time for the cases was 36 (2-123) months, and the median time after kidney metastasis was 8 (1-90) months. Nineteen (76%) cases had died, and six (24%) were alive. There was a statistically significant difference in survival

times between the group with only kidney metastasis and the group with metastasis to another organ as well ($p=0.048$). The median survival time for those with only kidney metastasis was 93.00 ± 26.35 months, while for those with metastasis to another organ as well, it was 18.00 ± 9.60 months.




Figure 1. Histopathological and immunohistochemical findings of some tumors metastasizing to the kidney.

A. Malignant melanoma, HMB45 and SOX 10 immunohistochemical staining required for diagnosis .

B. Small cell carcinoma, TTF 1 and Synaptophysin immunohistochemical staining required for diagnosis and primary focus.

C. Prostatic adenocarcinoma, Immunohistochemical staining required to show prostate origin is NKX3.1 positivity and PAX8 negativity, which is positive in kidney tumors.

D. Immunohistochemical CD117 and CK7 positivity in our patient with adenoid cystic carcinoma forming solid and cribriform structures,

E. Immunohistochemical GATA3 and Estrogen positivity

in our case of breast carcinoma forming solid groups under urothelial epithelium,

F. Lung adenocarcinoma, Immunohistochemical TTF1 positivity and histochemical PAS positivity for adenocarcinoma metastasis forming glandular structures in the interstitium and tubules and tumour origin. (H&E and IHC , x100)

H&E: Hematoxylin&Eosin,

IHC: immunohistochemistry

DISCUSSION

Metastatic tumors of the kidney pose a diagnostic challenge due to their varied origins and clinical and radiological appearances. Early and accurate diagnosis is considered as critical for optimal treatment planning. In cases with isolated kidney masses of unknown primary origin, the radiological distinction may not be possible, increasing the rate of unnecessary resections. While the standard treatment for renal cell carcinoma is surgery, there are no clear guidelines for metastases. However, studies indicate that curative surgical resection in oligometastasis can improve survival. Autopsy series showing incidental detection rates of 2.36-12.6% highlight the high rate of incidental findings (1,2,5). Similar to primary tumors, metastatic tumors can cause symptoms like flank pain and hematuria, and rarely, acute kidney failure. The most common primary sites were the lung, lymph nodes, gastrointestinal system, and skin, similar to other series where the lung, breast, and gastrointestinal system were predominant (7), Zhou et al. reported a series of 151 cases of lung (43.7%), colorectal (10.6%), head and neck (6%), breast (5.3%), soft tissue (5.3%), and thyroid (5.3%), while Chen et al. reported lung (60%), colon (8.6%), esophagus (5.7%), breast (5.7%), ovary (5.7%), and liver, endometrium, thyroid, parotid, and melanoma at 2.9% each (5,8). Additionally, rare metastases such as cervix and Merkel cell carcinoma have been described (9,10). Our cases also included notable metastases from the nasal sinus, prostate, and gall bladder, which are rare in the literature.

While a tumor can metastasize to any organ, it is often multifocal or bilateral. Interestingly, most kidney metastases are solitary (5,8,11,12,13). Additionally, rare cases of extensive metastasis resembling primary renal cell carcinoma have been reported, such as breast metastasis presenting as a single mass with vena cava inferior thrombus, and esophageal squamous cell carcinoma infiltrating the entire kidney, including the pelvis and adrenal gland (14,15). In our study, most cases

were solitary and endophytic. Primary kidney tumors can be recognized radiologically even when multifocal (e.g., Burt Hugg-Dube syndrome, Von Hippel-Lindau syndrome). However, metastases are less common than primary tumors, leading to cases misdiagnosed as primary tumors. Therefore, the possibility of metastasis should always be considered, especially in known primary tumor cases.

Among the metastatic tumors of the kidney, epithelial tumors are the most common (5). Additionally, melanoma, lymphoma, and mesenchymal tumors can metastasize to the kidney. As in our study, adenocarcinoma is the most common epithelial tumor in the literature, with the lung being the most common primary site. Among our lung primary cases, seven were adenocarcinomas and one was small cell carcinoma. Lian et al. found a series of six cases with lung primary metastasizing to the kidney similar results, with adenocarcinoma being the most common (four cases), followed by one case each of squamous cell carcinoma and small cell carcinoma (16). To support lung adenocarcinoma metastasis, clinical history, morphological findings, and immunohistochemical stains (TTF1, Napsin A, CK7) were positive in our cases (16). For squamous cell carcinoma metastasis, when the primary site is unknown, distinguishing it from a primary renal pelvis squamous cell carcinoma without dysplastic epithelium favors metastasis. Among our cases, we had an adenoid cystic carcinoma metastasis, a rare metastatic tumor of the kidney. The primary site was the nasal sinus, with lung metastasis preceding kidney metastasis. Although less common, mesenchymal tumors can also metastasize to the kidney, including osteosarcoma and synovial sarcoma in the literature (5). We did not encounter mesenchymal tumors in our study. Lymphomas, although less common, can also metastasize to the kidney, with diffuse large B-cell lymphoma being the most common type, as in our study.

The longest time from primary diagnosis to kidney metastasis in the literature was 156 months in Chen et al.'s study, with a diagnosis of kidney metastasis from breast cancer (8). In our study, the longest time was 84 months for nasal sinus adenoid cystic carcinoma. Seventeen cases had metastases to other organs before kidney metastasis. Additionally, the median survival times of the cases significantly decreased after kidney metastasis. Similarly, Zhou et al. reported shorter survival times after kidney metastasis (5).

We could not reach the survival times of patients diagnosed in our hospital that is limitation of this study, but it is followed

up in other centers. Our number of cases may be lower compared to the literature, but it is higher in terms of case diversity.

CONCLUSION

By increasing use of molecular examinations, organ-specific treatments are also increasing. Although the rate of metastatic tumors in the kidney is low, the possibility of metastasis should be considered, especially in elderly patients, and confirmed with systemic and radiological findings. In addition, metastasis should be kept in mind when histopathological morphology is different from the classical tumours of the kidney. There are very few series of renal metastases in the literature, and they are usually described as case reports. New studies with large series are needed to determine the true incidence of renal metastases.

Ethics Committee Report: This retrospective study was approved by Bezmialem Vakıf University Rectorate Technology Transfer Office Ethics Committees Unit. Protocol: Decision No: 333, Date: 22.11.2023.

REFERENCES

1. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. *Cancer* 1950;3(1):74-85. [https://doi.org/10.1002/1097-0142\(1950\)3:1](https://doi.org/10.1002/1097-0142(1950)3:1)
2. Bracken RB, Chica G, Johnson DE, Luna M. Secondary renal neoplasms: an autopsy study. *South Med J*. 1979;72(7):806-7. <https://doi.org/10.1097/00007611-197907000-00013>
3. Klinger ME. Secondary tumors of the genito-urinary tract. *J Urol*. 1951;65(1):144-53. [https://doi.org/10.1016/S0022-5347\(17\)68470-2](https://doi.org/10.1016/S0022-5347(17)68470-2)
4. Gao Y, Deng W, Chen Y, Fan Y, Guo Z. Renal metastases as the initial presentation of papillary thyroid carcinoma: A case report and literature review. *Mol Clin Oncol*. 2017;6(6):821-824. <https://doi.org/10.3892/mco.2017.1243>
5. Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, et al. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. *BJU Int*. 2016;117(5):775-82. <https://doi.org/10.1111/bju.13194>
6. Wang J, Wang L, Long L, Tao Q, Xu F, Luo F. Solitary renal

- metastasis from squamous cell carcinoma of the lung: a case report. *Medicine (Baltimore)*. 2019;98(5):e14310. <https://doi.org/10.1097/MD.00000000000014310>
7. Adamy A, Von Bodman C, Ghoneim T, Favaretto RL, Bernstein M, Russo P. Solitary, isolated metastatic disease to the kidney: Memorial Sloan-Kettering Cancer Center experience. *BJU Int*. 2011;108(3):338-42. <https://doi.org/10.1111/j.1464-410X.2010.09771.x>
 8. Chen J, Qi N, Zhu S. Metastases to the Kidney: An Analysis of 35 Cases and a Review of Literature. *Front Oncol*. 2021;19:10:632221. <https://doi.org/10.3389/fonc.2020.632221>
 9. Bazine A, Zniber HO, Ghaouti M, Bazine A, Baydada A, Sifat H. An Uncommon Case of Renal Metastasis from Cervical Cancer. *Cureus*. 2017 Dec 13;9(12):e1941. <https://doi.org/10.7759/cureus.1941>
 10. Anastasiou A, Moulavasilis N, Leotsakos I, Nerantzis CE, Anastasiou I. Merkel cell carcinoma with kidney metastasis in a 81-year-old man. A rare case report. *Arch Ital Urol Androl*. 2019 Jul 2;91(2). <https://doi.org/10.4081/aiua.2019.2.133>
 11. Wu A, Mehra R, Hafez K, Wolf JS, Jr SW, Kunju LP. Metastases to the kidney: a clinicopathological study of 43 cases with an emphasis on deceptive features. *Histopathology*. 2015;66(4):587-97. <https://doi.org/10.1111/his.12524>
 12. Pagani JJ. Solid renal mass in the cancer patient: second primary renal cell carcinoma versus renal metastasis. *J Comput Assist Tomogr*. 1983;7(3):444-8. <https://doi.org/10.1097/00004728-198306000-00011>
 13. Hietala SO, Wahlqvist L. Metastatic tumors to the kidney. A postmortem, radiologic and clinical investigation. *Acta Radiol Diagn (Stockh)*. 1982;23(6):585-91. <https://doi.org/10.1177/028418518202300610>
 14. Nagata A, Shinden Y, Nomoto Y, Saho H, Nakajo A, Minami K, Kumagae Y, et al. Metastasis of breast cancer to the right kidney with a tumor thrombus in the inferior vena cava: a case report. *Surg Case Rep*. 2022 Jan 17;8(1):13. <https://doi.org/10.1186/s40792-022-01364-2>
 15. Chang K, Huang C, Chang H. Solitary renal metastasis of esophageal squamous cell carcinoma mimicking primary renal neoplasm – A case report and literature review. *Biomedicine (Taipei)*. 2016 Mar;6(1):6. <https://doi.org/10.7603/s40681-016-0006-4>
 16. Lian H, Pan X, Hong B, Min J, Huang F. Metastases to the kidney from primary lung cancer: clinicopathological analysis of six cases in a single center. *Lian et al. Diagn Pathol*. 2023 May 9;18(1):60. <https://doi.org/10.1186/s13000-023-01344-6>

Microscopic Testicular Sperm Extraction in Patients with Klinefelter Syndrome: Long-Term Outcomes from a Single Center

Eyyup Sabri Pelit, Bülent Kati

Department of Urology, Harran University, Şanlıurfa

Submitted: 2024-08-06

Accepted: 2024-10-15

Corresponding Author;

Eyyup Sabri Pelit, MD

Department of Urology,

Harran University

Şanlıurfa, Türkiye

E-mail: dreyyupsabri@hotmail.com

ORCID

E.S.P. [0000-0001-8550-5072](https://orcid.org/0000-0001-8550-5072)

B.K. [0000-0002-4024-5147](https://orcid.org/0000-0002-4024-5147)

Abstract

Objective: Klinefelter syndrome (KS) represents a sex chromosome anomaly observed in approximately 1 in 500–600 phenotypic males. It is observed in 3% of infertile males and up to 11.9% of azoospermic males. KS manifests in either non-mosaic (47, XXY) or mosaic (47, XXY/46, XY) forms, with 85% of cases presenting as the non-mosaic 47, XXY karyotype. The average rate of surgical sperm retrieval in patients with KS is around 50%, ranging from 28% to 69%. In this study, we aimed to present the outcomes of microscopic testicular sperm extraction (micro-TESE) in patients with non-mosaic KS.

Material and Methods: The results of 61 patients diagnosed with KS, who presented to the Harran University Urology Clinic with azoospermia between 2017 and 2024, were retrospectively reviewed. Hormonal assessments, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and total testosterone (TT), were conducted for all patients, and their partners underwent gynecological evaluations for infertility. Testicular dimensions were recorded via scrotal ultrasonography. Patients were categorized into TESE-positive and TESE-negative groups, and parameters were compared between these groups.

Results: The mean age of the patients was 29.0 ± 5.1 years, and their mean infertility duration was 5.9 ± 4.1 years. The sperm retrieval rate was 29.5% (n=18). Mean levels of FSH, LH, prolactin, estradiol, and TT were 44.9 IU/L, 23.3 IU/L, 10 nmol/L, 31.4 pmol/dL, and 219 ng/dL, respectively. Sperm was retrieved in 18 patients (29.5%), while no sperm was obtained in 43 (70.5%). No significant correlation was observed between patient age, testicular size, serum levels of FSH, LH, prolactin, estradiol, and TT, and sperm retrieval rates when comparing the TESE-positive and TESE-negative groups ($P > 0.005$).

Conclusion: In patients with non-mosaic KS, hormonal parameters, age, and infertility duration were not found to be significant predictors of the success of micro-TESE in sperm retrieval.

Keywords: klinefelter syndrome,, microscopic testicular sperm extraction, azoospermia

INTRODUCTION

Infertility affects approximately 15% of the general population, with azoospermia identified in about 13% of those seeking treatment for infertility (1). Genetic analysis and hormonal evaluation are essential for azoospermic males due to underlying genetic and hormonal disorders.

Klinefelter syndrome (KS) is the most common sex chromosome anomaly, and it is occurring in approximately 1 in 500–600 phenotypic males. It is observed in 3% of infertile male patients and up to 11.9% of azoospermic males (2). KS can manifest in non-mosaic (47, XXY) or mosaic (47, XXY/46, XY) forms (3). Leydig cell dysfunction is also prevalent in men with KS, leading to lower testosterone levels compared to the general population (4).

Microscopic testicular sperm extraction (micro-TESE) is the gold standard treatment for sperm retrieval in azoospermic patients. The success rate of micro-TESE in the general population without genetic anomalies is approximately 50%. In patients with KS, sperm retrieval rates with micro-TESE range from 28% to 69%, with significant variations across studies. Several studies have shown that performing micro-TESE at an early age may improve sperm retrieval success (5), although this remains a topic of debate.

In this study, we aimed to present the outcomes of micro-TESE in patients with non-mosaic KS.

MATERIAL AND METHODS

The study was initiated after approval was obtained from the Harran University Ethics Committee on 27.05.2024 with session number 07 and decision number 05. In this study, the data of 61 patients with non-mosaic KS, who presented to the Urology Clinic of Harran University with azoospermia and underwent micro-TESE between 2017 and 2024, were retrospectively screened. According to the genetic analysis patients reported as 47 XXY were included in the study. Those who had previously TESE, varicocele and undescended testicle surgery and those receiving hormonal treatment were excluded from the study.

Detailed anamnesis, physical examination, semen analysis, and hormone profiles were assessed for all patients. Semen samples were obtained through masturbation following three to five days of sexual abstinence and collected in sterile containers. The presence of azoospermia was confirmed with at least two semen samples taken two weeks apart. All samples

were centrifuged at 3,000 g, and the resuspended pellet was thoroughly examined. Physical examinations included assessments of testicular size, the presence of varicocele, the development of secondary sexual characteristics, signs of orchitis, and palpation of the vas deferens. Preoperatively, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and total testosterone (TT) levels were measured, karyotype analysis was performed, the presence of Y microdeletion was investigated, and the results of previous sperm extraction interventions were evaluated. Testicular dimensions were measured using scrotal ultrasonography.

The micro-TESE procedure was performed under spinal anesthesia via a midline scrotal raphe incision. After passing through the dartos and tunica vaginalis, a longitudinal incision was made in the avascular area of the tunica albuginea. Testicular parenchymal dissection was conducted under a microscope with 18–22x magnification, selecting enlarged and opaque tubules. The testicular tissues obtained were examined by an embryologist under an inverted microscope for the presence of spermatozoa. The tunica albuginea was closed with continuous 5-0 nylon sutures. Following hemostasis, layers were closed anatomically, and patients were discharged on the postoperative first day.

The retrieved sperm cells were cryopreserved. Intracytoplasmic sperm injection (ICSI) was performed in a separate session using the obtained sperm cells. Pathological sampling was conducted on TESE-negative patients.

In the descriptive statistics of the data, mean, standard deviation, median lowest, highest, frequency and ratio values were used. The distribution of variables was measured by Kolmogorov-Smirnov, Shapiro-Wilk test. Independent sample t test was used in the analysis of quantitative independent data with normal distribution. Mann-Whitney U test was used in the analysis of quantitative independent data with non-normal distribution. Chi-square test was used in the analysis of qualitative independent data, and Fischer test was used when chi-square test conditions were not met. The effect level was investigated with univariate and multivariate logistic regression. SPSS 28.0 program was used in the analyses.

RESULTS

A total of 61 patients were included in the study. The mean age was 29.0 ± 5.1 years, and the mean duration of infertility was 5.9 ± 4.1 years. The sperm retrieval rate was 29.5% ($n =$

18). Mean levels of FSH, LH, prolactin, estradiol, and TT were 44.9 IU/L, 23.3 IU/L, 10 nmol/L, 31.4 pmol/dL, and 219 ng/dL, respectively (Table 1). Sperm was retrieved in 18 patients (29.5%), while no sperm was obtained in 43 patients (70.5%). No significant correlation was observed between patient age, testicular size, serum levels of FSH, LH, prolactin, estradiol, and TT, and sperm retrieval rates when comparing the TESE-positive and TESE-negative groups ($P > 0.005$).

Among the 43 patients reported as TESE-negative, 23 had Sertoli cell-only syndrome, 12 exhibited complete hyalinization with no seminiferous tubules observed, five had maturation arrest, and three showed hypospermatogenesis (Table 3).

Postoperative complications included wound infection in three patients and scrotal hematoma in one patient, all of which were managed with medical treatment.

Table 3. Pathology results of TESE-negative patients

	n (%)
Hypospermatogenesis	3 (6.9%)
Maturation arrest	5 (11.6%)
Sertoli cell-only syndrome	23 (53.4%)
Complete fibrosis	12 (27.9%)

Table 1. Demographic and clinical characteristics of participants

	Min-Max	Median	Mean ± SD/n, %
Age	21.0 - 43.0	29.0	29.0 ± 5.1
Infertility duration	1.0 - 25.0	5.0	5.9 ± 4.1
FSH	30.1 - 90.6	43.0	44.9 ± 17.5
LH	12.6 - 39.5	23.4	23.3 ± 8.0
Testosterone	38.4 - 471.3	201.9	219.0 ± 111.5
Prolactin	4.7 - 19.8	9.4	10.0 ± 3.2
Estradiol	7.5 - 63.0	31.3	31.4 ± 11.8
Testicular volume (cc)	10.0 - 23.0	17.0	16.3 ± 3.6
TESE	(-)		43 70.5%
	(+)		18 29.5%

SD: standard deviation, FSH: follicle-stimulating hormone, LH: luteinizing hormone, TESE: testicular sperm extraction

Table 2. Comparison of demographic and clinical characteristic between the study groups

	TESE (-)			TESE (+)			P
	Mean ± SD n = 43 (70.5%)	Median		Mean ± SD n = 18 (29.5%)	Median		
Age	29.0 ± 5.3	29.0		29.2 ± 4.7	28.5		0.680 ^m
Infertility duration	5.9 ± 4.6	5.0		5.8 ± 2.6	6.0		0.609 ^m
FSH	46.4 ± 19.0	44.0		41.1 ± 13.1	37.6		0.217 ^m
LH	23.9 ± 8.5	23.4		21.9 ± 6.7	23.4		0.390 ^t
Testosterone	278.0 ± 123.5	269.2		279.2 ± 97.6	269.9		0.712 ^m
Prolactin	10.2 ± 3.4	9.8		9.5 ± 2.8	9.0		0.704 ^m
Estradiol	30.9 ± 11.9	30.6		32.6 ± 11.7	35.0		0.605 ^t
Testicular volume	16.2 ± 3.7	16.0		16.7 ± 3.3	17.5		0.617 ^m

^tIndependent-samples t-test / ^mMann-Whitney U test

TESE: testicular sperm extraction, SD: standard deviation

DISCUSSION

KS is the most prevalent sex chromosome anomaly (6). Due to fibrotic testes, patients with KS typically exhibit low testosterone levels and elevated serum FSH and LH levels, consistent with primary testicular failure. Approximately 11–14% of azoospermic patients are diagnosed with KS. Due to testicular atrophy and fibrosis, the micro-TESE method is employed to retrieve sperm in azoospermic patients with KS. The first positive TESE procedure in patients with KS was described by Tournaye et al. in 1996, followed by TESE + ICSI and the subsequent report of the first successful pregnancy (7-10).

The literature reports a wide range of sperm retrieval rates via micro-TESE in patients with KS, ranging from 28% to 69% (11-13). In the current study, the TESE positivity rate in patients with non-mosaic KS was 29.5% (n = 18/61). Many studies have administered preoperative hormone therapy to patients before performing the TESE procedure, which contributes to varying sperm retrieval rates. In a comparative study by Guo et al., patients received preoperative human chorionic gonadotropin (hCG) therapy. The authors found no statistical difference between the treated and untreated groups in terms of sperm retrieval rates (44% vs. 43.3%) (14). In another study, Majzoub et al. reported that sperm retrieval was achieved in 27.8% of patients given aromatase inhibitors and 12.5% of those given clomiphene citrate plus hCG, while no sperm was retrieved in the untreated group. However, that study had a limited sample size, which is a notable limitation (15). Ramasay et al. found that patients who responded to hormone therapy with testosterone levels exceeding 250 ng/dL had sperm retrieval rates of 77%, compared to 55% in those who did not respond to therapy (16).

Several parameters are investigated to predict sperm retrieval success in patients with KS, but no definitive predictors have been established in the literature. Nevertheless, studies suggest that performing TESE at an earlier age yields more successful outcomes in this patient population (17,18). Liu et al. determined that testicular volume, FSH, LH, and testosterone were not predictors of sperm retrieval success in patients with KS. Instead, patient age and anti-Müllerian hormone levels showed some predictive value (19). Another study reported a micro-TESE success rate of 37.8% in patients with KS, with preoperative testosterone levels being the most significant predictor when comparing successful and unsuccessful groups (20). A study from Turkey involving 67 patients with KS found that early-age TESE increased sperm

retrieval success, while other parameters, such as FSH, LH, prolactin, and TT levels, did not show any significant differences (21). In our study, no significant differences were observed in hormone levels, age, infertility duration, or testicular volume between the TESE-positive and TESE-negative patients. Sperm retrieval rates vary in the literature and in our study, sperm retrieval rates were close to the lower limit. The main factors that can cause and this can be interpreted as the older age of our patient population and the lack of any preoperative hormonal treatment. However, according to the guidelines, still there is currently no hormonal treatment method that can be applied before TESE to increase the sperm retrieval rates (22).

The primary factors negatively affecting sperm retrieval in patients with KS are testicular hyalinization and fibrosis. Histopathological examinations in these patients frequently reveal sclerosis, hyalinization in seminiferous tubules, and Sertoli cell-only syndrome (23). Studies have shown that testicular hyalinization increases with age, which decreases sperm retrieval rates in patients with KS, suggesting that earlier micro-TESE may have higher success rates (18). In the current study, no significant differences were found between the TESE-positive and TESE-negative groups. We found that 53.4% of the patients had Sertoli cell-only syndrome, and 27.9% had complete fibrosis, which is consistent with previous studies.

The limitations of our study include its retrospective nature, the limited number of patients, and the absence of an evaluation of ICSI, fertilization, and live birth outcomes.

CONCLUSION

The success rate of micro-TESE in patients with non-mosaic KS varies widely in the literature. The current study reveals that a rate of 29.5%. Hormonal parameters, age, and infertility duration were not found to be significant predictors of sperm retrieval success.

Ethics Committee Report: The study was initiated after approval was obtained from the Harran University Ethics Committee on 27.05.2024 with session number 07 and decision number 05.

REFERENCES

1. Thoma ME, McLain AC, Louis JF, et al. Prevalence of infertility in the United States as estimated by the

- current duration approach and a traditional constructed approach. *Fertil Steril*. 2013;99(5):1324-1331.e1. <https://doi.org/10.1016/j.fertnstert.2012.11.037>
2. Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter's syndrome. *Lancet*. 2004;364(9430):273-283. [https://doi.org/10.1016/S0140-6736\(04\)16678-6](https://doi.org/10.1016/S0140-6736(04)16678-6)
 3. Visoosak J, Graham JM Jr. Klinefelter syndrome and other sex chromosomal aneuploidies. *Orphanet J Rare Dis*. 2006;1:42. Published 2006 Oct 24. <https://doi.org/10.1186/1750-1172-1-42>
 4. Pozzi E, Boeri L, Capogrosso P, et al. Rates of hypogonadism forms in Klinefelter patients undergoing testicular sperm extraction: A multicenter cross-sectional study. *Andrology*. 2020;8(6):1705-1711. <https://doi.org/10.1111/andr.12843>
 5. Okada H, Goda K, Yamamoto Y, et al. Age as a limiting factor for successful sperm retrieval in patients with nonmosaic Klinefelter's syndrome. *Fertil Steril*. 2005;84(6):1662-1664. <https://doi.org/10.1016/j.fertnstert.2005.05.053>
 6. Ron-el R, Friedler S, Strassburger D, Komarovsky D, Schachter M, Raziel A. Birth of a healthy neonate following the intracytoplasmic injection of testicular spermatozoa from a patient with Klinefelter's syndrome. *Hum Reprod*. 1999;14(2):368-370. <https://doi.org/10.1093/humrep/14.2.368>
 7. Tournaye H, Staessen C, Liebaers I, et al. Testicular sperm recovery in nine 47,XXY Klinefelter patients. *Hum Reprod*. 1996;11(8):1644-1649. <https://doi.org/10.1093/oxfordjournals.humrep.a019462>
 8. Palermo GD, Schlegel PN, Sills ES, et al. Births after intracytoplasmic injection of sperm obtained by testicular extraction from men with nonmosaic Klinefelter's syndrome. *N Engl J Med*. 1998;338(9):588-590. <https://doi.org/10.1056/NEJM199802263380905>
 9. Hinney B, Guttenbach M, Schmid M, Engel W, Michelmann HW. Pregnancy after intracytoplasmic sperm injection with sperm from a man with a 47,XXY Klinefelter's karyotype. *Fertil Steril*. 1997;68(4):718-720. [https://doi.org/10.1016/s0015-0282\(97\)00280-x](https://doi.org/10.1016/s0015-0282(97)00280-x)
 10. Bourne H, Stern K, Clarke G, Pertile M, Speirs A, Baker HW. Delivery of normal twins following the intracytoplasmic injection of spermatozoa from a patient with 47,XXY Klinefelter's syndrome. *Hum Reprod*. 1997;12(11):2447-2450. <https://doi.org/10.1093/humrep/12.11.2447>
 11. Fullerton G, Hamilton M, Maheshwari A. Should non-mosaic Klinefelter syndrome men be labelled as infertile in 2009?. *Hum Reprod*. 2010;25(3):588-597. <https://doi.org/10.1093/humrep/dep431>
 12. Corona G, Pizzocaro A, Lanfranco F, et al. Sperm recovery and ICSI outcomes in Klinefelter syndrome: a systematic review and meta-analysis. *Hum Reprod Update*. 2017;23(3):265-275. <https://doi.org/10.1093/humupd/dmx008>
 13. Mehta A, Paduch DA. Klinefelter syndrome: an argument for early aggressive hormonal and fertility management. *Fertil Steril*. 2012;98(2):274-283. <https://doi.org/10.1016/j.fertnstert.2012.06.001>
 14. Guo F, Fang A, Fan Y, et al. Role of treatment with human chorionic gonadotropin and clinical parameters on testicular sperm recovery with microdissection testicular sperm extraction and intracytoplasmic sperm injection outcomes in 184 Klinefelter syndrome patients. *Fertil Steril*. 2020;114(5):997-1005. <https://doi.org/10.1016/j.fertnstert.2020.05.043>
 15. A Majzoub , M Arafa , S Al Said , A Agarwal , A Seif , A Al Naimi , H El Bardisi . Outcome of testicular sperm extraction in nonmosaic Klinefelter syndrome patients: what is the best approach? *Andrologia*. 2016 Mar;48(2):171-6. <https://doi.org/10.1111/and.12428>. Epub 2015 May 1.
 16. Ranjith Ramasamy , Joseph A Ricci, Gianpiero D Palermo, Lucinda Veeck Gosden, Zev Rosenwaks, Peter N Schlegel. Successful fertility treatment for Klinefelter's syndrome. *J Urol*. 2009 Sep;182(3):1108-13. <https://doi.org/10.1016/j.juro.2009.05.019>. Epub 2009 Jul 18.
 17. Deebel NA, Galdon G, Zarandi NP, et al. Age-related presence of spermatogonia in patients with Klinefelter syndrome: a systematic review and meta-analysis. *Hum Reprod Update*. 2020;26(1):58-72. <https://doi.org/10.1093/humupd/dmz038>
 18. Okada H, Goda K, Yamamoto Y, et al. Age as a limiting factor for successful sperm retrieval in patients with nonmosaic Klinefelter's syndrome. *Fertil Steril*. 2005;84(6):1662-1664. <https://doi.org/10.1016/j.fertnstert.2005.05.053>

19. Liu DF, Wu H, Zhang Z, Hong K, Lin HC, Mao JM, et al. Factors influencing the sperm retrieval rate of microdissection testicular sperm extraction in patients with nonmosaic Klinefelter syndrome. *Asian J Androl*. 2023 Nov 1;25(6):704-707. <https://doi.org/10.4103/aja2022124>. Epub 2023 Mar 31.
20. Kei-Ichiro Uemura , Toshiyuki Iwahata , Hisamitsu Ide , Akiyoshi Osaka , Ippei Hiramatsu , Kouhei Sugimoto , et al. . Preoperative testosterone and follicle stimulating hormone levels are important predictors for sperm retrieval by microdissection testicular sperm extraction in non-mosaic Klinefelter syndrome. *Andrologia*. 2022 Dec;54(11):e14588. <https://doi.org/10.1111/and.14588>. Epub 2022 Sep 13.
21. Burak Özkan , Enis Rauf Coşkuner , Tansu Güdelci . Predictive Factors and Intracytoplasmic Sperm Injection Results for Sperm Retrieval by Microdissection Testicular Sperm Extraction (micro-TESE) in Patients with Klinefelter Syndrome. *Urology*. 2022;16:59-64. <https://doi.org/10.1016/j.urology.2021.12.012>. Epub 2021 Dec 29.
22. EAU Guidelines On Sexual And Reproductive Health. A. Salonia (Chair), C. Bettocchi, P. Capogrosso, J. Carvalho, G. Corona, M. Dinkelman-Smit, G. Hatzichristodoulou, U T.H. Jones, A. Kadioglu, J.I. Martinez-Salamanca, S. Minhas (Vice-Chair), E.C. Serefoglu, P. Verze Guidelines Associates: L. Boeri, A. Cocci, M. Falcone, M. Gül, A. Kalkanli, L.A. Morgado, U. Milenkovic, G. Russo Guidelines Office: C. Bezuidenhout, Ej. Smith. European Association of Urology 2024
23. Koga M, Tsujimura A, Takeyama M, Kiuchi H, Takao T, Miyagawa Y, et al. Clinical comparison of successful and failed microdissection testicular sperm extraction in patients with nonmosaic Klinefelter syndrome. *Urology* 2007;70:341-5. <https://doi.org/10.1016/j.urology.2007.03.056>

Evaluation of the Impact of Body Mass Index on the Outcomes of Supine Percutaneous Nephrolithotomy

Ender Cem Bulut, Burak Elmas, Bora Küpeli

¹Department of Urology, Gazi University, School of Medicine, Ankara, Türkiye

Submitted: 2024-01-08

Accepted: 2024-04-30

Corresponding Author;

Ender Cem Bulut, MD

Emniyet mah. Gazi üniversitesi Tıp

Fakültesi Hastanesi, A Blok 12.Kat

Üroloji Anabilim Dalı

Yenimahalle/Ankara, Türkiye

E-mail: endercem@hotmail.com

ORCID

E.C.B. [0000-0002-5002-5471](https://orcid.org/0000-0002-5002-5471)

B.E. [0000-0003-0131-0740](https://orcid.org/0000-0003-0131-0740)

B.K. [0000-0003-0708-7535](https://orcid.org/0000-0003-0708-7535)

Abstract

Objective: This study aimed to evaluate the impact of obesity on the outcomes of supine percutaneous nephrolithotomy (PCNL) at a tertiary university hospital. Understanding surgical outcomes in obese patients, given their rising prevalence and urolithiasis risk, is crucial for optimizing treatment strategies.

Material and Methods: This retrospective study included data from 256 patients aged 18 and older who underwent PCNL in the Galdakao-Valdivia position between July 2021 and July 2024 at a tertiary care hospital. Patients were divided into three groups according to their body mass index (BMI): normal weight (BMI: 18-24.9 kg/m²), overweight (BMI: 25-29.9 kg/m²), and obese (BMI: 30-34.9 kg/m²). Demographic data, stone characteristics, operative time, fluoroscopy time, hospital stay, nephrostomy duration, stone free rates (SFR), and complications were analyzed and compared among the groups.

Results: No significant difference was found among the groups regarding age, sex, stone laterality, location, or size ($p>0.05$). Median BMI values were 23 (19-24), 27 (25-29.8) and 31.2 (30-34.7) for normal weight, overweight and obese groups, respectively. SFR were 79.2% (61), 77% (124), and 75% (18) for the normal, overweight, and obese groups, respectively ($p>0.05$). No significant differences were observed in operative time, fluoroscopy time, length of hospital stay, or nephrostomy duration between the groups ($p>0.05$). The rates of minor and major complications were similar among all groups ($p>0.05$).

Conclusion: Obesity does not appear to significantly impact the outcomes of supine PCNL, including operative time, SFR, or complication rates. These findings suggest that with experienced surgeons, supine PCNL is a reliable and efficient treatment option for obese patients, though further prospective studies are needed to confirm these results.

Keywords: supine percutaneous nephrolithotomy; kidney stone; obesity; body mass index

INTRODUCTION

Kidney stones are a common urological condition that significantly affect patients' health and quality of life.

Kidney stones can cause severe patient morbidity by leading to symptoms such as abdominal pain, infections, hydronephrosis, and decreased kidney function (1).

Cite; Bulut EC, Elmas B, Kupeli B. Evaluation of the Impact of Body Mass Index on the Outcomes of Supine Percutaneous Nephrolithotomy. New J Urol. 2024;19(3):121-128. doi: <https://doi.org/10.33719/nju1534944>

Percutaneous nephrolithotomy (PCNL) is a well-established, secure, and it is an efficient treatment method for kidney stones. It is now considered that preferred treatment for large kidney stones, widely recommended by American, European, and various national guidelines. (2-4). Kidney stone formation is influenced by both genetic and environmental risk factors. Gender, age, race, cardiovascular disease, diabetes, chronic kidney disease, hypertension, and obesity are all factors that increase the risk of kidney stone disease (5-7).

The prevalence of obesity has increased from 1% to 8% from 1975 to 2016 and is now described as an epidemic (8). The increasing prevalence of obesity, known as an independent risk factor for urinary stone formation, has resulted in a higher number of obese stone patients undergoing surgery (9). PCNL performed on obese patients presents challenges such as difficulty in precisely locating the stone with X-ray and ultrasound (US) due to increased skin-to-stone distance (SSD), loss of anatomical landmarks, and inadequate access sheath length. Additionally, PCNL in obese patients may result in longer operation times and higher retreatment rates (10-12). Moreover, surgical planning for these patients is often more challenging due to high morbidity from comorbidities such as diabetes, hypertension, coronary artery disease, atrial fibrillation, and heart failure (13).

This study aims to assess the effects of obesity on the outcomes of supine percutaneous nephrolithotomy (PCNL) at a tertiary university hospital.

MATERIAL AND METHODS

Data from 271 patients aged 18 and older who underwent PCNL in the Galdakao-Valdivia position at a tertiary care hospital between July 2021 and July 2024 were retrospectively analyzed. Patients under 18 years of age, those with abnormal bleeding parameters, active urinary tract infections, congenital kidney anomalies, incomplete data, or those lost to follow-up were excluded. The study included a total of 256 patients.

Three patient groups were formed according to the World Health Organization (WHO) Body Mass Index (BMI) classification: Group 1 included patients with normal BMI (BMI: 18-24.9 kg/m²); Group 2 consisted of overweight patients (BMI: 25-29.9 kg/m²); and Group 3 comprised obese patients (BMI: 30-34.9 kg/m²).

The age, gender, BMI, stone laterality, location and size, complications (according to the Clavien-Dindo classification), hospital stay duration, operative time, fluoroscopy time, nephrostomy time, and stone-free status were recorded. Stone size was recorded as the largest diameter observed in preoperative computed tomography (CT) scans. The total size of all stones was recorded for patients with multiple stones. Stone-free status was determined by the absence of residual fragments exceeding 4 mm in size. Patients who underwent endoscopic combined intrarenal surgery were not included in the study. The surgeries were performed after obtaining a sterile urine culture. Antibiotic treatment was administered for patients with positive preoperative urine cultures for 7-10 days on an outpatient or inpatient basis, according to the antibiogram results. Patients who could not achieve a sterile urine culture were operated on under antibiotic suppression as the Infectious Diseases and Clinical Microbiology department recommended.

After the decision to treat with PCNL based on the stone characteristics, preoperative blood tests, including complete blood count, renal function tests (serum urea, blood urea nitrogen, and creatinine), electrolytes, and coagulation tests were performed. Complete blood count and renal function tests were repeated within the first three hours postoperatively. Kidney-ureter-bladder radiography (KUB) imaging was performed on the patients on the first postoperative day.

Surgical Technique:

Following the acquisition of informed consent, the patient was transferred to the operating room. A 5 Fr ureteral catheter was placed into the ureter on the side of the stone in the Galdakao-modified Valdivia position, and the procedure continued in the same position. The renal collecting system was visualized using retrograde pyelography under fluoroscopic guidance. Calyceal access was obtained under scope guidance using an 18 Gauge and 20 centimeters access needle, through which a 0.035 inch hydrophilic guidewire was advanced. Access to the most appropriate calyx was obtained to ensure adequate lithotripsy and stone removal. Either a 30 Fr Amplatz dilator set (Actomed, Ankara, Turkey) or a Nephromax balloon dilator (Boston Scientific, MA, USA) with a calibration of 30 Fr was employed based on the surgeon's decision. To reduce radiation exposure for the operator and the patient, continuous scopy use was avoided, and pulse fluoroscopy (intermittent use) was applied. Once the collecting system was accessed using a

26 Fr rigid nephroscope (Karl Storz, Tuttlingen, Germany), the stones were fragmented with a pneumatic lithotripter (Vibrolith, Elmed, Turkey) and extracted using forceps. Following the surgery, a 4.7 Fr 28 cm DJ stent was inserted antegradely, and a 14 Fr nephrostomy tube was inserted in some patients depending on the surgeon’s preference. On the first postoperative day, if a nephrostomy tube was present, it was clamped and removed after 6 hours if there was no flank pain or leakage around the nephrostomy tube.

The stone-free status of the patients was assessed one month after surgery using KUB, US, or CT. If the patient was evaluated as stone-free postoperatively, further evaluation was conducted using either KUB or US, as preferred by the physician, in order to avoid additional radiation exposure. If there was a suspicion of clinically significant residual fragments or if further treatment was needed, the patient was evaluated with a CT scan.

This study received approval from the Ethics Committee of Gazi University on 30 July 2024, with an approval number of 1268.

Statistical Analysis:

The statistical analysis was conducted using SPSS software (Statistical Package for the Social Sciences, version 23, Armonk, NY, USA). The Chi-square test was employed to compare categorical data among groups., and the Kruskal-

Wallis test was employed for continuous variables. A p-value below 0.05 was considered indicative of statistical significance. The normality of the data distribution was assessed using the Kolmogorov-Smirnov test.

RESULTS

No statistically significant differences were observed between Groups 1, 2, and 3 regarding age, gender, stone laterality, location, or size (p=0.903, p=0.366, p=0.974, p=0.504, and p=0.191, respectively). The median BMI values for Groups 1, 2, and 3 were 23 (19-24), 27 (25-29.8), and 31.2 (30-34.7), respectively (Table 1).

The stone-free rates (SFR) for Groups 1, 2, and 3 were 61 (79.2%), 124 (77%), and 18 (75%), respectively. There were no statistically significant differences between the groups regarding SFR and median values for operative time, fluoroscopy time, hospital stay, and nephrostomy time (p=0.888, p=0.274, p=0.830, p=0.892, and p=0.772, respectively) (Table 2).

The number and rates of minor complications (Clavien 1-2) for Groups 1, 2, and 3 were 7 (9.1%), 13 (8.1%), and 3 (12.5%), respectively. The number and rates of major complications (Clavien 3-4) for Groups 1, 2, and 3 were 1 (1.3%), 2 (1.2%), and 1 (4.2%), respectively. There were no statistically significant differences in the complication rates between the groups (p=0.770) (Table 2).

Table 1. Demographic and Clinical Characteristics

Characteristics	Group 1 Normal Weight (BMI: 18-24,9 kg/m ²) (n:77)	Group 2 Over Weight (BMI: 25-29,9 kg/m ²) (n:161)	Group 3 Obese (BMI: 30-34,9 kg/m ²) (n:24)	P
Age (year) (median (min-max))	57 (18-82)	53 (19-79)	56.5 (33-86)	0.903
Gender				0.366
Male n(%)	44 (57.1%)	91 (56.5%)	10 (41.7%)	
Female n(%)	33 (42.9%)	70 (43.5%)	14 (58.3%)	
Side				0.974
Right n(%)	38 (49.4%)	82 (50.9%)	12 (50%)	
Left n(%)	39 (50.6%)	79 (49.1%)	12 (50%)	

Stone Location				0.504
Pelvis n(%)	46 (59.7%)	106 (65.8%)	12 (50%)	
Lower calyx n(%)	17 (22.1%)	18 (11.2%)	4 (16.7%)	
Middle calyx n(%)	3 (3.9%)	10 (6.2%)	3 (12.5%)	
Upper calyx n(%)	1 (1.3%)	5 (3.1%)	1 (4.2%)	
UP junction n(%)	5 (6.5%)	10 (6.2%)	2 (8.3%)	
Staghorn n(%)	4 (5.2%)	12 (7.5%)	2 (8.3%)	
Stone Size (mm) (median (min-max))	23 (8-46)	24 (9-62)	21.5 (10-38)	0.191
BMI (kg/m ²) (median (min-max))	23 (19-24)	27 (25-29.8)	31.2 (30-34.7)	<0.001

UP: Ureteropelvic, BMI: Body-Mass Index, min-max: minimum-maximum

Table 2. Comparison of the Groups According to Operation Outcomes

	Group 1 Normal Weight (BMI: 18-24.9 kg/m ²) (n:77)	Group 2 Over Weight (BMI: 25-29.9 kg/m ²) (n:161)	Group 3 Obese (BMI: 30-34.9 kg/m ²) (n:24)	P
Stone Free Rate n(%) (median (min-max))	61 (79.2%)	124 (77%)	18 (75%)	0.888
Fluoroscopy Time (second) (median (min-max))	24 (6-89)	26 (5-89)	28 (9-44)	0.830
Operative Time (minute) (median (min-max))	110 (70-190)	105 (70-180)	110 (90-160)	0.274
Hospital Stay (day) (median (min-max))	2 (1-6)	2 (1-14)	2 (1-7)	0.892
Nephrostomy Time (median (min-max))	2 (0-4)	1 (0-7)	2 (0-4)	0.772
Complication (Clavien-Dindo)				0.770
Minor Complication (Clavien 1-2)	7 (9.1%)	13 (8.1%)	3 (12.5%)	
Major Complication (Clavien 3-4)	1 (1.3%)	2 (1.2%)	1 (4.2%)	

min-max: minimum-maximum

DISCUSSION

Overweight, obese, and morbidly obese patients present significant challenges for both physicians and surgeons. This patient group frequently presents with multiple medical comorbidities, including cardiovascular, metabolic, and respiratory conditions, complicating the surgical management of any underlying pathologies (14, 15). Consequently, surgical procedures in these patients can be more complex, with a reduced likelihood of surgical success and higher complication rates (16, 17).

This complexity extends to the treatment of urinary stone disease in these patients. Due to the increased SSD in obese patients, ureteroscopy (URS) and PCNL are preferred over Extracorporeal Shock Wave Lithotripsy (ESWL) for treating kidney stones. Therefore, PCNL is the standard procedure for stones larger than 2 cm in obese patients (18).

In a study of 5,803 patients, Fuller et al. compared the PCNL outcomes between obese and non-obese groups and reported that the operative time was longer for obese

patients (11). Contrary to these findings, two separate studies by El-Assmy et al. and Carson et al. concluded that obesity did not affect operative time (19, 20). Similarly, in another study involving 1,152 patients, Dauw et al. reported that BMI did not influence operative time, even in patients with a BMI over 50 kg/m²(21). Slade et al., in their study examining the outcomes of mini-PCNL in obese patients, also reported that obesity did not prolong the operative time (22). Additionally, in different groups based on SSD, it was observed that long SSD did not extend operative time either (23). In our study, no significant differences were found between the groups regarding operative time or fluoroscopy time, particularly during critical stages of the procedure, such as access, stone control, and ureteral stent placement. These findings suggest that BMI may be a manageable factor for PCNL when performed by experienced surgeons.

In the study by Sergeyev et al., which evaluated normal, overweight, and obese patient groups, the length of hospital stay was higher in the normal-weight group. They attributed this difference to the prolonged hospital stay of two patients who had experienced pulmonary embolism and postoperative sepsis (24). However, studies evaluating the impact of obesity on PCNL outcomes have generally reported that body mass does not affect the length of hospital stay (10, 23, 25, 26). Our study's absence of differences in hospital stay duration among the weight groups further supports the idea that body mass may not influence outcomes in supine PCNL.

In the study by Burns et al., the SFR in the severely obese patient group (BMI: 35-39.9) was lower than in the normal, overweight, and obese groups. However, the authors suggested that this difference was due to the higher stone burden in severely obese patients (10). In obese patients, comorbid conditions such as diabetes and metabolic syndrome can lead to a decrease in urine pH and an increase in solute load, which in turn can result in a higher stone burden and a higher incidence of staghorn stones (11, 27). Therefore, inadequate surgical success in these patients may be attributed more to the stone burden rather than obesity itself. However, the high SFR achieved with the PCNL technique may limit the evaluation of obesity's impact on stone-free outcomes. In studies conducted by Iqbal et al. and Ferreira et al., no difference in SFRs was found between BMI groups, supported by other studies (24-26, 28). In the study by Slade et al., although there was a significant difference between groups (%84 vs. %67), the small number of patients in each group (33 vs. 34) rendered the difference statistically

insignificant. In this study, the sum of all stone diameters was higher in the obese group (22). In a meta-analysis of 18 studies by Xu et al., no difference in SFRs was observed between obese and normal BMI patient groups in all but one study. However, when the study with a large number of participants by Fuller et al. was included in the analysis, a difference emerged between the two groups (9). In Fuller et al.'s study, the incidence of staghorn stones in the morbidly obese group was 1.5 times higher than in the normal BMI group (40.2% vs 26%) (11). In our study, no difference in SFRs was found. Although a higher incidence of staghorn stones may be expected in obese patients, the absence of this finding in our study may have contributed to similar SFRs.

Since PCNL is performed under general anesthesia, obese patients may be at increased risk for intraoperative respiratory complications, which may require higher ventilation pressures. Additionally, they may encounter an increased risk of general postoperative complications such as wound infections, atelectasis, and thromboembolism (29). In the literature, the incidence of minor complications following PCNL ranges from 23% to 80%, while major complications occur at a rate of 1.1% to 7% (30). In a study by Burns et al., although they reported significantly fewer complications in the normal-weight patient group, they found no statistically significant difference, which they attributed to the small sample size in the study (10). Similarly, Ferreira et al. found a higher rate of significant complications (Clavien \geq 3) in obese patients, but again, no statistically significant difference was observed (26). Larger studies conducted by Fuller et al. and Dauw et al. reported no difference in overall complication rates (11, 21). However, Fuller et al. noted that while the rate of minor complications (Clavien 1-2) was lower in the morbidly obese group, the rate of significant complications (Clavien 3-5) was higher (11). El-Assmy et al. also found no difference in postoperative complication rates among obese patients (19). Iqbal et al. evaluated the Clavien grades individually across normal, overweight, and obese patient groups and found no differences in any of the grades from 1 to 5(25). Similarly, Slade et al. conducted the same comparison for mini-PCNL and found no significant differences (22). Although the rate of major complications was higher in the obese patient group, the difference was not statistically significant. The limited number of patients might have hindered an optimal evaluation of this finding.

The study has important limitations. The retrospective nature of our study represents one of the primary sources

of bias. The retrospective nature of the study may lead to incomplete or inaccurate data recording, as well as information gaps due to the lack of a standardized protocol. Additionally, there is a risk of selection bias, as the decision to not perform PCNL on certain patients was largely at the discretion of the researchers. Since the data was collected retrospectively, variations in pre-intervention characteristics among the patient groups may have been overlooked. Additionally, the small sample size might have prevented us from obtaining strong and reliable results from our analyses. Moreover, using non-standard equipment for dilation may have influenced the fluoroscopy time. Assessing stone size in just one dimension may not accurately reflect the total burden and represents a significant bias in this study. Using different imaging modalities to assess SFRs also reduces the reliability of these results. The power of KUB, USG, and CT in evaluating stone-free status may not be the same.

RESULTS

Our findings suggest that supine PCNL performed by experienced surgeons is a safe and effective treatment option for obese patients. However, given the retrospective design of our study and the limited sample size, these results should be validated through prospective studies with larger patient populations.

Conflict of Interest: The authors declare that they have no conflicts of interest.

Ethical Approval: This study received approval from the Ethics Committee of Gazi University on 30 July 2024, with an approval number of 1268.

Authors' Contribution: All authors reviewed and approved the final version of the manuscript.

Ender Cem Bulut, Bora Küpeli: Study Design. Ender Cem Bulut, Burak Elmas: Analysis. Ender Cem Bulut, Burak Elmas: Data Curation. Ender Cem Bulut, Burak Elmas, Bora Küpeli: Writing Manuscript (Original draft preparation) Ender Cem Bulut, Burak Elmas, Bora Küpeli: Literature Investigation.

REFERENCES

1. Wang W, Fan J, Huang G, Li J, Zhu X, Tian Y, et al. Prevalence of kidney stones in mainland China: a systematic review. *Scientific reports*. 2017;7(1):41630. <https://doi.org/10.1038/srep41630>

2. Seitz C, Desai M, Häcker A, Hakenberg OW, Liatsikos E, Nagele U, et al. Incidence, prevention, and management of complications following percutaneous nephrolitholapaxy. *European urology*. 2012;61(1):146-58. <https://doi.org/10.1016/j.eururo.2011.09.016>
3. Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, et al. Surgical management of stones: American urological association/endourological society guideline, PART I. *The Journal of urology*. 2016;196(4):1153-60. <https://doi.org/10.1016/j.juro.2016.05.090>
4. EAU. EAU Guidelines; Edn. presented at the EAU Annual Congress Paris 2024; EAU Guidelines Office: Arnhem, The Netherlands, 2024; ISBN 978-94-92671-23-3.
5. Jiang Y, He L, Luo G, Zhang X. Prevalence of kidney stones and associated risk factors in the Shunyi District of Beijing, China. *Hong Kong Medical Journal*. 2017;23(5):462. <https://doi.org/10.12809/hkmj164904>
6. Romero V, Akpınar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. *Reviews in urology*. 2010;12(2-3):e86.
7. Moe OW. Kidney stones: pathophysiology and medical management. *The lancet*. 2006;367(9507):333-44. [https://doi.org/10.1016/S0140-6736\(06\)68071-9](https://doi.org/10.1016/S0140-6736(06)68071-9)
8. Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, et al. The obesity transition: stages of the global epidemic. *The lancet Diabetes & endocrinology*. 2019;7(3):231-40. [https://doi.org/10.1016/S2213-8587\(19\)30026-9](https://doi.org/10.1016/S2213-8587(19)30026-9)
9. Xu Y, Huang X. Effect of body mass index on outcomes of percutaneous nephrolithotomy: a systematic review and meta-analysis. *Frontiers in Surgery*. 2022;9:922451. <https://doi.org/10.3389/fsurg.2022.922451>
10. Burns H, Ahmad N, Hendry J, Nalagatla S. Does body mass index impact the efficacy and complication rate of mini-percutaneous nephrolithotomy? *Journal of Clinical Urology*. 2021;14(2):120-4. <https://doi.org/10.1177/2051415820936887>
11. Fuller A, Razvi H, Denstedt JD, Nott L, Pearle M, Cauda F, et al. The CROES percutaneous nephrolithotomy global study: the influence of body mass index on outcome. *The Journal of urology*. 2012;188(1):138-44. <https://doi.org/10.1016/j.juro.2012.03.013>

12. Alyami FA, Skinner TA, Norman RW. Impact of body mass index on clinical outcomes associated with percutaneous nephrolithotomy. *Canadian Urological Association Journal*. 2013;7(3-4):E197. <https://doi.org/10.5489/cuaj.11229>
13. Apovian CM. Obesity: definition, comorbidities, causes, and burden. *Am J Manag Care*. 2016;22(7 Suppl):s176-85.
14. Neeland IJ, Poirier P, Després J-P. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. *Circulation*. 2018;137(13):1391-406. <https://doi.org/10.1161/CIRCULATIONAHA.117.029617>
15. Nasraway Jr SA, Albert M, Donnelly AM, Ruthazer R, Shikora SA, Saltzman E. Morbid obesity is an independent determinant of death among surgical critically ill patients. *Critical care medicine*. 2006;34(4):964-70. <https://doi.org/10.1097/01.CCM.0000205758.18891.70>
16. Unruh KR, Bastawrous AL, Kaplan JA, Moonka R, Rashidi L, Simianu VV. The impact of obesity on minimally invasive colorectal surgery: a report from the Surgical Care Outcomes Assessment Program collaborative. *The American Journal of Surgery*. 2021;221(6):1211-20. <https://doi.org/10.1016/j.amjsurg.2021.03.019>
17. Goyal A, Elminawy M, Kerezoudis P, Lu VM, Yolcu Y, Alvi MA, et al. Impact of obesity on outcomes following lumbar spine surgery: a systematic review and meta-analysis. *Clinical neurology and neurosurgery*. 2019;177:27-36. <https://doi.org/10.1016/j.clineuro.2018.12.012>
18. Thomas R, Cass AS. Extracorporeal shock wave lithotripsy in morbidly obese patients. *The Journal of urology*. 1993;150(1):30-2. [https://doi.org/10.1016/s0022-5347\(17\)35389-2](https://doi.org/10.1016/s0022-5347(17)35389-2)
19. El-Assmy AM, Shokeir AA, El-Nahas AR, Shoma AM, Eraky I, El-Kenawy MR, et al. Outcome of percutaneous nephrolithotomy: effect of body mass index. *European urology*. 2007;52(1):199-205. <https://doi.org/10.1016/j.eururo.2006.11.049>
20. Carson III CC, Danneberger JE, Weinerth JL. Percutaneous lithotripsy in morbid obesity. *The Journal of urology*. 1988;139(2):243-5. [https://doi.org/10.1016/s0022-5347\(17\)42375-5](https://doi.org/10.1016/s0022-5347(17)42375-5)
21. Dauw CA, Borofsky MS, York N, Lingeman JE. Percutaneous nephrolithotomy in the superobese: A comparison of outcomes based on body mass index. *Journal of endourology*. 2016;30(9):987-91. <https://doi.org/10.1089/end.2016.0437>
22. Slade A, Large T, Sahm E, Rivera M. Mini-percutaneous nephrolithotomy outcomes in the obese population: a retrospective review. *Journal of Endourology*. 2023;37(6):623-7. <https://doi.org/10.1089/end.2022.0749>
23. Gonulalan U, Akand M, Coban G, Cicek T, Kosan M, Goktas S, et al. Skin-to-stone distance has no impact on outcomes of percutaneous nephrolithotomy. *Urologia Internationalis*. 2014;92(4):444-8. <https://doi.org/10.1159/000356562>
24. Sergeev I, Koi PT, Jacobs SL, Godelman A, Hoenig DM. Outcome of percutaneous surgery stratified according to body mass index and kidney stone size. *Surgical Laparoscopy Endoscopy & Percutaneous Techniques*. 2007;17(3):179-83. <https://doi.org/10.1097/SLE.0b013e318051543d>
25. Iqbal N, Hasan A, Razzaq S, Rashid FS. Effect of Body Mass Index on complications and success rates of percutaneous nephrolithotomy-A tertiary care hospital experience. *Pakistan Journal of Medical Sciences*. 2022;38(8):2112. <https://doi.org/10.12669/pjms.38.8.3663>
26. Ferreira TAC, Dutra MMG, Vicentini FC, Szwarc M, Mota PKV, Eisner B, et al. Impact of obesity on outcomes of supine percutaneous nephrolithotomy. *Journal of Endourology*. 2020;34(12):1219-22. <https://doi.org/10.1089/end.2020.0576>
27. Ozgor F, Yanaral F, Savun M, Ozdemir H, Sarilar O, Binbay M. Comparison of STONE, CROES and Guy's nephrolithometry scoring systems for predicting stone-free status and complication rates after percutaneous nephrolithotomy in obese patients. *Urolithiasis*. 2018;46:471-7. <https://doi.org/10.1007/s00240-017-1003-0>
28. Bagrodia A, Gupta A, Raman JD, Bensalah K, Pearle MS, Lotan Y. Impact of body mass index on cost and clinical outcomes after percutaneous nephrostolithotomy. *Urology*. 2008;72(4):756-60. <https://doi.org/10.1016/j.urology.2008.06.054>
29. Calvert RC, Burgess NA. Urolithiasis and obesity: metabolic and technical considerations. *Current*

opinion in urology. 2005;15(2):113-7. <https://doi.org/10.1097/01.mou.0000160626.36236.22>

30. Öztürk H. Gastrointestinal system complications in percutaneous nephrolithotomy: a systematic review. *Journal of Endourology.* 2014;28(11):1256-67. <https://doi.org/10.1089/end.2014.0344>

Effect of Atomoxetine on Mouse Isolated Vas Deferens Contractility

Seçkin Engin, Mehmet Kağan Altınbaş

Department of Pharmacology, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Türkiye

Submitted: 2024-08-26

Accepted: 2024-10-29

Corresponding Author;

Seçkin Engin, PhD

Department of Pharmacology,
Faculty of Pharmacy, Karadeniz
Technical University, 61080,
Trabzon, Türkiye

E-mail: seckinengin@ktu.edu.tr

ORCID

S.E. [0000-0002-1982-7820](https://orcid.org/0000-0002-1982-7820)

M.K.A. [0009-0008-1125-0132](https://orcid.org/0009-0008-1125-0132)

Abstract

Objective: Atomoxetine (ATX), a selective noradrenaline re-uptake inhibitor, is a preferred drug with sufficient efficacy and favorable safety profile for the treatment of attention-deficit hyperactivity disorder. Ejaculatory dysfunctions have been reported in the patients receiving ATX as sexual side effects, of which underlying mechanisms are largely unknown. The present study aimed to investigate the effect of ATX on mouse isolated vas deferens (VD) contractility as a potential mechanism of ATX-induced ejaculatory dysfunction.

Material and Methods: Isolated organ bath studies were performed on prostatic parts of VD obtained from adult male Balb/c mice. The effect of ATX (10^{-6} , 10^{-5} , 3×10^{-5} and 10^{-4} M) on KCl (80 mM)-, phenylephrine (PhE, 3×10^{-4} M)-, adenosine 5'-triphosphate (ATP, 10^{-2} M)- and electrical field stimulation (EFS; 100 V, 64 Hz)-induced contractions of VD strips were evaluated in concentration dependent manner.

Results: ATX at 10^{-6} and 10^{-5} did not alter the contractile responses ($p > 0.05$), however, higher concentrations of ATX (3×10^{-5} or 10^{-4} M) significantly inhibited the KCl-, PhE-, ATP- and EFS-induced contractions of VD strips ($p < 0.05$).

Conclusion: The present study demonstrated for the first time that ATX decreased the contractile responses of mouse isolated VD concentration-dependently. Our results suggest that ejaculatory dysfunction might be related to the inhibitory effect of ATX on VD.

Keywords: atomoxetine, contraction, ejaculation, isolated organ bath, vas deferens

INTRODUCTION

Atomoxetine (ATX) was introduced in 2002 as the first approved non-stimulant drug available for the treatment of attention-deficit hyperactivity disorder (ADHD) in children, adolescents and adults (1). ATX is usually prescribed as second-line treatment option following the standard first-line therapy including stimulants such as methylphenidate and amphetamines (2). Mechanistically, ATX is a highly selective noradrenaline re-uptake inhibitor leading to increased synaptic availability of noradrenaline in the central nervous system, which consists of the main underlying mechanism

of its therapeutic effects in ADHD. ATX increases synaptic noradrenaline in multiple brain regions involved in attention, learning, memory, and adaptive response (3). Unlike stimulant drugs, ATX has also much lower affinity for various receptors such as serotonergic, cholinergic, histaminic, alpha-adrenergic and other transporters including the dopamine transporter. Thus, ATX is considered to have superiority because of its favorable safety profile with decreased adverse motor reactions and abuse liability, making it more preferred drug for the treatment of ADHD (4,5).

Vas deferens (VD) is a muscular tube connecting the epididymis to the ejaculatory duct to serve as a conduit conveying spermatozoa prior to ejaculation (6). Normal ejaculation primarily occur via the rhythmic contractions of VD tightly regulated by several neurotransmitters, receptors and signaling pathways (7). Among them, noradrenaline and adenosine 5'-triphosphate (ATP) coreleased from sympathetic nerve endings have been reported to be master regulators of VD contractions. In addition, VD is also innervated by cholinergic and non-adrenergic non-cholinergic nerves to modulate the contractility of VD (8-10). Dysregulation of VD contractility is associated with ejaculatory disorders manifested with a broad spectrum ranging from premature ejaculation to delayed ejaculation and anejaculation (10).

Recently, some reports have described ejaculatory dysfunctions including delayed or spontaneous ejaculation in the patients under ATX treatment (11-14). However, the exact mechanisms of ATX-related ejaculatory dysfunction have not been clearly defined yet. Thus, this study aimed to investigate whether ATX affects mouse isolated VD contractility in concentration-dependent manner as a potential mechanism of the reported ejaculatory dysfunction secondary to ATX treatment.

MATERIAL AND METHODS

Chemicals

Atomoxetine hydrochloride (ATX) was provided by Ali Raif Pharmaceuticals, Türkiye. Phenylephrine hydrochloride (PhE) and ATP were purchased Sigma-Aldrich (St. Louis, MO, USA). Stock solutions of ATX, PhE and ATP were freshly prepared in distilled water and then the drugs were serially diluted in distilled water to the required concentrations prior to the administration for contractility studies. This study was approved by the Karadeniz Technical University Rectorate Animal Experiments Local Ethics Committee (Date: 15.09.2023 Protocol: 2023/32).

Animals

A total of 20 male BALB/c mice (25–35 g) supplied by Surgical Application and Research Center of Karadeniz Technical University (Trabzon, Türkiye) were used. Animals were housed in cages maintained at constant conditions ($22 \pm 3^\circ\text{C}$, $55 \pm 5\%$ humidity) with a 12-hour light-dark cycle and ad libitum access to standard pellets and water. All experimental procedures were approved by Institutional Animal Care and Use Committee (approval number, 2023/32) and performed in compliance with the Guide for the Care and Use of

Laboratory Animals.

Contractility Studies

Mice were sacrificed by cervical dislocation, and pairs of VD were excised and immediately placed in a petri dish with Krebs solution containing 118 mM NaCl, 4.7 mM KCl, 1.2 mM NaH_2PO_4 , 1.3 mM MgSO_4 , 2.5 mM CaCl_2 , 25 mM NaHCO_3 and 11 mM glucose. The surrounding connective tissue was removed and then prostatic portions of VD were cut into strips (length, 1 cm, each). Two prostatic VD strips were prepared from each mouse. The strips were suspended longitudinally in 10-30 mL isolated tissue bath containing Krebs solution constantly bubbled with 95% O_2 /5% CO_2 at 37°C . Each strip was preloaded to a resting tension of 1 g and equilibrated for 60 min with fresh replacement of the bath solution every 20 min. Isometric contractions were measured with a force displacement transducer (FDT-10A MAYCOM-Ankara, Türkiye) and recorded using a data acquisition system a (Biopac MP 35 System; Biopac, Santa Barbara, CA, USA). At the end of the equilibration period, the strips were challenged with KCl (80 mM) to test tissue viability. After that, the strips were subjected to experimental protocols based on previous studies with minor modifications (15-17). Each experimental protocol was performed in separate sets of VD strips. 1-) To investigate the effect of ATX on KCl-induced contractions, the strips initially contracted by KCl (80 mM) to obtain control response. Then, the strips were preincubated with ATX (10^{-6} , 10^{-5} , 3×10^{-5} or 10^{-4} M) for 20 min and KCl-induced contractile response was repeated. 2-) To assess the effect of ATX on the adrenergic contractile responses, PhE (3×10^{-4} M) -induced contractions of the strips were obtained before and after ATX (10^{-6} , 10^{-5} , 3×10^{-5} or 10^{-4} M) preincubation for 20 min. 3-) In order to examine the effect of ATX on the purinergic contractile responses, ATP (10^{-2} M)-induced contractions of the strips were obtained with or without ATX (10^{-6} , 10^{-5} or 10^{-4} M) preincubation for 20 min. 4-) To test the effect of ATX on neurogenic contractions, electrical field stimulation (EFS) was applied in strips placed between two parallel platinum electrodes connected to a stimulator (ST95 PT, Commat, Ankara, Türkiye). EFS (100 V, pulse duration 0.2 msec, 64 Hz)-induced contractile responses of the strips were obtained before and after ATX (10^{-6} , 10^{-5} , 3×10^{-5} or 10^{-4} M) preincubation for 20 min. Contraction was expressed as the percentage of control or KCl-induced contractile response.

Statistical Analysis

Data were expressed as means \pm standard error of the mean (SEM). The maximum responses (E_{max}) to contractile agents

were calculated and indicated as the percentages of control or KCl-induced responses. Data were analysed and graphs were generated with GraphPad Prism 5.01 (GraphPad Software, USA). Data were normally distributed according to the Kolmogorov–Smirnov test. Statistical comparisons were performed using ANOVA, followed by Bonferroni multiple comparison test. $P < 0.05$ was considered statistically significant.

RESULTS

Preincubation with ATX at 10^{-6} and 10^{-5} M did not alter KCl-induced contractile response ($p > 0.05$). However, ATX at 3×10^{-5} M ($E_{\max} = 38.95 \pm 10.59\%$) and 10^{-4} M ($E_{\max} = 4.14 \pm 1.35\%$) caused a significant ($p < 0.001$) decrease in KCl-induced contractions of VD strips compared to the control response (Table 1, Figure 1A and 1B).

While preincubation with ATX at 10^{-6} and 10^{-5} M have no effect, ATX at 3×10^{-5} M ($E_{\max} = 45.04 \pm 7.38\%$) and 10^{-4} M ($E_{\max} = 12.06 \pm 2.91\%$) significantly ($p < 0.01$) decreased the PhE-induced contractions of VD strips compared to control response (Table 2, Figure 2A and 2B).

Preincubation with ATX at 10^{-4} M ($E_{\max} = 4.98 \pm 2.21\%$) markedly ($p < 0.01$) decreased the ATP-induced contractions of VD strips and lower concentrations of ATX did not induce any changes compared to the control ($E_{\max} = 32.72 \pm 4.26\%$) (Table 3, Figure 3A and 3B).

Preincubation with ATX at 10^{-6} and 10^{-5} M did not alter EFS-induced contractions ($p > 0.05$). However, ATX at 3×10^{-5} M ($E_{\max} = 36.61 \pm 5.67\%$) and 10^{-4} M ($E_{\max} = 5.47 \pm 1.45\%$) significantly ($p < 0.001$) decreased the EFS-induced contractions of VD strips compared to the control response (Table 4, Figure 4A and 4B).

Table 1. E_{\max} values of KCl-induced contractions of mouse isolated VD strips.

	E_{\max} (%)	n
Control	100±00.00	3
ATX (10^{-6} M)	104.80±5.93	3
ATX (10^{-5} M)	77.88±5.76	3
ATX (3×10^{-5} M)	38.95±10.59***	4
ATX (10^{-4} M)	4.14±1.35***	3

Data were expressed as mean \pm SEM ($n = 3-4$). ***significantly different from control at $p < 0.001$ determined by one-way ANOVA followed by Bonferroni's multiple comparisons test. ATX, atomoxetine. E_{\max} , maximal contraction evoked by

KCl. VD, vas deferens. n indicates number of independent experiments.

Table 2. E_{\max} values of PhE-induced contractions of mouse isolated VD strips.

	E_{\max} (%)	n
Control	100±00.00	3
ATX (10^{-6} M)	109.00±10.97	3
ATX (10^{-5} M)	73.95±8.71	4
ATX (3×10^{-5} M)	45.04±7.38***	3
ATX (10^{-4} M)	12.06±2.91***	3

Data were expressed as mean \pm SEM ($n = 3-4$). ** $p < 0.01$, *** $p < 0.001$ significantly different from control determined by one-way ANOVA followed by Bonferroni's multiple comparisons test. ATX, atomoxetine. E_{\max} , maximal contraction evoked by PhE. PhE, phenylephrine. VD, vas deferens. n indicates number of independent experiments.

Table 3. E_{\max} values of ATP-induced contractions of mouse isolated VD strips.

	E_{\max} (%)	n
Control	32.72±4.26	3
ATX (10^{-6} M)	31.21±2.87	3
ATX (10^{-5} M)	28.70±5.09	3
ATX (10^{-4} M)	4.98±2.21**	3

Data were expressed as mean \pm SEM ($n = 3$). **significantly different from control at $p < 0.01$ determined by one-way ANOVA followed by Bonferroni's multiple comparisons test. ATX, atomoxetine. E_{\max} , maximal contraction evoked by ATP. VD, vas deferens. n indicates number of independent experiments.

Table 4. E_{\max} values of EFS-induced contractions of mouse isolated VD strips.

	E_{\max} (%)	n
Control	100±00.00	3
ATX (10^{-6} M)	106.10±11.00	3
ATX (10^{-5} M)	88.29±6.45	3
ATX (3×10^{-5} M)	36.61±5.67***	3
ATX (10^{-4} M)	5.47±1.45***	3

Data were expressed as mean \pm SEM ($n = 3$). ***significantly different from control at $p < 0.001$ determined by one-way ANOVA followed by Bonferroni's multiple comparisons test. ATX, atomoxetine. EFS, electrical field stimulation. E_{\max} , maximal contraction evoked by EFS. VD, vas deferens. n indicates number of independent experiments.




Figure 1. Effect of ATX on the KCl-induced contractions of mouse isolated VD strips. (A) Representative original traces of KCl-induced contractions and (B) KCl-induced maximum contractions of VD strips the absence (control) and presence of ATX (10^{-6} , 10^{-5} , 3×10^{-5} or 10^{-4} M). Data were expressed as mean \pm SEM (n = 3-4). ***p < 0.001 significantly different from the control; and #p < 0.05, ***p < 0.001 as indicated. ATX, atomoxetine. VD, vas deferens.




Figure 2. Effect of ATX on the PhE-induced contractions of mouse isolated VD strips. (A) Representative original traces of PhE-induced contractions and (B) PhE-induced maximum contractions of VD strips the absence (control) and presence of ATX (10^{-6} , 10^{-5} , 3×10^{-5} or 10^{-4} M). Data were expressed as mean \pm SEM (n = 3-4). ** p < 0.01, *** p < 0.001 significantly different from the control; and #p < 0.01, ***p < 0.001 as indicated. ATX, atomoxetine. VD, vas deferens.




Figure 3. Effect of ATX on the ATP-induced contractions of mouse isolated VD strips. (A) Representative original traces of ATP-induced contractions and (B) ATP-induced maximum contractions of VD strips the absence (control) and presence of ATX (10^{-6} , 10^{-5} or 10^{-4} M). Data were expressed as mean \pm SEM (n = 3). **p < 0.01 significantly different from the control; and *p < 0.05, ##p < 0.01 as indicated. ATP, adenosine 5'-triphosphate. ATX, atomoxetine. VD, vas deferens.




Figure 4. Effect of ATX on the EFS-induced contractions of mouse isolated VD strips. (A) Representative original traces of EFS-induced contractions and (B) EFS-induced maximum contractions of VD strips the absence (control) and presence of ATX (10^{-6} , 10^{-5} , 3×10^{-5} or 10^{-4} M). Data were expressed as mean \pm SEM (n = 3). ***p < 0.001 significantly different from the control; and ##p < 0.01, ###p < 0.001 as indicated. ATX, atomoxetine. EFS, electrical field stimulation. VD, vas deferens.

DISCUSSION

ATX is the first non-stimulant drug used for the treatment of ADHD. It works by enhancing the noradrenergic input via the inhibition of norepinephrine re-uptake selectively in central nervous system. ATX is thought to have little or no affinity for other transporters and receptors, making it safer than the stimulant drugs approved for ADHD (1,3). ATX is accepted as a well-tolerated drug with a very low incidence of serious side effects. Common side effects of ATX are generally mild to moderate, including abdominal pain, decreased appetite, nausea, vomiting and somnolence (3,18). ATX is rarely associated with sexual side effects. However, erectile dysfunction, dysmenorrhea, delayed ejaculation, spontaneous ejaculation and decreased libido have been reported in the adults receiving ATX (11,19). It is speculated that ATX leads to noradrenergic potentiation and thus decreased ejaculatory latency, causing spontaneous ejaculation (13,20). However, the exact molecular mechanisms of ATX-induced ejaculatory dysfunction are not clear. Therefore, the present study aimed to investigate the effect of ATX on mouse isolated VD contractility concentration-dependently.

The VD is a tube of smooth muscle, which contributes to ejaculation as a convey to transport sperm from the epididymides to the ejaculatory ducts (6). Until now, various neurotransmitters have been shown to regulate the contractility of VD and thus mediate normal ejaculation (7). Noradrenaline and ATP are main transmitters coreleased from sympathetic nerve terminals to induce contractions in VD upon stimulation of post-synaptic α 1-adrenoceptor and purinergic P2X1 receptors, respectively (8,9). Noradrenaline activates postsynaptic α 1-adrenoceptor coupled with phospholipase C to produce inositol (1,4,5) triphosphate that stimulates Ca^{2+} release from the sarcoplasmic reticulum, subsequently results in smooth muscle contraction of VD (7,9). ATP evokes contraction in VD by activating purinergic P2X1 receptors, leading to extracellular Ca^{2+} influx through voltage-sensitive calcium channels (8,9). Also, EFS of VD is well-known to induce a contraction depend on the neuronal release of noradrenaline and ATP from sympathetic nerve terminals (7).

In the present study, we found that ATX at 3×10^{-5} and 10^{-4} M significantly decreased KCl-induced contraction of VD strips. High K^+ polarizes the plasma membrane of smooth muscle cells, thereby opening the L-type voltage-dependent Ca^{2+} channels, resulting in Ca^{2+} influx and subsequent contraction. Our result suggests that the inhibitory of ATX

on KCl-induced contraction of VD might be related to the blockade of L-type voltage-dependent Ca^{2+} channels by ATX. In addition, ATX at 3×10^{-5} and 10^{-4} M markedly diminished the contractile response-induced by PhE, an adrenergic receptor agonist. This result demonstrates that ATX might be able to block the adrenergic receptors directly or interfere with the signal transduction associated with adrenergic receptor stimulation. Moreover, we showed that ATX at 10^{-4} M caused a significant decrease in ATP-induced contractions of VD strips, indicating the possible blockade of purinergic P2X1 receptors or L-type voltage-dependent Ca^{2+} channels by ATX. EFS-induced contraction of VD was also drastically decreased by ATX at 3×10^{-5} and 10^{-4} M, which may be related to the inhibition of the release noradrenaline and/or ATP, or blockade of postsynaptic receptors by ATX. In addition to the functional studies, molecular studies are required to identify the exact mechanism of ATX on ion channels and receptors mediating VD contractility, including patch clamp technique and receptor binding assays.

CONCLUSIONS

The present study provides the first evidence that KCl-, PhE, ATP-, and EFS-induced contractions of VD strips were significantly attenuated by ATX. Our results suggest that the inhibitory effect of ATX on VD contractility might be potential mechanism of delayed ejaculation. Further studies could be performed to investigate the effect of ATX on the contractile responses induced by other agents like dopamine and serotonin. A possibility to be speculate is that ATX could influence central regulation of ejaculation, leading to spontaneous ejaculation. More studies are needed to clarify the mechanism of ejaculatory dysfunction secondary to ATX.

Acknowledgments

This study was supported by a grant from TUBITAK Research Project Support Programme for Undergraduate Students (2209-A 2023/1, Project no. 1919B012306489).

Ethics Committee Report: Karadeniz Technical University Rectorate Animal Experiments Local Ethics Committee. Date: 15.09.2023 Protocol: 2023/32.

REFERENCES

1. Veronesi GF, Gabellone A, Tomlinson A, Solmi M, Correll CU, Cortese S. Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults. *Neurosci Biobehav Rev.* 2024;163:105774. <https://doi.org/10.1016/j.neubi.2024.105774>

- doi.org/10.1016/j.neubiorev.2024.105774
2. Mechler K, Banaschewski T, Hohmann S, Häge A. Evidence-based pharmacological treatment options for ADHD in children and adolescents. *Pharmacol Ther.* 2022;230:107940. <https://doi.org/10.1016/j.pharmthera.2021.107940>
 3. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. *Paediatr Drugs.* 2009;11(3):203-226. <https://doi.org/10.2165/00148581-200911030-00005>
 4. Kohn MR, Tsang TW, Clarke SD. Efficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder. *Clin Med Insights Pediatr.* 2012;6:95-162. <https://doi.org/10.4137/CMPed.S78>
 5. Groom MJ, Cortese S. Current Pharmacological Treatments for ADHD. *Curr Top Behav Neurosci.* 2022;57:19-50. https://doi.org/10.1007/7854_2022_330
 6. Steers WD. Physiology of the vas deferens. *World J Urol.* 1994;12(5):281-285. <https://doi.org/10.1007/BF00191208>
 7. Clement P, Giuliano F. Physiology and Pharmacology of Ejaculation. *Basic Clin Pharmacol Toxicol.* 2016;119 Suppl 3:18-25. <https://doi.org/10.1111/bcpt.1254>
 8. Burnstock G. Purinergic cotransmission. *F1000 Biol Rep.* 2009;1:46. [https://doi.org/10.1016/S0361-9230\(99\)00103-3](https://doi.org/10.1016/S0361-9230(99)00103-3)
 9. Michel MC. Alpha1-adrenoceptors and ejaculatory function. *Br J Pharmacol.* 2007;152(3):289-290. <https://doi.org/10.1038/sj.bjp.0707369>
 10. Koslov DS, Andersson KE. Physiological and pharmacological aspects of the vas deferens-an update. *Front Pharmacol.* 2013;4:101. <https://doi.org/10.3389/fphar.2013.00101>
 11. Camporeale A, Day KA, Ruff D, Arsenault J, Williams D, Kelsey DK. Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. *Drug Saf.* 2013;36(8):663-671. <https://doi.org/10.1007/s40264-013-0074-2>
 12. MacDonald T, Wimalaguna PS, Akosile W. Case report: Severe and treatment-resistant spontaneous ejaculation secondary to atomoxetine. *Australas Psychiatry.* 2019;27(2):198-199. <https://doi.org/10.1177/1039856218815>
 13. Rizvi A, Srinivas S, Jain S. Spontaneous Ejaculation Associated With Atomoxetine. *Prim Care Companion CNS Disord.* 2022;24(3):21cr03136. <https://doi.org/10.4088/PCC.21cr03136>.
 14. Yaylacı F, Şahbudak B, Küçük Ö. Spontaneous Ejaculation Induced with Atomoxetine. *Psychopharmacol Bull.* 2020;50(1):40-43.
 15. Gur S, Sikka SC, Knight GE, Burnstock G, Hellstrom WJ. Purinergic contraction of the rat vas deferens in L-NAME-induced hypertension: effect of sildenafil. *Asian J Androl.* 2010;12(3):415-421. <https://doi.org/10.1038/aja.2009.70>
 16. Tanyeri MH, Büyükokuroğlu ME, Tanyeri P, Keleş R, Başarır Bozkurt ŞN, Mutlu O, Akar F, Erden BF, Ulak G. Chronic Effects of Loxapine, Iloperidone, Paliperidone on Mice Isolated Vas Deferens Contractility. *OTJHS.* March 2022;7(1):40-46. <https://doi.org/10.26453/otjhs.987184>
 17. Banks FC, Knight GE, Calvert RC, Thompson CS, Morgan RJ, Burnstock G. The purinergic component of human vas deferens contraction. *Fertil Steril.* 2006;85(4):932-939. <https://doi.org/10.1016/j.fertnstert.2005.09.024>
 18. Reed VA, Buitelaar JK, Anand E, et al. The safety of atomoxetine for the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder: A comprehensive review of over a decade of research. *CNS Drugs.* 2016;30(7):603-628. <https://doi.org/10.1007/s40263-016-0349-0>
 19. McGrane IR, Campbell TJ. Probable genitourinary adverse events associated with atomoxetine in an adult male: A case report. *J Pharm Pract.* 2021;34(6):962-965. <https://doi.org/10.1177/0897190020953022>
 20. Sivrioglu EY, Topaloglu VC, Sarandol A, Akkaya C, Eker SS, Kirli S. Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition. *Prog Neuropsychopharmacol Biol Psychiatry.* 2007;31(2):548-550. <https://doi.org/10.1016/j.pnpbp.2006.10.006>

Factors Affecting Biochemical Recurrence After Radical Prostatectomy and Validity of CAPRA Score in Predicting Biochemical Recurrence

Yusuf Arıkan¹, Berat Aydın Enginler¹, Enes Dumanlı¹, Deniz Noyan Özlü², Buşra Emir³, Mehmet Zeynel Keskin¹

¹ Izmir Tepecik Training and Research Hospital, Department of Urology, Izmir, Türkiye

² Bitlis State Hospital, Department of Urology, Bitlis, Türkiye

³ Izmir Katip Celebi University Faculty of Medicine, Department of Biostatistics, Izmir, Türkiye

Submitted: 2024-09-02

Accepted: 2024-10-16

Corresponding Author;

Yusuf Arıkan, MD

Izmir Tepecik Training and
Research Hospital, Department of
Urology, Izmir, Türkiye

E-mail: dryusufarikan@gmail.com

ORCID

Y.A. [0000-0003-0823-7400](https://orcid.org/0000-0003-0823-7400)

B.A.E. [0000-0002-9993-0501](https://orcid.org/0000-0002-9993-0501)

E.D. [0009-0001-5305-477X](https://orcid.org/0009-0001-5305-477X)

D.N.Ö. [0000-0003-2435-5482](https://orcid.org/0000-0003-2435-5482)

B.E. [0000-0003-4694-1319](https://orcid.org/0000-0003-4694-1319)

M.Z.K. [0000-0002-9206-5586](https://orcid.org/0000-0002-9206-5586)

Abstract

Objective: Biochemical recurrence (BCR) after prostate cancer (PCa) treatment is undesirable. It is important to inform a patient about BCR in preoperative evaluation. We aimed to demonstrate the effectiveness of the (The Prostate Cancer Risk Assessment) CAPRA score used to predict this situation in our study.

Material and Methods: The study included 348 patients who underwent Radical Prostatectomy (RP) for localized PCa. Demographic, preoperative and postoperative data were collected. CAPRA score based on preoperative total PSA value, Gleason Score, clinical T stage, percentage of positive biopsy cores and age was calculated using these data. BCR was defined as a total PSA value >0.2 ng/dL for two consecutive times after RP. Follow-up periods, recurrence status and time of recurrence were recorded.

Results: BCR positivity was detected in 60 (17.2%) of 348 patients. In univariate analyses, PSA level, lesion volume on MRI, ISUP grade, D'Amico risk classification, Seminal vesicle invasion (SVI) and CAPRA score were statistically significant in the groups. In multivariate analyses, PSA level, Neutrophile Lymphocyte Ratio, lesion dimension, intermediate risk according to D'Amico classification, Extraprostatic extension (EPE) showed differences between both groups. The probability of biochemical progression-free in CAPRA risk groups shows a significant decrease in the probability of biochemical progression-free in the long term as risk increases in CAPRA risk groups: 91.4% in the low-risk group, 77.8% in the intermediate-risk group and only 61.7% in the high-risk group at 80-month follow-up.

Conclusion: CAPRA scoring system should be supported by MpmMRI findings and a new nomogram should be developed with these findings.

Keywords: CAPRA score, radical prostatectomy, biochemical recurrence, prostate cancer

Cite; Arıkan Y, Aydın B, Dumanlı E, Özlü DN, Emir B, Keskin MZ. Factors Affecting Biochemical Recurrence After Radical Prostatectomy and Validity of CAPRA Score in Predicting Biochemical Recurrence. New J Urol. 2024;19(3):136-144. doi: <https://doi.org/10.33719/nju1540186>

INTRODUCTION

Prostate cancer (PCa) remains one of the most common malignancies affecting men worldwide (1). Despite advances in diagnostic and treatment strategies, predicting disease progression, particularly biochemical recurrence (BCR), remains a clinical challenge. BCR of PCa is defined as an increase in prostate-specific antigen (PSA) levels following primary treatment, such as radical prostatectomy (RP) or radiation therapy, indicating potential disease progression (2). Accurate prediction of BCR is crucial for timely intervention and management (3). The Prostate Cancer Risk Assessment (CAPRA) score developed by the University of California, San Francisco (UCSF) has emerged as a crucial tool in stratifying risk and predicting outcomes for patients with PCa (4). Higher scores indicate a higher risk of recurrence and a worse prognosis (4). This article examines the utility of the CAPRA score in predicting BCR after treatment.

MATERIAL AND METHODS

The study included 348 patients who underwent RP between 2015 and 2022 for localized PCa. Local ethics committee approval was obtained and the study was conducted according to the Declaration of Helsinki Declaration of Human Rights. Patients who were diagnosed with localized PCa, underwent RP operation and were followed up regularly for BCR were included in our study. Patients diagnosed with metastatic PCa, patients with pathologic lymph node metastases, patients receiving neo-adjuvant hormone therapy or radio-chemotherapy, and patients without regular follow-up were excluded. Age, Body Mass Index (BMI), American Society of Anesthesiologists (ASA) score demographic data, preoperative laboratory tests (neutrophils, lymphocytes, platelets, monocytes, AST, ALT) preoperative total PSA value, prostate volume, PSA density data were recorded. Each patient underwent 3.0 Tesla multiparametric magnetic resonance imaging (mpMRI) for local staging. The size of the lesion, Prostate Imaging-Reporting and Data System (PIRADS) score, lesion volume were recorded. Lesion density was calculated by dividing the lesion size by the lesion volume. PCa was diagnosed by transrectal USG-guided and/or MR fusion-guided biopsy. The positive core rate and International Society of Urological Pathology (ISUP) grade were evaluated and patients were classified according to the D'Amico classification in terms of risk.

CAPRA Scoring was based on preoperative total PSA value, GS pattern, clinical T stage, percentage of positive

biopsy cores and age (5). Patients whose CAPRA score was calculated between 0-10 according to the values in these parameters were defined as low risk between 0- 2 points, intermediate risk between 3-5 points, and high risk with a score of 6 and above (5). The need for lymph node dissection was calculated for each patient according to the Briganti nomogram in the preoperative period and bilateral extended lymph node dissection was performed in addition to RP in patients with $>5\%$ according to the nomogram (6). In pathological evaluation, T stage, nodal involvement, tumor percentage, Extraprostatic extension (EPE) status, Seminal vesicle invasion (SVI), ISUP grade data were recorded. Upgrade status was evaluated according to preoperative and postoperative ISUP pathology results. PSA was evaluated 4-6 weeks after RP and total PSA was evaluated every 3 months for the first two years and then every 6 months for up to 5 years. BCR was defined as a total PSA value >0.2 ng/dL for two consecutive times after RP (7). Follow-up periods, recurrence status and time of recurrence were recorded.

Statistical Analysis

Data analyses were performed using IBM SPSS Statistics for Windows version 24.0 (IBM Corp., Armonk, NY, USA). Distribution of continuous variables was assessed by Shapiro-Wilk's test. Continuous variables are presented as mean and standard deviation (SD) or median (1st-3rd interquartile ranges (IQR)). Categorical variables were presented as number and frequencies. Mann-Whitney *U* tests were used for comparing the continuous variables based on the distribution. *Chi-square* test (Pearson Chi-Square) was used to compare the categorical variables. The performances of the CAPRA score groups and to predict the BCR-free probability were examined by Cox proportional hazards regression (Backward Wald method) and Kaplan-Meier analysis. A significance level of $p < 0.05$ was considered statistically significant.

RESULTS

In our study, BCR positivity was detected in 60 (17.2%) of 348 patients. When BCR (-) and BCR (+) patients were compared, no difference was detected between age, BMI, ASA scores among demographic data. In the preoperative laboratory evaluation, there was no difference in Neutrophil, Lymphocyte, Platelet, Monocyte, AST, ALT values, but PSA value was statistically higher in the BCR (+) group ($p < 0.001$). There was no difference between LMR, PLR, De-Ritis ratio in laboratory-based ratios, while NLR was statistically higher

in the BCR (+) group (p:0.006). Demographic and laboratory data of the patients are given in Table 1.

In terms of preoperative MpMRI, PIRADS scores, lesion size and volume were higher in the group with BCR (+) (p<0.001). EPE was 19.4% vs 31.7% (p:0.036) and SVI was 8.3% vs 23.3% (p:0.002) in BCR (-) and (+) groups, respectively. In the biopsy results of the patients, ISUP grade was higher in BCR (+) patients. In the D’Amico classification of the patients according to PSA and biopsy results, high-risk patients were 13.2% in the BCR (-) group and 40% in the BCR (+) group (p<0.001). In postoperative pathology results, EPE, SVI rate and ISUP grade were higher in BCR (+) patients (p<0.001). The MpMRI and pathologic data of the patients are shown in Table 2.

In univariate analyses, PSA level, NLR, lesion volume on MpMRI, ISUP grade, D’Amico risk classification, SVI on

MpMRI and pathologic specimen and CAPRA score were statistically significant in the group with and without BCR. In multivariate analyses, PSA level, NLR, lesion dimension, intermediate risk according to D’Amico classification, EPE on MpMRI and pathology results showed differences between both groups. Univariate and multivariate analysis results are shown in Table 3.

The probability of biochemical progression-free in CAPRA risk groups shows a significant decrease in the probability of biochemical progression-free in the long term as risk increases in CAPRA risk groups: 91.4% in the low-risk group, 77.8% in the intermediate-risk group and only 61.7% in the high-risk group at 80-month follow-up. The data of patients with biochemical progression-free disease according to CAPRA scores and the respective hazard ratios by CAPRA groups are listed in Table 4 and shown as a Kaplan-Meier curve in Figure 1.

Table 1. Demographic and clinical features of the patients

	All patients (n=348)	BCR (-) (n=288)	BCR (+) (n=60)	p value
Age (year)	62.29±5.97	62.12±5.93	63.12±6.14	0.187
BMI (kg/m ²)	26.47±2.48	26.49±2.60	26.38±1.87	0.932
ASA (n /%)				0.305
1	33 (9.5)	27 (9.4)	6 (10.0)	
2	299 (85.9)	250 (86.8)	49 (81.7)	
3	16 (4.6)	11 (3.8)	5 (8.3)	
PSA (ng/dL)	10.20±8.54	9.22±6.92	14.94±12.98	<0.001
PSAD	0.26±0.24	0.23±0.24	0.36±0.26	<0.001
PV (cc)	46.01±19.06	46.45±19.68	43.88±15.73	0.721
Neutrophil (×10 ³ per µl)	5.02±4.47	4.84±3.45	5.92±7.66	0.119
Lymphocyte (×10 ³ per µl)	2.51±2.13	2.50±1.79	2.58±3.33	0.084
Platelet (×10 ³ per µl)	248.36±66.49	251.20±69.31	234.75±49.00	0.103
Monocyte (×10 ³ per µl)	0.68±0.38	0.67±0.23	0.71±0.76	0.246
AST (IU/L)	23.46±9.96	23.62±10.15	22.71±9.03	0.296
ALT (IU/L)	24.08±13.34	24.48±13.86	22.14±10.36	0.414
NLR	2.24±1.22	2.14±0.99	2.70±1.91	0.006
PLR	115.83±52.09	114.13±46.24	123.95±73.98	0.415
MLR	0.32±0.39	0.30±0.13	0.43±0.90	0.587
De Ritis Ratio	1.11±0.62	1.11±0.66	1.11±0.34	0.416
Percentage of positive correlation in biopsy	0.35±0.21	0.34±0.21	0.40±0.22	0.052

Table 2. Data of MpMRI and Pathology results of the groups

	All patients (n=348)	BCR(-) (n=288)	BCR (+) (n=60)	p value
	n (%)	n (%)	n (%)	
PIRADS Score (n /%)				<0.001
2	83 (23.9)	74 (25.7) ^a	9 (15.0) ^a	
3	49 (14.1)	45 (15.6) ^a	4 (6.7) ^a	
4	159 (45.7)	134 (46.5) ^a	25 (41.7) ^a	
5	57 (16.4)	35 (12.2) ^a	22 (36.7) ^b	
Lesion Diameter (mm)	10.08±8.74	9.51±8.59	12.83±9.01	0.001
Lesion Volume (mm ³)	440.02±1157.56	323.50±621.55	999.33±2370.02	<0.001
Total Lesion Density	11.57±34.69	8.11±17.04	28.17±73.73	0.001
EPE on MpMRI (n /%)				0.036
(-)	273 (78.4)	232 (80.6) ^a	41 (68.3) ^b	
(+)	75 (21.6)	56 (19.4) ^a	19 (31.7)	
SVI on MpMRI (n /%)				0.002
(-)	310 (89.1)	264 (91.7) ^a	46 (76.7) ^b	
(+)	38 (10.9)	24 (8.3) ^a	14 (23.3) ^b	
BX ISUP (n /%)				<0.001
1	169 (48.6)	155 (53.8) ^a	14 (23.3) ^b	
2	118 (33.9)	92 (31.9) ^a	26 (43.3) ^a	
3	36 (10.3)	26 (9.0) ^a	10 (16.7) ^a	
4	20 (5.7)	11 (3.8) ^a	9 (15.0) ^b	
5	5 (1.4)	4 (1.4) ^a	1 (1.7) ^a	
D'Amico Risk classification (n /%)				<0.001
Low	121 (42.0)	127 (36.5) ^b	6 (10) ^b	
Intermediate	133 (46.2)	167 (48.0) ^a	34 (56.7) ^a	
High	34 (11.8)	54 (15.5) ^a	20 (33.3) ^a	
CAPRA Score (n /%)				<0.001
0-2 (Low Risk)	123 (35.3)	118 (41.0) ^a	5 (8.3) ^b	
3-5 (Intermediate Risk)	163 (46.8)	132 (45.8) ^a	31 (51.7) ^a	
≥6 (High Risk)	62 (17.8)	38 (13.2) ^a	24 (40.0) ^b	
Upgrade (n /%)				0.570
(-)	174 (50.0)	142 (49.3)	32 (53.3)	
(+)	174 (50.0)	146 (50.7)	28 (46.7)	
EPE (n /%)				<0.001
(-)	260 (74.7)	228 (79.1) ^a	32 (53.3) ^b	
(+)	88 (25.3)	60 (20.9) ^a	28 (46.7)	
SVI (n /%)				<0.001
(-)	298 (85.6)	258 (89.5) ^a	40 (66.6) ^b	
(+)	50 (14.4)	30 (10.5) ^a	20 (33.3) ^b	
Pathology ISUP (n /%)				<0.001
1	66 (18.7)	65 (22.3) ^a	1 (1.7) ^b	
2	154 (44.3)	139 (48.3) ^a	15 (25.0) ^b	
3	88 (25.3)	62 (21.5) ^a	26 (43.3) ^b	

4	16 (4.6)	11 (3.8) ^a	5 (8.3) ^a	
5	24 (6.9)	11 (3.8) ^a	13 (21.7) ^b	
Percent tumor involment	22.37±18.88	19.19±15.76	37.67±24.54	<0.001


Table 3. Risk factors affecting BCR with univariate and multivariate analysis results

Variables	Univariate		Multivariate	
	HR (95 % CI)	p value	HR (95 % CI)	p value
PSA	1.028 (1.005-1.051)	0.016	1.051 (1.021-1.083)	< 0.001
PSAD	1.274 (0.623-2.605)	0.507	---	---
NLR	1.182 (1.055-1.324)	0.004	1.158 (1.030-1.302)	0.014
Lesion Diameter	1.020 (0.998-1.042)	0.075	1.000 (1.000-1.000)	0.002
Lesion Volume	1.000 (1.000-1.000)	0.005	---	---
BX ISUP				
1	1 (Ref.)			
2	3.155 (1.644-6.057)	< 0.001	---	---
3	3.730 (1.653-8.415)	0.002		
4	2.607 (1.115-6.093)	0.027		
5	1.207 (0.158-9.246)	0.856		
D'Amico Risk classification				
Low	1 (Ref.)		1 (Ref.)	
Intermediate	5.316 (2.225-12.698)	< 0.001	3.618 (1.480-8.844)	0.005
High	3.008 (1.173-7.713)	0.022	0.915 (0.287-2.917)	0.881
PIRADS Score				
2	1 (Ref.)	0.078		
3	0.623 (0.192-2.026)	0.431	---	---
4	1.228 (0.572-2.636)	0.599		
5	2.026 (0.922-4.455)	0.079		
SV on MpMRI				
(-)	1 (Ref.)		---	---
(+)	2.251 (1.228-4.127)	0.009	---	---
EPE on MpMRI				
(-)	1 (Ref.)		1 (Ref.)	---
(+)	1.231 (0.713-2.127)	0.456	0.279 (0.131-0.592)	< 0.001
CAPRA Score				
0-2 low	1 (Ref.)			
3-5 intermediate	4.328 (1.680-11.150)	0.002	---	---
≥6 high	5.234 (1.977-13.856)	< 0.001		
SVI				
(-)	1 (Ref.)		---	---
(+)	1.748 (1.428-3.827)	0.008	---	---
EPE				
(-)	1 (Ref.)	0.456	1 (Ref.)	---
(+)	1.693 (0.601-3.612)		0.179 (0.091-0.637)	< 0.001

HR Hazard Ratio, CI Confidence Interval

Table 4. BCR free probabilities for CAPRA score groups

Score/Risk level	HR (95 % CI)	p value	BCR free probability (95% CI)
CAPRA Score			
0-2 low	1 (Ref.)	0.004	91.41 (80.70-100.00)
3-5 intermediate	4.328 (1.680-11.150)	0.002	77.80 (69.81-85.79)
≥6 high	5.234 (1.977-13.856)	<0.001	61.71 (50.43-72.98)

**Figure 1.** Probability of BCR-free survival of CAPRA risk groups according to Kaplan-Meier survival analysis

DISCUSSION

BCR after RP is the condition that can be encountered in clinical practice due to heterogeneity in prostate cancer. In patients with localized PCa, BCR with post-treatment PSA follow-up is the main predictor of additional treatment (8). Following RP, approximately 20-50% of patients develop BCR within 10 years and BCR is associated with an increased need for secondary treatment, which may negatively affect quality of life (9-10).

BCR depends on many factors such as local staging of the disease on MpMRI, preoperative and postoperative pathology results (11-14). In our study, BCR was determined as PSA, NLR, lesion volume, biopsy ISUP grade, D'amico risk classification, SVI on MpMRI, CAPRA score and SVI on pathologic specimen in univariate analyses while PSA, NLR, Lesion Diameter, being in the intermediate risk class in

D'Amico risk classification, EPE on MpMRI and pathology specimen were determined as risk factors in multivariate analyses.

Recently, laboratory-based studies have tried to predict BCR. The most frequently emphasized ratio in these studies is NLR (15). In the study conducted by Minardi et al.(15), NLR>3 was found to be a risk factor for BCR. Similarly, Jang et al. (16) showed in their study that high postoperative NLR was significantly associated with decreased biochemical recurrence-free survival and overall survival. In our study, NLR was found to be one of the factors affecting BCR. We did not set any cut-off value for NLR in our study, but NLR was found to be higher in patients who developed BCR.

Preoperative MpMRI not only provides clinical staging, but also aids in better anatomic control and higher surgical

success (17). Improved strategies for predicting BCR in PCa are increasingly being evaluated in pathologic studies; however, there have been few studies using MRI-based features to noninvasively predict BCR (18-20). Findings such as lesion volume/percentage, EPE and SVI on MpMRI have been identified as risk factors for BCR (12). Manceau et al. (18) emphasized that MpMRI has a very important role in predicting BCR and should be performed preoperatively in every patient. Sademan et al. (19) reported that MpMRI has the ability to predict BCR after RP and a new nomogram can be developed by adding MR data to the scoring systems. Copogrosso et al. (20), on the contrary, did not find any correlation between BCR and MpMRI findings. Contradictory findings in the literature on this subject draw attention. In our study, PIRADS score, lesion size and volume were higher in patients with BCR (+) groups among MpMRI findings. In addition, EPE and SVI were more common in patients with BCR (+) groups. In multivariate analysis of these data, lesion size was found to be statistically significant. As in the study of Sademan et al., we suggest that a new nomogram that predicts BCR should be developed using MpMRI data.

Since there are many factors affecting BCR, nomograms have been developed and it has been aimed to predict the BCR rate (21,22). One of these nomograms is CAPRA scoring. In this scoring system, which ranges from 0 to 10 points and risk classification is determined according to the score obtained, Cooperberg et al. found biochemical recurrence-free survival in the low (0-2 points), intermediate (3-5 points) and high (6 points) groups to be approximately 90%, 65% and 25% in 5 years, respectively (4,21). In the cohort of 2670 patients of Punnen et al. (23), the recurrence-free probability at 5 years was 62%, 39% and 17% lower compared to Cooperberg's first study. May et al. (24) evaluated 3- and 5-year recurrence rates in high-risk patients in their study on CAPRA score and found RFS rates of 44% and 31%. Budäus et al. (25) reported 5-year RFS rates of 95.4% in low-risk patients, 82% in intermediate-risk patients and 63.1% in high-risk patients. In our study, CAPRA score was statistically higher in patients with BCR (+) groups. Low risk, intermediate risk and high risk percentages were 8.3%, 51.7% and 40%, respectively, in patients with BCR (+) groups. CAPRA score was also a factor affecting BCR in univariate analyses. In addition, BCR free probabilities were 91.4%, 77.8%, 61.7% in low, intermediate and high risk patients with CAPRA score, respectively.

There are some limitations in our study. The limitations of our study are firstly, the retrospective design, secondly, the

shorter follow-up period compared to other studies, and thirdly, the small number of patients.

CONCLUSION

The development of BCR after primary treatment in patients with localized PCa necessitates additional treatment. Therefore, factors affecting BCR can be identified and recurrence can be predicted. The CAPRA score is a nomogram developed to predict BCR. We can state that the CAPRA scoring system should be supported by MpMRI findings (Lesion diameter and volume, EPE) and a new nomogram should be developed with these findings.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

Consent to participate: For this type of retrospective study, formal consent is not required.

Experimental-Informed Consent: Written informed consent was obtained from patients who participated in this study.

No artificial intelligence program was used in our article.

Inform of publication: The results of the study were not published in full or in part in the form of an abstract.

Authors Contribution: Conception: YA, ED, BAE, Design: YA, MZK, Supervision: DNO, MZK, BE, Data Collection: YA, ED, BEA, Analysis: BE, Literature Review: YA, DNÖ, Writer: YA, ED, Critical Review: MZK, BE, DNÖ

Ethics Committee Approval: Ethics committee approval was received for this study from the ethics committee of Health Science University Izmir Tepecik Training and Research Hospital Decision No: 2024/07-17 Date: 19/08/2024.

Research involving human participants and/or animals:

This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were by the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

REFERENCES

1. Van den Broeck T, van den Bergh RCN, Arfi N, et al, Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. *Eur Urol.* 2019;75(6):967-987. <https://doi.org/10.1016/j.eururo.2018.10.011>. Epub 2018 Oct 17.
2. Brockman JA, Alanee S, Vickers AJ, et al, Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. *Eur Urol.* 2015;67(6):1160-1167. <https://doi.org/10.1016/j.eururo.2014.09.019>. Epub 2014 Oct 6.
3. Artibani W, Porcaro AB, De Marco V, Cerruto MA, Siracusano S. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review. *Urol Int.* 2018;100(3):251-262. <https://doi.org/10.1159/000481438>. Epub 2017 Nov 21.
4. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. *Cancer.* 2011;117(22):5039-5046. <https://doi.org/10.1002/cncr.26169>
5. Meurs P, Galvin R, Fanning DM, Fahey T. Prognostic value of the CAPRA clinical prediction rule: a systematic review and meta-analysis. *BJU Int.* 2013;111(3):427-36. <https://doi.org/10.1111/j.1464-410X.2012.11400.x>. Epub 2012 Aug 9.
6. Briganti A, Abdollah F, Nini A, et al, Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. *Eur Urol.* 2012 Jun;61(6):1132-8. <https://doi.org/10.1016/j.eururo.2011.11.008>. Epub 2011 Nov 12.
7. Kim WT, Kim J, Kim WJ. How can we best manage biochemical failure after radical prostatectomy? *Investig Clin Urol.* 2022;63(6):592-601. <https://doi.org/10.4111/icu.20220294>.
8. Seo WI, Kang PM, Kang DI, Yoon JH, Kim W, Chung JI. Cancer of the Prostate Risk Assessment (CAPRA) Preoperative Score Versus Postoperative Score (CAPRA-S): ability to predict cancer progression and decision-making regarding adjuvant therapy after radical prostatectomy. *J Korean Med Sci.* 2014;29(9):1212-6. <https://doi.org/10.3346/jkms.2014.29.9.1212>. Epub 2014 Sep 2.
9. Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. *Prostate Cancer Prostatic Dis.* 2024;27(2):192-201. <https://doi.org/10.1038/s41391-023-00712-z>. Epub 2023 Sep 7.
10. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. *JAMA.* 2005 Jul 27;294(4):433-9. <https://doi.org/10.1001/jama.294.4.433>
11. Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. *Prostate Cancer Prostatic Dis.* 2024 Jun;27(2):192-201. <https://doi.org/10.1038/s41391-023-00712-z>. Epub 2023 Sep 7.
12. Duenweg SR, Bobholz SA, Barrett MJ, et al, T2-Weighted MRI Radiomic Features Predict Prostate Cancer Presence and Eventual Biochemical Recurrence. *Cancers (Basel).* 2023 Sep 6;15(18):4437. <https://doi.org/10.3390/cancers15184437>
13. Falagarino UG, Abbadi A, Remmers S, et al, Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy. *JAMA Netw Open.* 2023 Sep 5;6(9):e2332900. <https://doi.org/10.1001/jamanetworkopen.2023.32900>
14. Tilki D, Preisser F, Graefen M, Huland H, Pompe RS. External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. *Eur Urol.* 2019;75(6):896-900. <https://doi.org/10.1016/j.eururo.2019.03.016>. Epub 2019 Apr 5. PMID: 30955970.
15. Minardi D, Scartozzi M, Montesi L, et al, Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. *Springerplus.* 2015 Jun 12;4:255. <https://doi.org/10.1186/s40064-015-1036-1>
16. Jang WS, Cho KS, Kim MS, et al, The prognostic significance of postoperative neutrophil- to-lymphocyte ratio after radical prostatectomy for localized prostate cancer. *Oncotarget.* 2017 Feb 14;8(7):11778-11787. <https://doi.org/10.18632/oncotarget.14349>
17. Danacioglu YO, Turkay R, Yildiz O, et al, A Critical Analysis of the Magnetic Resonance Imaging Lesion

- Diameter Threshold for Adverse Pathology Features. Prague Med Rep. 2023;124(1):40-51. <https://doi.org/10.14712/23362936.2023.4>
18. Manceau C, Beauval JB, Lesourd M, Almeras C, Aziza R, Gautier JR, Loison G, Salin A, Tollon C, Soulié M, Malavaud B, Roumiguié M, Ploussard G. MRI Characteristics Accurately Predict Biochemical Recurrence after Radical Prostatectomy. J Clin Med. 2020 Nov 26;9(12):3841. <https://doi.org/10.3390/jcm9123841>
 19. Sandeman K, Eineluoto JT, Pohjonen J, et al, Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy. PLoS One. 2020 Jul 9;15(7):e0235779. <https://doi.org/10.1371/journal.pone.0235779>.
 20. Capogrosso P, Vertosick EA, Benfante NE, Sjoberg DD, Vickers AJ, Eastham JA. Can We Improve the Preoperative Prediction of Prostate Cancer Recurrence With Multiparametric MRI?. Clin Genitourin Cancer. 2019;17(4):e745-e750. <https://doi.org/10.1016/j.clgc.2019.03.022>
 21. Cooperberg MR, Pasta DJ, Elkin EP, et al, The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005 Jun;173(6):1938-42. <https://doi.org/10.1097/01.ju.0000158155.33890.e7>. Erratum in: J Urol. 2006;175(6):2369.
 22. Kutluhan MA, Ünal S, Özsoy E, et al, Evaluation of four pre-operative models for prediction of biochemical recurrence after radical prostatectomy in localised prostate cancer. Int J Clin Pract. 2021;75(10):e14682. <https://doi.org/10.1111/ijcp.14682>. Epub 2021 Aug 6.
 23. Punnen S, Freedland SJ, Presti JC Jr, et al. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2014;65(6):1171-1177. <https://doi.org/10.1016/j.eururo.2013.03.058>
 24. May M, Knoll N, Siegsmond M, et al, Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients. J Urol. 2007;178(5):1957-62; discussion 1962. <https://doi.org/10.1016/j.juro.2007.07.043>. Epub 2007 Sep 17.
 25. Budäus L, Isbarn H, Tennstedt P, et al, Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients. BJU Int. 2012;110(11):1714-20. <https://doi.org/10.1111/j.1464-410X.2012.11147.x>. Epub 2012 Apr 23.

Outcomes of Emergency Surgical Treatment for Penile Fractures: A Study on Suture Materials, Delayed Repair, and Postoperative Results

Süleyman Sağır¹, Ferhat Çelikkaleli², Müslüm Ergün³, Cüneyt Özden⁴, Mustafa Güler⁴, İzzettin Toktaş⁵

¹Department of Urology, Faculty of Medicine, Mardin Artuklu University, Mardin, Türkiye

²Mardin Training and Research Hospital, Mardin, Türkiye

³Department of Urology, Faculty of Medicine, İstanbul Atlas University, İstanbul, Türkiye

⁴Department of Urology, Ankara Bilkent City Hospital, Ankara, Türkiye

⁵Department of Public Health, Mardin Artuklu University, Mardin, Türkiye

Submitted: 2024-09-09

Accepted: 2024-10-22

Corresponding Author;

Süleyman Sağır, MD

Mardin Artuklu University, Faculty of Medicine, Department of Urology, 47200, Mardin, Türkiye

E-mail: dr.sagioglu414@gmail.com

ORCID

S.S. [0000-0001-5300-8071](https://orcid.org/0000-0001-5300-8071)

F.Ç. [0000-0002-4145-6923](https://orcid.org/0000-0002-4145-6923)

M.E. [0000-0002-7297-5785](https://orcid.org/0000-0002-7297-5785)

C.Ö. [0000-0003-0101-6904](https://orcid.org/0000-0003-0101-6904)

M.G. [0000-0001-5004-8756](https://orcid.org/0000-0001-5004-8756)

İ.T. [0000-0002-3616-9399](https://orcid.org/0000-0002-3616-9399)

Abstract

Objective: This study examines the impact of surgical timing and suture materials on postoperative outcomes in penile fracture patients, particularly focusing on the development of penile curvature (PC). Specifically, it focuses on the role of delayed surgical intervention in the development of PC.

Material and Methods: A retrospective analysis was conducted on 63 patients treated for penile fractures between 2015 and 2024. Data on the time to surgery, suture materials, and postoperative complications such as PC were collected.

Results: PC occurred in 27% of patients, with a significantly longer surgical delay in those with PC compared to those without. Suture material type (2-0 Prolene vs. 3-0 Vicryl) had no significant effect on PC or nodule formation.

Conclusion: Delayed surgical intervention is associated with an increased risk of PC. Early surgery is recommended to reduce complications, while suture material does not influence outcomes.

Keywords: penile fracture, surgical timing, penile curvature, suture materials, postoperative outcomes.

INTRODUCTION

Penile fracture (PF) is defined as the rupture of the tunica albuginea of the corpus cavernosum (1). This rupture occurs due to severe bending during an erect state, often resulting from vigorous vaginal penetration, anal intercourse, forceful manipulation, firearm injury, masturbation, or any other mechanical trauma (2, 3). In Europe and the United States, the most common cause of this injury is trauma during sexual intercourse (4).

Historically, in cases with a history of PF, conservative treatment methods such as penile splinting, compression, anti-inflammatory, antifibrinolytic, and analgesic medications were commonly preferred (5). However, these treatment methods often led to long-term complications, including painful erections, fibrotic penile lesions that interfere with erections, PC, arteriovenous fistula, infection, and erectile dysfunction (ED) (5). Due to the high rate of complications

Cite; Sağır S, Celikkaleli F, Ergun M, Ozden C, Guler M, Toktas I. Outcomes of Emergency Surgical Treatment for Penile Fractures: A Study on Suture Materials, Delayed Repair, and Postoperative Results. New J Urol. 2024;19(3):145-150. doi: <https://doi.org/10.33719/nju1545993>

and prolonged hospital stays, emergency surgical repair is now the preferred treatment method over conservative approaches (6, 7). Surgical treatment involves hematoma evacuation, penile exploration, and repair of the local defects in the tunica albuginea and urethra. Common postoperative complications include penile nodules (PN), lower urinary tract symptoms, ED, and PC. However, some studies have reported no impact of PF repair on the development of PC and ED. These studies, which advocate for emergency surgical repair, report lower complication rates (8).

Our study aims to make a significant contribution to the literature by comprehensively exploring the connection between the timing of surgical intervention and the incidence of PC in patients with PF. Specifically, we analyze how delays in surgical treatment may increase both the risk and the severity of PC development. In addition to the timing aspect, our research also investigates the role of different suture materials, such as 2-0 Prolene and 3-0 Vicryl, in influencing postoperative outcomes. By examining the combined effects of surgical delay and suture type, we aim to provide a clearer understanding of how these factors interact and their overall impact on minimizing long-term complications like penile curvature and nodule formation.

MATERIAL AND METHODS

Study Population

This cross-sectional, retrospective study was conducted on 63 patients who underwent surgery for PF between 2015 and 2024 at Ankara City Hospital and Mardin Training and Research Hospital. Ethical approval was obtained from the Gazi Yaşargil Training and Research Hospital, Health Sciences University, on June 7, 2024, with reference number 88. All patients provided informed consent for the study.

PC who agreed to participate in the study, had no loss of sexual performance (International Index of Erectile Function [IIEF] score > 25), attended the 6-month follow-up, and were reachable by phone were included. Patients with pre-existing PC, ED, Peyronie's disease, chronic comorbid conditions, alcoholism, or psychological disorders were excluded.

Procedure

All PF patients underwent surgery using a classic circumcision incision, where the penile skin was degloved, hematomas (if present) were evacuated, and necessary repairs were performed. Postoperative care included wound checks on the 10th day and a follow-up evaluation at 6 months post-surgery.

Data regarding age, defect size, marital status, fracture location, urethral injury, type of sutures used, and lower urinary tract symptoms were extracted from medical records and included in the survey. Additional data on the time from PF occurrence to surgical intervention and the presence of PC were also collected. PC was defined as penile curvature of 30° or more when erect. Measurements were evaluated using photographs of patients in the erect state, and the angle of curvature was determined for the patient using a goniometer.

Statistical Analysis

The statistical analysis was performed using IBM SPSS Statistics for Windows version 26.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics such as median (IQR: Interquartile range), number, and percentage were provided. The Kolmogorov-Smirnov test was used to assess the normal distribution of numerical data. The Mann-Whitney U test was applied for comparisons of quantitative data, while the Pearson Chi-Square and Fisher's Exact tests were used for categorical data comparisons. A p-value of < 0.05 was considered statistically significant.

RESULTS

In accordance with the inclusion and exclusion criteria, the study was conducted on 63 patients. Among these, 17 patients presented with PC, while 46 did not. There was no statistically significant difference between the two groups in terms of average age, height, weight, or Body Mass Index (BMI) ($p > 0.05$). The intervention time was nearly double in patients with PC [Median: 17(6) hours] compared to those without PC [Median: 10(5) hours], and this difference was statistically significant ($p < 0.001$) (Table 1). There was no statistically significant relationship between BMI and the presence of PC ($p = 0.439$) (Table 2), indicating that PC can occur independently of BMI.

The rupture site appeared to play a significant role in the development of PC, although the effect of ruptures in the right and left cavernosal bodies on PC was borderline significant ($p = 0.103$) (Table 2). No significant relationship was found between the direction of the rupture and the presence of PC ($p = 0.133$), though ventral ruptures seemed to pose a higher risk for developing PC. There was no statistically significant relationship between the presence of urethral injury and PC ($p = 0.061$), suggesting that urethral injury is not a determining factor in the development of PC (Table 2).

Among patients with nodules, 21.1% had PC, while 29.5%

of those without nodules had PC, indicating no significant difference in the development of PC based on the presence of nodules (Table 2). There was no significant difference in the presence of PC between patients who had 2-0 Prolene sutures and those who had 3-0 Vicryl sutures ($p=0.883$) (Table 2), suggesting that the type of suture material used is not a

determining factor for PC development. In patients where 2-0 Prolene sutures were used, 28.0% developed nodules, while 72.0% did not. Among those with 3-0 Vicryl sutures, 31.6% developed nodules, and 68.4% did not. There was no significant difference between the two groups regarding nodule formation ($p=0.762$) (Table 3).

Table 1. Evaluation of Penile Curvature Presence Based on Age and Anthropometric Measurements

	Curvature Present (n=17) Median (IQR)	Curvature Absent (n=46) Median (IQR)	P-value*
Intervention Time (Hours)	17 (6)	10 (5)	<0.001
Age	42 (13.5)	40 (24.25)	0.309
Height	171 (15)	166 (6.25)	0.087
Weight	75 (16)	78.5 (10.25)	0.963
BMI	27.70 (15.08)	27.70 (4.63)	0.394

IQR: Interquartile range

*: Statistical analysis was performed using the Mann-Whitney U test.

Table 2. Presence of Penile Curvature According to Deformity Characteristics in Penile Fracture

	Curvature Present n (%)	Curvature Absent n (%)	Total	P-value**
BMI				0.439
Normal	5 (41.7)	7 (58.3)	12	
Overweight	8 (22.9)	27 (77.1)	35	
Obese	4 (25.0)	12 (75.0)	16	
Rupture Site				0.103
Right Cavernous	6 (20.7)	25 (79.3)	31	
Left Cavernous	11 (39.3)	17 (60.7)	28	
Bilateral Cavernous	- (0.0)	4 (100.0)	4	
Rupture Direction				0.061
Ventral	14 (37.8)	23 (62.2)	37	
Ventrolateral	3 (13.0)	20 (87.0)	23	
Dorsolateral*	- (0.0)	2 (100.0)	2	
Dorsal*	- (0.0)	1 (100.0)	1	
Urethral Injury				1.000***
Present	1 (16.7)	5 (83.3)	6	
Absent	16 (28.1)	41 (71.9)	57	
Nodule Presence				0.486
Present	4 (21.1)	15 (78.9)	19	
Absent	13 (29.5)	31 (70.5)	44	
Suture Type				0.883
2-0 Prolen	7 (28.0)	18 (72.0)	25	
3-0 Vicril	10 (26.3)	28 (73.7)	38	

*Since the expected value in each cell was below 5, the data were combined and statistical analysis was performed.

Pearson Chi-Square and *Fisher's Exact tests were used for statistical analysis.

Table 3. Relationship Between Suture Type and Nodule Presence

Suture Type	Nodule Absent n (%)	Nodule Present n (%)	P-value*
2-0 Prolen	18 (72.0)	7 (28.0)	0.762
3-0 Vicryl	26 (68.4)	12 (31.6)	
Total	44 (69.8)	19 (30.2)	

*: Statistical analysis was performed using the Pearson Chi-Square test.

DISCUSSION

Our study was based upon the retrospective data of 63 patients who underwent emergency surgical treatment from the moment they presented to the hospital. All cases resulted from trauma during sexual intercourse. Emergency surgical intervention was performed after optimal conditions were ensured for all patients from the time of presentation. In the treatment of PF, which is one of the urgent urological conditions, the most effective approach is emergency surgical repair. However, postoperative complications such as ED, PN, PF, and painful erection are common in these patients (9). A study by Muentener et al. observed good results in 92% of patients who underwent surgery for PF. Emergency surgical intervention in patients with PF leads to excellent outcomes and is superior to non-surgical treatment (2). Other studies and guidelines also recommend emergency surgical intervention for PF treatment due to the early return to sexual activity and reduced morbidity (10).

Regan et al. observed that monofilament sutures are superior to Vicryl for penile nodules resulting from penile fractures (11). Niessen et al. compared poliglecaprone-25 and polyglactin-910, finding that poliglecaprone-25 resulted in less hypertrophic scar formation (12). Therefore, it is recommended to pay more attention to the type of suture used in the surgery of patients with penile fractures. We preferred to use Vicryl (NJ, USA) and Prolene (J&J, USA) for the repair of tunica albuginea tears. In our study, we did not find a statistically significant difference in terms of curvature and nodule formation between the types of sutures used ($p > 0.05$) (Table 3). Both types of sutures appeared to have similar effects on nodule development. This suggests that the choice of suture type does not make a significant difference in terms of nodule formation for surgeons.

In the study by Altan et al., postoperative penile necrosis

was observed in 7 out of 25 PF cases (28%) (13). Yilmaz et al. reported that 8 out of 53 PF patients (15%) had associated urethral rupture (14). The location of PF is generally transverse and unilateral (15). In our study, the most common type was right cavernous rupture ($n=31$, 49%), while bilateral cavernous rupture was the least common ($n=4$, 6%). The incidence of concomitant urethral rupture in the study by Fergany et al. was lower than 22% of their patients (16). In our cases, only six patients (9%) had complete urethral rupture, which was repaired simultaneously.

Several studies have reported that emergency surgical repair yields better long-term results compared to conservative treatments (17-19). In our study, the effect of delayed surgical repair on penile necrosis was statistically significant (Table 2). Wong et al. compared immediate and delayed surgical repair for PF and noted that the curvature in the immediate repair group was 1.8%, whereas it increased approximately threefold to 4.5% in the delayed group (20). Amer et al. reported an incidence of PC of about 2.7% after PF repair in their recent meta-analysis (21).

Dell et al. observed that 77.7% of patients had a post-operative curvature greater than 30° after tunica closure, and correction of cavernous body deviation was necessary (22). The reconstruction of the corporal bodies depends on the extent of the tunica tear. The optimal surgical treatment for PF is still debated, and the long-term quality of life outcomes of genital reconstructive surgery are still relevant in practice.

Various authors have reported different incisions for accessing the injury site, including circular degloving, inguinoscrotal, lateral, and midline incisions. In our patients, a degloving procedure was performed after a subcoronal incision, which we believe provided excellent exposure of the entire penis and urethra.

Limitations

The limitations of this study are evident. The retrospective nature may result in unrecognized biases. Firstly, all surgeries were performed at two high-volume centers, which may affect the results. Our data should be validated by future multicenter studies. Secondly, there was no control group with early intraoperative curvature correction to assess the effects on surgical and functional outcomes. Thirdly, recurrence of curvature, nodularity, postoperative erections, and penile length were reported by patients and not objectively verified with pharmacologically induced erections.

CONCLUSIONS

This study highlights the critical role of timely surgical intervention in reducing postoperative complications, particularly PC, following penile fractures. Our findings demonstrate that a significant delay in surgery markedly increases the risk of PC, emphasizing the importance of emergency surgical repair. Interestingly, the choice of suture material, whether 2-0 Prolene or 3-0 Vicryl, did not show a significant impact on the development of PC or postoperative nodule formation. This suggests that the timing of surgery, rather than the suture material, is the key determinant in postoperative outcomes.

Based on these results, the focus should shift toward minimizing delays in surgical intervention for penile fractures to improve patient prognosis. Early surgical repair not only reduces the risk of PC but also ensures better overall functional outcomes, including reduced rates of ED and other long-term complications. Our study contributes valuable insights into the management of penile fractures and supports existing recommendations favoring prompt surgical treatment. Further multicenter studies with larger patient cohorts could help validate these findings and solidify the surgical protocols for treating penile fractures.

Data Sharing Statement: It is not open to data sharing due to personal data.

Conflicts of Interest: Authors have no conflicts of interest. The authors have nothing to disclose.

Funding: No funding was used.

Conflict of Interest: The authors declare to have no conflicts of interest.

Financial Disclosure: The authors declared that this study has received no financial support.

Ethical Approval: Ethical approval was obtained from the Gazi Yaşargil Training and Research Hospital, Health Sciences University, on June 7, 2024, with reference number 88. The study protocol conformed to the ethical guidelines of the Helsinki Declaration.

Author Contributions: Conception and design of the study: S.S., F. C., Experimental protocols: S.S, M.E., Acquisition of data: S.S., M.E., F. C., C.Ö.,M.G., İ.T., Analysis, and

interpretation of data: S.S., M.E., F. C., İ.T. Drafting the article: S.S., U.S., Critical review: S.S., M.E., F. C., C.Ö.,M.G., İ.T., All authors read and approved the final version of the manuscript.

REFERENCES

1. Kominsky H, Beebe S, Shah N, et al. Surgical reconstruction for penile fracture: a systematic review. *Sexual Med J.* 2019;2:1-9. <https://doi.org/10.1089/end.2008.0596>
2. Muentener M. Long term experience with surgical and conservative treatment of penile fracture. *J Urol.* 2004;172:576-589. <https://doi.org/10.1097/01.ju.0000123641.48653.5d>
3. Shafi H, Ramaji A, Kasaeian A, et al. Report of 84 cases of penile fracture in Beheshti Hospital center. *J Mazandaran Univ Med Sci.* 2005;15:37-43.
4. Ateyah A, Mostafa T, Nasser TA, et al. Penile fracture: surgical repair and late effects on erectile function. *J Sex Med.* 2008;5:1496-1502. <https://doi.org/10.1111/j.1743-6109.2008.00740.x>
5. Jack GS, Garraway I, Reznichuk R, Rajfer J. Current treatment options for penile fractures. *Rev Urol.* 2004;6(3):114-120.
6. Mydlo J. Surgeon experience with penile fracture. *J Urol.* 2001;166:526. [https://doi.org/10.1016/S0022-5347\(05\)65831-3](https://doi.org/10.1016/S0022-5347(05)65831-3)
7. Zargooshi J. Penile fracture in Kermanshah, Iran: the long-term results of surgical treatment. *BJU Int.* 2002;89:890-897. <https://doi.org/10.1046/j.1464-410x.2002.02795.x>
8. Bolat M. Effects of penile fracture and its surgical treatment on psychosocial and sexual function. *Int J Impotence Res.* 2017;29:244-249. <https://doi.org/10.1038/ijir.2017.11>
9. Reise L. Mechanisms predisposing penile fracture and long-term outcomes on erectile and voiding functions. *Advances in Urol.* 2014;1-9. <https://doi.org/10.1155/2014/878132>
10. Ahmad A, Majzoub A, Canguven O, Raidh TA. Alteration in the etiology of penile fracture in the Middle East and Central Asia regions in the last decade; a literature review. *Urol Ann.* 2015;7:284-288. <https://doi.org/10.4103/0974-7796.152933>
11. Regan T. Comparison of Poliglecaprone-25 and Polyglactin-910 in cutaneous surgery. *Dermatol Surg.* 2013;39:1340-1344. <https://doi.org/10.1111/dsu.12248>

12. Niessen FB, Spauwen PH, Kon M. The role of suture material in hypertrophic scar formation: Monocryl vs Vicryl-rapid. *Ann Plast Surg.* 2000;39:254-260. <https://doi.org/10.1097/00000637-200009000-00009>
13. Altan M, Hazir B, Baltaci KE, et al. Long term complications of penile fracture repair: Erectile dysfunction and penile curvature. *Rev Int Androl.* 2022;20(2):116-120. <https://doi.org/10.1016/j.androl.2022.01.001>
14. Yilmaz H, Avci IE, Cinar NB, et al. Urethral rupture concomitant with penile fracture does not adversely affect functional outcomes. *Urologia.* 2023;90(3):553-558. <https://doi.org/10.1177/03915603221108505>
15. Chahal R, Gogoi NK, Sundaram SK, Weston PM. Corporal plication for penile curvature caused by Peyronie's disease: the patients' perspective. *BJU Int.* 2001;87:352-356. <https://doi.org/10.1046/j.1464-410x.2001.00142.x>
16. Fergany AF, Angermeier KW, Montague DK. Review of Cleveland Clinic experience with penile fracture. *Urology.* 1999;54:352-355. [https://doi.org/10.1016/S0090-4295\(99\)00231-5](https://doi.org/10.1016/S0090-4295(99)00231-5)
17. Muentener M, Suter S, Hauri D, Sulser T. Long-term experience with surgical and conservative treatment of penile fracture. *J Urol.* 2004;172:576-579. <https://doi.org/10.1097/01.ju.0000123641.48653.5d>
18. Yapanoglu T, Aksoy Y, Adanur S, et al. Seventeen years' experience of penile fracture: conservative vs. surgical treatment. *J Sex Med.* 2009;6:2058-2063. <https://doi.org/10.1111/j.1743-6109.2009.01309.x>
19. Gamal WM, Osman MM, Hammady A, et al. Penile fracture: long-term results of surgical and conservative management. *J Trauma.* 2011;71:491-493. <https://doi.org/10.1097/TA.0b013e3182225e4d>
20. Wong NC, Dason S, Bansal RK, et al. Can it wait? A systematic review of immediate vs. delayed surgical repair of penile fractures. *Can Urol Assoc J.* 2017;11:53-60. <https://doi.org/10.5489/cuaj.4017>
21. Amer T, Wilson R, Chlosta P, et al. Penile fracture: a meta-analysis. *Urol Int.* 2016;96:315-329. <https://doi.org/10.1159/000444710>
22. Dell'Atti L, Scarcella S, Tallè M, et al. Simultaneous curvature correction at the time of the penile fracture repair: surgical and functional outcomes. *Res Rep Urol.* 2019;11:105-110. <https://doi.org/10.2147/RRU.S198365>

Artificial Intelligence in Prostate Cancer Diagnosis

Adem Alcin, Asif Yildirim

Department of Urology, Istanbul Medeniyet University, School of Medicine, Istanbul, Türkiye

Submitted: 2024-09-29

Accepted: 2024-10-09

Corresponding Author;

Adem Alcin, MD

Esenevler Neighborhood, Filizler
Street, No:11/3 Umraniye/Istanbul,
Türkiye

E-mail: alcinadem33@gmail.com

ORCID

A.A. [0000-0002-5026-5168](https://orcid.org/0000-0002-5026-5168)

A.Y. [0000-0002-3386-971X](https://orcid.org/0000-0002-3386-971X)

Abstract

Prostate cancer (PCa) is a cancer with a broad spectrum of biological behavior and it is a heterogeneous nature. In order to prevent overdiagnosis and overtreatment, and to detect clinically significant PCa, standardized scoring and grading systems are used in imaging and pathological examinations. However, reproducibility and agreement between readers in these diagnostic stages, which require experience, are low. Promising results have been achieved by integrating artificial intelligence (AI)-based applications into the diagnosis and management of PCa. In radiological and pathological imaging, computer-aided diagnostic tools have increased clinical efficiency and achieved diagnostic accuracy comparable to that of experienced healthcare professionals. This review provides an overview of AI applications used in radiological imaging, prostate biopsy, and histopathological examination in the diagnosis of PCa.

INTRODUCTION

Prostate cancer (PCa), the second most frequently diagnosed cancer in men, and it is definitively diagnosed through histopathological evaluation (1). Prostate sampling is performed via targeted and/or systematic biopsy under transrectal ultrasonography (TRUS) guidance to confirm cancer suspicion, which arises from elevated prostate-specific antigen (PSA) levels or suspicious digital rectal examination findings. With the use of standardized Prostate Imaging Reporting and Data System (PI-RADS) scoring through multiparametric magnetic resonance imaging (MpMRI) of the prostate prior to biopsy, MRI-targeted biopsies (MRI-TB) have been applied, gaining importance in diagnosing clinically significant PCa (csPCa) (2). The Gleason score is determined based on the histological features observed in

tissue samples stained with hematoxylin and eosin (H&E), and grading is performed using the International Society of Urological Pathology (ISUP) grade grouping (3).

PCa has the widest biological behavior spectrum among urological cancers. It is mostly multifocal within the prostate gland, exhibiting a heterogeneous nature and a wide range of prognoses (4). The goal is to enhance diagnostic accuracy and csPCa detection rates while preventing unnecessary treatments and overdiagnosis. However, despite standardized pathological evaluation and supportive radiological imaging, there are some limitations. Interpreting MpMRI requires experience, and inter-radiologist agreement can vary (5). Due to the subjective nature of Gleason scoring and tumor heterogeneity, reproducibility between pathologists is

poor (6). The use of artificial intelligence (AI)-based tools is increasing to improve clinical efficiency and diagnostic performance by reducing variability in interpretations among radiologists and pathologists (7).

Machine learning (ML) is an AI system that can automatically learn in an unsupervised manner or through supervised data labeled by humans by creating mathematical algorithms. Deep learning (DL) is a subset of ML that uses artificial neural networks to mimic the human brain and can independently derive nonlinear relationships and features (8). The ability of AI in diagnostic evaluation has brought its use in image analysis into the practice of pathology and radiology.

In this study, we present a summary of the use of AI in radiological and pathological evaluation for the diagnosis of PCa.

MpMRI Interpretation and Artificial Intelligence

Prostate MpMRI is recommended by guidelines for the local staging of PCa. Additionally, by combining MRI images and suspicious lesions with ultrasonography (US), fusion biopsy can be performed, contributing to increased diagnostic efficiency (9). AI applications in MpMRI have improved diagnostic performance by reducing the workload of radiologists in prostate segmentation, lesion detection, and characterization (10).

Despite the increased use of MpMRI and improvements in radiologist interpretation accuracy, particularly after standardization with PI-RADS, there are still some limitations. Meta-analyses have found the pooled specificity of MpMRI for PCa detection to be 0.73. It has been reported that 5-30% of cancers go undetected and readers have a 25% error margin (11,12). Another limitation is the low reproducibility of reporting among radiologists. Inter-reader agreement is around 50%, while intra-reader agreement is 60-74% (13). The use of AI in radiology and computer-aided diagnosis (CAD) systems is expected to increase inter-reader agreement and improve PCa detection rates in MpMRI.

Radiomics is a library that enables the high-throughput analysis of quantitative radiological features in medical imaging and forms the foundation for AI use in PCa management (14). In MpMRI, ML preprocesses prostate images and performs segmentation. Lesions are detected and classified in the recorded prostate image. The PI-RADS classification generated through ML analysis, predominantly

based on T2-weighted and diffusion-weighted imaging (DWI) in MpMRI, is verified by an experienced radiologist. This can reduce the need for experienced radiologists and alleviate their workload. Additionally, AI can improve reproducibility between radiologists and be used as an independent reader. However, experienced radiologists are also needed to input verified data for AI training and to validate the results generated by AI. Another challenge that complicates AI learning is data heterogeneity arising from variations in MpMRI acquisition (15).

Clinical studies and meta-analyses have shown that AI can perform on par with radiologists in detecting PCa in MpMRI, particularly with CAD systems. The benefits of using AI in MpMRI extend beyond lesion detection. AI can provide information about tumor characterization and aggressiveness, significantly reducing the time radiologists spend interpreting images. In studies on prostate segmentation, a similarity coefficient of 0.88-0.93 was achieved between manual segmentation and AI-based segmentations (16,17). In a study on AI-based lesion detection in MpMRI, a sensitivity of 78% was found for index lesions with PI-RADS ≥ 3 . For less experienced radiologists, detection sensitivity for transitional zone lesions was 66.9%, while this rate increased to 83.8% with CAD. Moreover, with CAD assistance, the MRI reading time for experienced radiologists decreased from 3.5 minutes to 2.7 minutes, and for moderately experienced radiologists, it decreased from 6.3 minutes to 4.4 minutes (18). In a study by Song et al. with 195 patients, AI demonstrated an 87% sensitivity in lesion detection (19). In another study comparing histopathological diagnosis, AI detected the index lesion with 3.4% lower sensitivity and clinically significant lesions with 1.5% lower sensitivity than experienced radiologists (20). In a study with 364 patients, Le et al. found that AI showed 100% sensitivity and 76.9% specificity in distinguishing clinically significant and insignificant cancer (21). In a study by Giannini et al., prostate segmentation and lesion detection were performed in MRI images of 131 patients, divided into training and validation groups, using CAD, and verified with pathology. The CAD system did not classify any aggressive tumors as benign, and the area under the curve (AUC) was found to be 0.96 in the training arm and 0.81 in the validation arm (22). On the other hand, Mehrlivand et al., in a multicenter study involving nine radiologists with varying levels of experience, found that AI did not significantly improve the performance of less experienced radiologists and had no noticeable effect on inter-reader disagreement. However, a significantly higher sensitivity for transitional

zone lesions was detected for AI (23). In a recently conducted large multicenter study, AI demonstrated 94.3% sensitivity in predicting csPCa (24). These studies are promising for personalized disease management in PCa patients using automatic CAD systems.

Prostate Biopsy and Artificial Intelligence

With the incorporation of MpMRI into routine practice for PCa management, fusion MRI-TB is recommended to increase diagnostic accuracy when suspicious lesions are present (25). AI applications used in prostate segmentation and lesion detection in MpMRI can be automatically combined with TRUS images for biopsy, increasing the precision of targeted biopsies and making the process more feasible for radiologists and urologists (26).

For fusion MRI-TB, accurately combining the TRUS image with target lesions and localizing the biopsy needles is of critical importance. In a retrospective study by Mehrtash et al., the needle trajectory was labeled in 71 patients who underwent MRI-TB, and this data was used for AI learning. Validation was conducted on 21 patients who had not been seen by the AI. They achieved accuracy with an acceptable error of 0.98 degree in the needle trajectory (27). Wang et al. in their prospective randomized controlled study compared targeted 6-core biopsy with AI-assisted prostate ultrasound, systematic biopsy under TRUS guidance, and cognitive fusion MRI combined biopsy. In this multicenter study, the detection rate of PCa and csPCA was found to be higher in biopsies performed with AI-assisted prostate ultrasound guidance (28). Anas et al. achieved similar accuracy to offline segmentations by performing real-time prostate segmentation during MRI-TB using AI (29). Real-time prostate segmentation enhances the feasibility of the MRI-TB procedure. AI-assisted biopsy has also been used in nerve-sparing robot-assisted radical prostatectomy for locally advanced PCa. After the prostate is removed, the presence of tumors in the neurovascular bundle is evaluated using a three-dimensional automatic augmented reality system, and selective excisional biopsy is performed. The presence and location of lesions in the neurovascular bundle were correctly identified with 87.5% accuracy. This AI-based application may allow for nerve-sparing surgery in locally advanced disease without compromising oncological outcomes (30).

Histopathological Evaluation and Artificial Intelligence

The gold standard method for diagnosing PCa is histopathological examination, which relies on scoring

biopsy material according to the Gleason grading system. This method categorizes tumors into risk groups and provides information about prognosis. However, there is low inter-reader agreement in histopathological scoring systems for PCa diagnosis, similar to what is observed in MpMRI. Studies indicate that the rate of discordance among pathologists ranges from 30% to 53% (31). Instead of microscopic examination, digital histological images offer the possibility of evaluation through CAD tools in various settings, aiming to reduce workforce demands and increase efficiency (32).

The use of AI in digital pathology is primarily focused on the Gleason grading system. Studies involving AI have evaluated the agreement with pathologists and the sensitivity of the system. Arvanti et al. reported a sensitivity of 70% when classifying tissues as benign and Gleason grades 3-5 in the evaluation of tissue microarrays by AI. Moreover, the agreement between the AI model and pathologist interpretations was also found to be high (kappa, 0.71-0.75) (33). In a study where slide images of prostatectomy material were graded for Gleason scores using a developed DL method on 311 slides, a sensitivity of 70% was identified (34). Subsequently, Karimi et al. achieved 92% accuracy in distinguishing benign tissue from malignant tissue and 90% accuracy in differentiating low and high-risk Gleason grades using their designed DL method. In an evaluation using 5,759 biopsy samples from 1,243 patients, the AI model demonstrated superior performance with a kappa score of 0.854, compared to 15 pathologists (35).

Shao et al. evaluated an AI model that analyzes digital pathology images of 502 patients who underwent radical prostatectomy and did not receive additional treatment, all of whom had long follow-up periods. They compared this AI model to risk classification nomograms for predicting biochemical recurrence. The AI model reclassified 3.9% of patients who were classified as low-risk in conventional nomograms as high-risk, while 21.3% of patients classified as high-risk were reclassified as low-risk. The authors noted that having this information post-radical prostatectomy would lead to different treatment approaches and patient counseling (36). In a recent study, 1,279 slides obtained from prostate biopsies were digitized and validated for use in AI learning. The developed AI model was integrated into routine clinical practice for three years, serving as a second-read system for biopsy material in approximately 9,200 patients. The AI model demonstrated 96.7% specificity and 96.6% sensitivity in detecting PCa, while showing 82.1% specificity and 81.1%

sensitivity in distinguishing low-risk PCa from intermediate-high risk PCa (37). AI-based models used in Gleason grading, which is one of the most important prognostic factors in PCa, assist pathologists by improving diagnostic performance.

CONCLUSION

AI, that is increasingly being used and gaining importance in the diagnosis and management of PCa, shows promise in reducing the workload and increasing the efficiency of urologists, pathologists, and radiologists. Studies have shown that AI achieves similar success to radiologists in lesion detection during MpMRI interpretation, enhances the applicability of MRI-TB, and improves concordance among pathologists during histopathological examination. It may also help mitigate potential shortcomings of less experienced clinicians. With large-sample, standardized studies conducted through collaboration between healthcare professionals and technology developers, the effectiveness of AI in improved patient outcomes and personalized patient management in PCa should be clearly demonstrated.

REFERENCES

1. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. *Eur Urol*. 2020;77(1):38-52. <https://doi.org/10.1016/j.eururo.2019.08.005>
2. Schoots IG, Padhani AR, Rouvière O, Barentsz JO, Richenberg J. Analysis of Magnetic Resonance Imaging-directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis. *Eur Urol Oncol*. 2020;3(1):32-41. <https://doi.org/10.1016/j.euo.2019.10.001>
3. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. *Am J Surg Pathol*. 2016;40(2):244-52. <https://doi.org/10.1097/PAS.0000000000000530>
4. Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Grönberg H, Luo J, Visakorpi T, Rubin MA. The mutational landscape of prostate cancer. *Eur Urol*. 2013;64(4):567-76. <https://doi.org/10.1016/j.eururo.2013.05.029>
5. Rosenkrantz AB, Ginocchio LA, Cornfeld D, Froemming AT, Gupta RT, Turkbey B, Westphalen AC, Babb JS, Margolis DJ. Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. *Radiology*. 2016;280(3):793-804. <https://doi.org/10.1148/radiol.2016152542>
6. Egevad L, Ahmad AS, Algaba F, Berney DM, Boccon-Gibod L, Compérat E, Evans AJ, Griffiths D, Grobholz R, Kristiansen G, Langner C, Lopez-Beltran A, Montironi R, Moss S, Oliveira P, Vainer B, Varma M, Camparo P. Standardization of Gleason grading among 337 European pathologists. *Histopathology*. 2013;62(2):247-56. <https://doi.org/10.1111/his.12008>
7. Goldenberg SL, Nir G, Salcudean SE. A new era: artificial intelligence and machine learning in prostate cancer. *Nat Rev Urol*. 2019;16(7):391-403. <https://doi.org/10.1038/s41585-019-0193-3>
8. Sherafatmandjoo H, Safaei AA, Ghaderi F, Allameh F. Prostate cancer diagnosis based on multi-parametric MRI, clinical and pathological factors using deep learning. *Sci Rep*. 2024 Jun 28;14(1):14951. <https://doi.org/10.1038/s41598-024-65354-0>
9. Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A, Cirillo S, Regge D, Faletti R, Passera R, Fiori C, De Luca S. Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer. *Eur Urol*. 2017;72(2):282-288. <https://doi.org/10.1016/j.eururo.2016.08.041>
10. Cacciamani GE, Sanford DI, Chu TN, Kaneko M, De Castro Abreu AL, Duddalwar V, Gill IS. Is Artificial Intelligence Replacing Our Radiology Stars? Not Yet! *Eur Urol Open Sci*. 2022 Dec 19;48:14-16. <https://doi.org/10.1016/j.euro.2022.09.024>
11. Rosenkrantz AB, Ayoola A, Hoffman D, Khasgiwala A, Prabhu V, Smereka P, Somberg M, Taneja SS. The Learning Curve in Prostate MRI Interpretation: Self-Directed Learning Versus Continual Reader Feedback. *AJR Am J Roentgenol*. 2017;208(3):W92-W100. <https://doi.org/10.2214/AJR.16.16876>
12. Richenberg J, Løgager V, Panebianco V, Rouviere O, Villeirs G, Schoots IG. The primacy of multiparametric MRI in men with suspected prostate cancer. *Eur Radiol*. 2019;29(12):6940-6952. <https://doi.org/10.1007/s00330-019-0193-3>

[019-06166-z](#)

13. Smith CP, Harmon SA, Barrett T, Bittencourt LK, Law YM, Shebel H, An JY, Czarniecki M, Mehralivand S, Coskun M, Wood BJ, Pinto PA, Shih JH, Choyke PL, Turkbey B. Intra- and interreader reproducibility of PI-RADSV2: A multireader study. *J Magn Reson Imaging*. 2019;49(6):1694-1703. <https://doi.org/10.1002/jmri.26555>
14. Sugano D, Sanford D, Abreu A, Duddalwar V, Gill I, Cacciamani GE. Impact of radiomics on prostate cancer detection: a systematic review of clinical applications. *Curr Opin Urol*. 2020;30(6):754-781. <https://doi.org/10.1097/MOU.0000000000000822>
15. Mata LA, Retamero JA, Gupta RT, García Figueras R, Luna A. Artificial Intelligence-assisted Prostate Cancer Diagnosis: Radiologic-Pathologic Correlation. *Radiographics*. 2021;41(6):1676-1697. <https://doi.org/10.1148/rg.2021210020>
16. Wang B, Lei Y, Tian S, Wang T, Liu Y, Patel P, Jani AB, Mao H, Curran WJ, Liu T, Yang X. Deeply supervised 3D fully convolutional networks with group dilated convolution for automatic MRI prostate segmentation. *Med Phys*. 2019;46(4):1707-1718. <https://doi.org/10.1002/mp.13416>
17. Sanford TH, Zhang L, Harmon SA, Sackett J, Yang D, Roth H, Xu Z, Kesani D, Mehralivand S, Baroni RH, Barrett T, Girometti R, Oto A, Purysko AS, Xu S, Pinto PA, Xu D, Wood BJ, Choyke PL, Turkbey B. Data Augmentation and Transfer Learning to Improve Generalizability of an Automated Prostate Segmentation Model. *AJR Am J Roentgenol*. 2020;215(6):1403-1410. <https://doi.org/10.2214/AJR.19.22347>
18. Gaur S, Lay N, Harmon SA, Doddakashi S, Mehralivand S, Argun B, Barrett T, Bednarova S, Girometti R, Karaarslan E, Kural AR, Oto A, Purysko AS, Antic T, Magi-Galluzzi C, Saglican Y, Sioletic S, Warren AY, Bittencourt L, Fütterer JJ, Gupta RT, Kabakus I, Law YM, Margolis DJ, Shebel H, Westphalen AC, Wood BJ, Pinto PA, Shih JH, Choyke PL, Summers RM, Turkbey B. Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation. *Oncotarget*. 2018 Sep 18;9(73):33804-33817. <https://doi.org/10.18632/oncotarget.26100>
19. Mehrdash A, Sedghi A, Ghafoorian M, Taghipour M, Tempany CM, Wells WM 3rd, Kapur T, Mousavi P, Abolmaesumi P, Fedorov A. Classification of Clinical Significance of MRI Prostate Findings Using 3D Convolutional Neural Networks. *Proc SPIE Int Soc Opt Eng*. 2017 Feb 11;10134:101342A. <https://doi.org/10.1117/12.2277123>
20. Cao R, Mohammadian Bajgiran A, Afshari Mirak S, Shakeri S, Zhong X, Enzmann D, Raman S, Sung K. Joint Prostate Cancer Detection and Gleason Score Prediction in mp-MRI via FocalNet. *IEEE Trans Med Imaging*. 2019;38(11):2496-2506. <https://doi.org/10.1109/TMI.2019.2901928>
21. Le MH, Chen J, Wang L, Wang Z, Liu W, Cheng KT, Yang X. Automated diagnosis of prostate cancer in multiparametric MRI based on multimodal convolutional neural networks. *Phys Med Biol*. 2017 Jul 24;62(16):6497-6514. <https://doi.org/10.1088/1361-6560/aa7731>
22. Giannini V, Mazzetti S, Defeudis A, Stranieri G, Calandri M, Bollito E, Bosco M, Poriglia F, Manfredi M, De Pascale A, Veltri A, Russo F, Regge D. A Fully Automatic Artificial Intelligence System Able to Detect and Characterize Prostate Cancer Using Multiparametric MRI: Multicenter and Multi-Scanner Validation. *Front Oncol*. 2021 Oct 1;11:718155. <https://doi.org/10.3389/fonc.2021.718155>
23. Mehralivand S, Harmon SA, Shih JH, Smith CP, Lay N, Argun B, Bednarova S, Baroni RH, Canda AE, Ercan K, Girometti R, Karaarslan E, Kural AR, Purysko AS, Rais-Bahrami S, Tonso VM, Magi-Galluzzi C, Gordetsky JB, Macarenco RSES, Merino MJ, Gumuskaya B, Saglican Y, Sioletic S, Warren AY, Barrett T, Bittencourt L, Coskun M, Knauss C, Law YM, Malayeri AA, Margolis DJ, Marko J, Yakar D, Wood BJ, Pinto PA, Choyke PL, Summers RM, Turkbey B. Multicenter Multireader Evaluation of an Artificial Intelligence-Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI. *AJR Am J Roentgenol*. 2020;215(4):903-912. <https://doi.org/10.2214/AJR.19.22573>
24. Sun Z, Wang K, Wu C, Chen Y, Kong Z, She L, Song B, Luo N, Wu P, Wang X, Zhang X, Wang X. Using an artificial intelligence model to detect and localize visible clinically significant prostate cancer in prostate magnetic resonance imaging: a multicenter external validation study. *Quant Imaging Med Surg*. 2024 Jan 3;14(1):43-60. <https://doi.org/10.21037/qims-23-791>
25. Mottet N, van den Bergh RCN, Briers E, Van den Broeck

- T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol.* 2021;79(2):243-262. <https://doi.org/10.1016/j.eururo.2020.09.042>
26. van Sloun RJG, Wildeboer RR, Mannaerts CK, Postema AW, Gayet M, Beerlage HP, Salomon G, Wijkstra H, Mischi M. Deep Learning for Real-time, Automatic, and Scanner-adapted Prostate (Zone) Segmentation of Transrectal Ultrasound, for Example, Magnetic Resonance Imaging-transrectal Ultrasound Fusion Prostate Biopsy. *Eur Urol Focus.* 2021;7(1):78-85. <https://doi.org/10.1016/j.euf.2019.04.009>
27. Mehrtash A, Ghafoorian M, Pernelle G, Ziaei A, Heslinga FG, Tuncali K, Fedorov A, Kikinis R, Tempny CM, Wells WM, Abolmaesumi P, Kapur T. Automatic Needle Segmentation and Localization in MRI With 3-D Convolutional Neural Networks: Application to MRI-Targeted Prostate Biopsy. *IEEE Trans Med Imaging.* 2019;38(4):1026-1036. <https://doi.org/10.1109/TMI.2018.2876796>
28. Wang X, Xie Y, Zheng X, Liu B, Chen H, Li J, Ma X, Xiang J, Weng G, Zhu W, Wang G, Fang Y, Cheng H, Xie L. A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosis. *World J Urol.* 2023;41(3):653-662. <https://doi.org/10.1007/s00345-022-04086-0>
29. Ling JQ, Mao J. [State of the art and perspective of pulp regeneration]. *Zhonghua Kou Qiang Yi Xue Za Zhi.* 2018 Jun 9;53(6):361-366. Chinese. <https://doi.org/10.3760/cma.j.issn.1002-0098.2018.06.001>
30. Checucci E, Piana A, Volpi G, Piazzolla P, Amparore D, De Cillis S, Piramide F, Gatti C, Stura I, Bollito E, Massa F, Di Dio M, Fiori C, Porpiglia F. Three-dimensional automatic artificial intelligence driven augmented-reality selective biopsy during nerve-sparing robot-assisted radical prostatectomy: A feasibility and accuracy study. *Asian J Urol.* 2023;10(4):407-415. <https://doi.org/10.1016/j.ajur.2023.08.001>
31. Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. *Hum Pathol.* 2001;32(1):81-8. <https://doi.org/10.1053/hupa.2001.21135>
32. Retamero JA, Aneiros-Fernandez J, Del Moral RG. Complete Digital Pathology for Routine Histopathology Diagnosis in a Multicenter Hospital Network. *Arch Pathol Lab Med.* 2020;144(2):221-228. <https://doi.org/10.5858/arpa.2018-0541-OA>
33. Arvaniti E, Fricker KS, Moret M, Rupp N, Hermanns T, Fankhauser C, Wey N, Wild PJ, Rüschoff JH, Claassen M. Automated Gleason grading of prostate cancer tissue microarrays via deep learning. *Sci Rep.* 2018 Aug 13;8(1):12054. <https://doi.org/10.1038/s41598-018-30535-1>
34. Nagpal K, Foote D, Liu Y, Chen PC, Wulczyn E, Tan F, Olson N, Smith JL, Mohtashamian A, Wren JH, Corrado GS, MacDonald R, Peng LH, Amin MB, Evans AJ, Sangoi AR, Mermel CH, Hipp JD, Stumpe MC. Development and validation of a deep learning algorithm for improving Gleason scoring of prostate cancer. *NPJ Digit Med.* 2019 Jun 7;2:48. <https://doi.org/10.1038/s41746-019-0112-2>
35. Bulten W, Pinckaers H, van Boven H, Vink R, de Bel T, van Ginneken B, van der Laak J, Hulsbergen-van de Kaa C, Litjens G. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. *Lancet Oncol.* 2020;21(2):233-241. [https://doi.org/10.1016/S1470-2045\(19\)30739-9](https://doi.org/10.1016/S1470-2045(19)30739-9)
36. Shao Y, Bazargani R, Karimi D, Wang J, Fazli L, Goldenberg SL, Gleave ME, Black PC, Bashashati A, Salcudean S. Prostate Cancer Risk Stratification by Digital Histopathology and Deep Learning. *JCO Clin Cancer Inform.* 2024;8:e2300184. <https://doi.org/10.1200/CCI.23.00184>
37. Santa-Rosario JC, Gustafson EA, Sanabria Bellasai DE, Gustafson PE, de Socarras M. Validation and three years of clinical experience in using an artificial intelligence algorithm as a second read system for prostate cancer diagnosis-real-world experience. *J Pathol Inform.* 2024 Apr 30;15:100378. <https://doi.org/10.1016/j.jpi.2024.100378>

Correction to: Evaluation of Perioperative Clinical Parameters and Quality of Life in Patients Undergoing Radical Perineal or Retropubic Prostatectomy: A Prospective Randomized Study

Utku Can¹, Alper Coskun¹

¹ Department of Urology, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Türkiye

Published: 2024-10-30

Corresponding Author

Utku Can, MD

Şemsi Denizer Cad. E-5 Karayolu

Cevizli Mevkii 34890

Kartal / İstanbul, Türkiye

E-mail: utkucan99@yahoo.com

ORCID

U.C. [0000-0002-9805-3930](https://orcid.org/0000-0002-9805-3930)

A.C. [0000-0003-4745-5160](https://orcid.org/0000-0003-4745-5160)

In the first published version of this article (1), the following erroneous text was deleted from the use of sources in paragraph 3 of the Introduction; “*as a historical open procedure, is modified to incorporate contemporary surgical ideas. There is relatively little in the literature regarding modern adaptations of perineal prostatectomy. This method of anatomic radical perineal prostatectomy has been developed to accomplish a minimally invasive method of achieving goals of disease control and preservation of genito-urinary functions.*”\n\nMETHODS: Prospective outcome data is accumulated on 508 consecutive radical perineal prostatectomies by a single surgeon. Pathologic stage and PSA detectability are measures of cancer control. Pad use and ability to complete intercourse measure urinary and sexual function. General complications and other outcome measures are evaluated.\n\nRESULTS: Freedom from PSA detectability by pathologic stage is 96.3%, 79.4%, and 69.4% for organ confined, specimen confined and margin positive in the absence of seminal vesical invasion with an average 4 years follow up (3-114 months”.

The author’s request for an addition to the information section has been accepted and the following information has been added;

This article is derived from the 2016 dissertation by Corresponding Author U Can. I would like to extend my gratitude to Cemal Göktaş for his invaluable contribution to the thesis process.

Funding Sources: This article has no funding source. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest: The authors declare that they have no conflict of interest.

Cite; Can U, Coskun A. Correction to: Evaluation of Perioperative Clinical Parameters and Quality of Life in Patients Undergoing Radical Perineal or Retropubic Prostatectomy: A Prospective Randomized Study. New J Urol. 2024;19(3):157-158. doi: [10.33719/nju1406425](https://doi.org/10.33719/nju1406425)

All authors have agreed to be so listed and have seen and approved the manuscript, its consent and submission.

Author Contribution: U Can; Protocol/project development, Data collection or management, Data analysis, Manuscript writing/editing.

A Coskun; Data collection or management, Manuscript writing/editing.

The authors take full responsibility for this confusion, and they apologize for the confusion.

Publisher's Note: The original article has been corrected, and a correction note was added.

REFERENCE

1. Can U, Coskun A. Evaluation of Perioperative Clinical Parameters and Quality of Life in Patients Undergoing Radical Perineal or Retropubic Prostatectomy: A Prospective Randomized Study. New J Urol. 2024;19(1):23-33. doi: [10.33719/nju1406425](https://doi.org/10.33719/nju1406425)

AUTHOR INDEX

2024

USLU M,	2024;(19)1:01-07.
EZER M,	2024;(19)1:01-07.
YILDIRIM Ü,	2024;(19)1:01-07.
BAĞCIOĞLU M,	2024;(19)1:01-07.
SARICA K,	2024;(19)1:01-07.
KIRIMLIOĞLU E,	2024;(19)1:08-15.
TÜRK S,	2024;(19)1:08-15.
CERNOMORCENCO A,	2024;(19)1:08-15.
CULHA Y,	2024;(19)1:16-22
SEYHAN AK E,	2024;(19)1:16-22
ÇULHA MG,	2024;(19)1:16-22
CAN U,	2024;(19)1:23-33. 2024;(19)3:157-158.
COSKUN A,	2024;(19)1:23-33. 2024;(19)3:157-158.
ALTAN ŞA,	2024;(19)1:34-37
KARAMAN ZS,	2024;(19)1:34-37
ADSAN Ö,	2024;(19)1:34-37
KILIÇ S,	2024;(19)1:38-41
VEREP S,	2024;(19)1:38-41
KAYNAR BM,	2024;(19)1:42-51
KALKAN S,	2024;(19)1:42-51
BAYRAKTAR Z,	2024;(19)1:52-60
AKSU S,	2024;(19)2:61-67
BAL H,	2024;(19)2:61-67
TARHAN H,	2024;(19)2:61-67
DELİKTAŞ H,	2024;(19)2:61-67
ŞAHİN H,	2024;(19)2:61-67
DEĞİRMEN TEPE RB,	2024;(19)2:68-77
BOZKURT M,	2024;(19)2:68-77
CAN O,	2024;(19)2:68-77
ERKOÇ M,	2024;(19)2:68-77
GÜRGEN HÖ,	2024;(19)2:68-77
YILDIRIM F,	2024;(19)2:68-77
HUNÇ F,	2024;(19)2:68-77
ERALDEMİR FC,	2024;(19)2:68-77
ÖTÜNÇTEMUR A,	2024;(19)2:68-77
ÇİVİLİBAL M,	2024;(19)2:78-84
ÇİVİLİBAL AM,	2024;(19)2:78-84
SILAY MS,	2024;(19)2:78-84
AYRANCI A,	2024;(19)2:85-89

ÇAĞLAR U,	2024;(19)2:85-89
ÇAKIR H,	2024;(19)2:85-89
MERİÇ A,	2024;(19)2:85-89
AKSU UC,	2024;(19)2:85-89
ÖZGÖR F,	2024;(19)2:85-89
SARILAR Ö,	2024;(19)2:85-89
ÇANAKÇI C,	2024;(19)2:90-94
DİNÇER E,	2024;(19)2:90-94
ÖZKAPTAN O,	2024;(19)2:90-94
SEVİNÇ M,	2024;(19)2:90-94
ERYILDIRIM B,	2024;(19)2:90-94
TÜRKOĞLU S,	2024;(19)2:95-102
GÖYA C,	2024;(19)2:95-102
DEMİR M,	2024;(19)2:95-102
BAYRAKTAR N,	2024;(19)3:103-109
TUĞCU S,	2024;(19)3:103-109
ÇOBAN G,	2024;(19)3:110-114
TOLUK Ö,	2024;(19)3:110-114
İLKTAÇ A,	2024;(19)3:110-114
PELİT ES,	2024;(19)3:115-120
KATI B,	2024;(19)3:115-120
BULUT EC,	2024;(19)3:121-128
ELMAS B,	2024;(19)3:121-128
KÜPELİ B,	2024;(19)3:121-128
ENGİN S,	2024;(19)3:129-135
ALTINBAŞ MK,	2024;(19)3:129-135
ARIKAN Y,	2024;(19)3:136-144
AYDIN B,	2024;(19)3:136-144
DUMANLI E,	2024;(19)3:136-144
ÖZLÜ DN,	2024;(19)3:136-144
EMİR B,	2024;(19)3:136-144
KESKİN MZ,	2024;(19)3:136-144
SAĞIR S,	2024;(19)3:145-150
ÇELİKKALELİ F,	2024;(19)3:145-150
ERGÜN M,	2024;(19)3:145-150
ÖZDEN C,	2024;(19)3:145-150
GÜLER M,	2024;(19)3:145-150
TOKTAŞ İ,	2024;(19)3:145-150
ALÇIN A,	2024;(19)3:151-156
YILDIRIM A,	2024;(19)3:151-156

THE NEW JOURNAL OF UROLOGY

AUTHOR GUIDELINES

AIM

The New Journal of Urology (New J Urol) is a scientific, referred, open access publication of the Eurasian Uro-oncological Association. The society is a non-profit organization and it aims to increase the standards in the field of urology including education of the academicians, professionals and public. The New Journal of Urology aims to create or make contributions for the development of technical, scientific and social facilities and it also cooperates with any and all related institutions, organizations, foundations and societies from the national and international area for this purpose.

The journal's financial expenses are covered by the Eurasian Uro-oncological Association. The journal is published quarterly – three times a year- in February, June and October, respectively and the language of the journal are English and Turkish.

The purpose of the New Journal of Urology is to contribute to the literature by publishing urological manuscripts such as scientific articles, reviews, letters to the editor, case reports, reports of surgical techniques, surgical history, ethics, surgical education and articles of forensic medicine.

The target group of the journal consists of academicians working in the field of urology, urologists, residents of urology and all other fields of expertise and practitioners interested in urology.

Urology specialists, medical specialty fellows and other specialists who are interested in the field of urology are the journal's target audience.

SCOPE

The New Journal of Urology is currently indexed by TUBITAK ULAKBIM-TR Directory, Google Scholar, TurkMedline (National Health Sciences-Periodicals Database), Turkish Citation Index, SOBIAD Citation Index, OAJI, İdeal Online, EuroPub, J-GATE, EBSCO, InfoBase. The journal is integrated with ORCID and CrosReff DOI.

All published content is available for free at <https://dergipark.org.tr/en/pub/yud>.

All manuscripts submitted to the journal should be submitted through the online submission system available at <https://dergipark.org.tr/en/pub/yud>.

Instructions for authors including technical information

and required forms can be found at the journal's website <https://dergipark.org.tr/en/pub/yud>.

Editorial and publication processes of the journal are shaped in accordance with the guidelines of the international organizations such as the International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the European Association of Science Editors (EASE). The journal is in conformity with Principles of Transparency and Best Practice in Scholarly Publishing. (<https://doaj.org/bestpractice>).

The statements and/or opinions indicated at the articles which are published at the journal reflect the views of the author, not the opinions of the editors, editorial board and / or the publisher of the Eurasian Uro-oncological Association; Editors and publishers do not accept any responsibility for such materials.

No fee is required for submitting articles, evaluation, processing or publishing process from the authors.

Editor-in-Chief

Ali İhsan Taşçı, Department of Urology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
e-mail : alihsantasci@hotmail.com

Editor

Yavuz Onur Danacıoğlu, Department of Urology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Turkey
e-mail: dr.yonur@hotmail.com

Deputy Editor-in-Chief

Mithat Ekşi, Department of Urology, Dr.Sadi Konuk Training and Research Hospital, Istanbul, Turkey
e-mail: mithat_eksi@hotmail.com

Publishing Services

Pera Publishing Service
info@perayayincilik.com
<https://www.perayayincilik.com>

THE NEW JOURNAL OF UROLOGY

AUTHOR GUIDELINES

INFORMATION ABOUT JOURNAL

The New Journal of Urology is an international, scientific, open access, online/published journal in accordance with independent, unbiased, and double-blinded peer-review principles, published three times a year on February, June and October. The New Journal of Urology is indexing in both international and national indexes and the publication language is English.

The New Journal of Urology has been indexed by [TUBITAK ULAKBIM-TR DİZİN](#), Google Scholar, [Index Copernicus](#), [Scilit](#), [EBSCO](#), [EuroPub](#), [SOBIAD Citation Index](#), [OAJI](#), [J-GATE](#), [İdealOnline](#), [Turkish Citation Index](#), and [TurkMedline](#) (National Health Sciences-Periodicals Database).

Yeni Üroloji Dergisi/The New Journal of Urology ceased printing in 2024 (ISSN: 1305-2489, eISSN: 2687-1955).

The New Journal of Urology is now only published online with the eISSN: 3023-6940.

The New Journal of Urology publishes papers on all aspects of urology and related topics. In addition to original articles, review articles, case reports and letters to the editor are also published.

The scientific board guiding the selection of the papers to be published in the journal consists of elected experts of the journal and if necessary, are selected from national and international authorities.

The authors should guarantee that the manuscripts have not been previously published and/or are under consideration for publication elsewhere. Only those data presented at scientific meetings in form of an abstract may be accepted for consideration, however, the date, name and place of the meeting in which the paper was presented should be stated. The signed statement of scientific contributions and responsibilities of all authors, and statement on the absence of conflict of interests are required. All manuscripts are reviewed by the editor and at least two experts/reviewers.

Manuscript format should be in accordance with Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication

(available at <https://www.icmje.org/>). The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Council of Medical Journal Editors (ICMJE). The journal conforms to the Principles of Transparency and Best Practice in Scholarly Publishing.

The New Journal of Urology does not charge for submitting articles, evaluation, processing or publishing process from the authors.

Authors' credentials and e-mail addresses are in no way used for other purposes.

The journal will allow the authors to retain publishing rights without restrictions.

All the content published in the journal can be accessed free of charge via the following link; <https://newjournalurology.com/archive>.

All submissions are screened by a similarity detection software (iThenticate by Crossref). In the event of alleged or suspected research misconduct, e.g., plagiarism, citation manipulation, and data falsification/fabrication, the Editorial Board will follow and act in accordance with COPE guidelines.

The authors should identify the individuals who accept direct responsibility for the manuscript. Each individual listed as an author should fully meet the criteria for authorship and should complete an authorship form (criteria recommended by the International Committee of Medical Journal Editors - www.icmje.org/). The corresponding author should clearly indicate the preferred citation and identify all individual authors.

When using previously published content, including figures, tables, or any other material in electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Statements or opinions expressed in the manuscripts published in The New Journal of Urology reflect the views of the author(s) and not the opinions of the editors, the editorial board, or the publisher; the editors, the editorial board, and the publisher disclaim any responsibility or liability for such materials. The final responsibility regarding the published content remains with the authors.

THE NEW JOURNAL OF UROLOGY

PREPARATION OF MANUSCRIPT

Journal Title:	The New Journal of Urology
Journal Abbreviation:	New J Urol
Frequency:	Tri-annual (February, June, October)
Publisher:	Ali İhsan Taşçı
Language:	English
Publication Date:	2008
Journal History:	Continues: Yeni üroloji dergisi (online) eISSN: 2687-1955 (2019-2024) Has other medium version: Yeni üroloji dergisi (printed), ISSN: 1305-2489 (2008-2024)
Continued by:	The New Journal of Urology (Online), 3023-6940 (2024-)
DOI Prefix:	10.33719
Broad Subject Term(s):	Oncology Urology & Nephrology
Open Access& Licensing:	OA Creative Commons CC BY, Attribution 4.0 International (http://creativecommons.org/licenses/by/4.0/)
Electronic Links:	https://newjournalurology.com/

GENERAL GUIDELINES

Manuscripts can only be submitted through the journal's online manuscript submission and evaluation system, available at the link. Manuscripts submitted via any other medium will not be evaluated. Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal's guidelines. Submissions that do not conform to the journal's guidelines will be returned to the submitting author with technical correction requests. The editor reserves the right to reject manuscripts that do not comply with the above-mentioned requirements. Editors have the right to make corrections without changing the main text. The ORCID (Open Researcher and Contributor ID) number of the authors should be provided while sending the

manuscript. A free registration can be done at <https://orcid.org>.

For experimental, clinical, and drug studies mandated to be approved by an ethical committee for publication in The New Journal of Urology, the authors must furnish an ethical committee approval report in line with international agreements (<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>).

In the case of experimental animal studies, adherence to animal rights guidelines ("Guide for the Care and Use of Laboratory Animals" <https://www.ncbi.nlm.nih.gov/books/NBK54050>) is mandatory, with requisite approval from the animal ethics committee.

The "Materials and Methods" section must specify the ethical committee's approval, including the approval number, and the provision of "informed consent" by patients.

Authors are obligated to disclose conflicts of interest and financial support related to their articles.

The rules for the title page, references, figures and tables are valid for all types of articles published in this journal.

Authors are required to submit the following:

- Cover Letter
- Copyright Agreement and Acknowledgement of Authorship Form
- Patient Consent Form
- ICMJE Disclosure of Interest
- Title Page
- Main text
- Figures
- Tables

PREPARATION OF THE MANUSCRIPT

Authors should adhere to the ICMJE recommendations for "preparing a manuscript for submission to a medical journal". <https://www.icmje.org/recommendations/browse/manuscript-preparation/preparing-for-submission.html>

The articles should be written in 12-point, Times New Roman, double-spaced with at least 2.5 cm margin on all edges

THE NEW JOURNAL OF UROLOGY

PREPARATION OF MANUSCRIPT

of each page. The main text should not include any information about the authors' names or affiliations. This information should only be included on the title page, along with their ORCID IDs, the title, abstract, and keywords.

All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be explained clearly in parentheses following the definition and custom abbreviations should not be used.

Statistical analysis is usually necessary to support results in original articles. Information on statistical analyses should be provided with a separate subheading under the Materials and Methods section and the statistical software that was used during the process must be specified.

Whenever a product, software, or software program is mentioned in the main text, product information (including state in the USA) must be given in parentheses, including the product name, product manufacturer, city of production, and country of the company.

All references, tables, and figures should be sequentially numbered and referred to in the main text. All pages of the manuscript should be numbered at the bottom center, except for the title page. Papers should include the necessary number of tables and figures to provide better understanding.

Authors are required to prepare manuscripts in accordance with the relevant guideline listed below:

- Randomized research studies and clinical trials: [CONSORT guidelines](#) (for protocols, please see the [SPIRIT guidance](#))
- Observational original research studies: [STROBE](#) guidelines
- Studies on diagnostic accuracy: [STARD](#) guidelines
- Systematic reviews and meta-analysis: [PRISMA](#) guidelines (for protocols, please see the [PRISMA-P guidelines](#))
- Experimental animal studies: [ARRIVE](#) guidelines and [Guide for the Care and Use of Laboratory Animals](#), 8th edition
- Nonrandomized evaluations of behavioral and public health interventions: [TREND](#) guidelines
- Case report: the [CARE case report guidelines](#)
- Genetic association studies: [STREGA](#)
- Qualitative research: [SRQR guidelines](#)

Manuscript Types

Original Articles

New Journal of Urology adopts the [ICMJE's clinical trial registration policy](#), which requires that clinical trials must be registered in a publicly accessible registry that is a primary register of the WHO International Trials Registry Platform (ICTRP) or in [ClinicalTrials.gov](#). Authors can help improve transparency and accountability in their research by recording clinical trials in a publicly accessible registry.

Original Research Articles should include subheadings below;

- Title
- Abstract
- Keywords
- Introduction
- Material and Methods
- Results
- Discussion
- Conclusions
- Figures and Tables Legend
- References

Review Articles

Review articles should provide a comprehensive overview of the current state of knowledge on a topic in clinical practice, and should include discussions and evaluations of relevant research. The subheadings of the review articles can be planned by the authors. Review articles are scientific analyses of recent developments on a specific topic as reported in the literature. No new information is described, and no opinions or personal experiences are expressed.

- Title
- Abstract (unstructured)
- Keywords (both Turkish and English)
- Main text
- Conclusion
- Figures and Tables Legend
- References

THE NEW JOURNAL OF UROLOGY

PREPARATION OF MANUSCRIPT

Case Reports

New, interesting and rare cases can be reported. They should be unique, describing a great diagnostic or therapeutic challenge and providing a learning point for the readers. Cases with clinical significance or implications will be given priority.

Case Reports should include subheadings below;

- Title
- Abstract (unstructured)
- Keywords (
- Introduction
- Case Presentation
- Discussion and Conclusion
- Figures and Tables Legend
- References

Letters to the Editor

A “Letter to the Editor” is a type of manuscript that discusses important or overlooked aspects of a previously published article. This type of manuscript may also present articles on subjects within the scope of the journal that are of interest to readers, particularly educational cases. Readers can also use the “Letter to the Editor” format to share their comments on published manuscripts. The text of a “Letter to the Editor” should be unstructured and should not include an abstract, keywords, tables, figures, images, or other media.

Letters to Editor should include subheadings below;

- Title
- Keywords
- Main text
- Figures and Table Legend
- References

Article Structure

Title page

A separate title page should be submitted with all submissions.

The title page should include:

1. The full title of the manuscript as well as a short title (running head) of ≤50 characters
2. Name(s), affiliations, highest academic degree(s), and ORCID IDs of the author(s),
3. Name, address, telephone (including the mobile phone

number), and email address of the corresponding author

4. If the author(s) is a member of the journal’s Editorial Board, this should be specified in the title page

5. If the content of the paper has been presented before, and if the summary has been published, the time and place of the conference should be denoted on this page.

6. If any grants or other financial support has been given by any institutions or firms for the study, information must be provided by the authors

7. Acknowledgment of the individuals who contributed to the preparation of the manuscript but who do not fulfill the authorship criteria should be included

Abstract

Original articles should have a structured English (Objective, Methods, Results, Conclusion). Review articles and case reports should have an unstructured abstract. Articles and abstracts should be written in accordance with the word limits specified in the table. References, tables and citations should not be used in an abstract.

Keywords

Each submission must be accompanied by a minimum of three to a maximum of six keywords for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (<https://www.nlm.nih.gov/mesh/MBrowser.html>).

Limitations for each manuscript type;

Type of Article	Abstract word limit	Word limit	References limit	Table limit	Figure limit
Original Article	250 (Structured)	3000	30	6	5
Review Article	250 (Unstructured)	4000	50	6	5
Case Reports	250 (Unstructured)	2000	10	1	3
Letter to the Editor	No abstract	1000	5	1	1

THE NEW JOURNAL OF UROLOGY

PREPARATION OF MANUSCRIPT

Figures and Tables

Figures, graphics, and photographs should be submitted as separate files (in JPEG format) through the submission system. The files should not be embedded in a Word file of the main document. When there are figure subunits, the subunits should not be merged to form a single image. Each subunit should be submitted separately through the submission system.

Images should be numbered by Arabic numbers to indicate figure subunits.

Thick and thin arrows, arrowheads, stars, asterisks, and similar marks can be used on the images to support figure legends. The minimum resolution of each submitted figure should be 300 DPI. Figures or illustrations must not permit the identification of patients and written informed consent for publication must be sought for any photograph.

Figure legends should be listed at the end of the main document. Figures should be referred to within the main text, and they should be numbered consecutively in the order in which they are mentioned.

Tables should embed in the main document. Tables should support and enhance the main text rather than repeat data presented in the main text. All tables should be numbered consecutively in the order they are used to within the main text. Tables legends should be listed at the end of the main document.

Units of Measurement

Units of length, weight and volume should be reported in metric (meter, kilogram, liter) system and in decimal multiples. Temperatures should be expressed in degrees Celsius, and blood pressures in millimeters of mercury. Both local and International Unit Systems (International System of Units, SI) should be used as measurement units. Drug concentrations should alternatively be given in either SI units or mass units written in parentheses.

Abbreviations and Symbols

Use only standard abbreviations, non-standard abbreviations can be very confusing for the reader. The use of abbreviation(s) should be avoided in the title. If there is no standard unit of measurement, provide the long version of the abbreviation in parentheses when it is first used in the text.

Supplementary Materials

Supplementary materials, including audio files, videos, datasets, and additional documents (e.g., appendices, additional figures, tables), are intended to complement the main text of the manuscript. These supplementary materials should be submitted as a separate section after the references list. Concise descriptions of each supplementary material should be included to explain their relevance to the manuscript. Page numbers are not required for supplementary materials.

Identifying products

When mentioning a drug, product, hardware, or software program in a manuscript, it is important to provide detailed information about the product in parentheses. This should include the name of the product, the producer of the product, and the city and country of the company.

Author Contributions

During the initial submission process to The New Journal of Urology, corresponding authors must submit a signed and scanned authorship contribution form. This form is available for download through <https://dergipark.org.tr/tr/journal/1455/file/2260/download>. The purpose of this requirement is to ensure appropriate authorship rights and prevent ghost or honorary authorship.

Manuscript Retraction: Authors may withdraw their manuscript from the journal by providing a written declaration.

References

While citing publications, preference should be given to the latest, most up-to-date publications. Authors should avoid using references that are older than ten years. All the references should be written according to the Vancouver reference style. The references used in the article must be written in parenthesis, at the end of the sentences. References should be numbered in the order they appear in the text and listed in the same order in which they are cited in the text. Be consistent with your referencing style across the document.

References must contain surnames and initials of all authors, article title, name of the journal, the year and the first and last page numbers. If there are more than 6 authors, an

THE NEW JOURNAL OF UROLOGY

PREPARATION OF MANUSCRIPT

abbreviation of “et al.” should be used for the authors out of the first three.

You must add the DOI (Digital object identifier) at end of each reference.

For Examples

Article in journal: Tasci A, Tugcu V, Ozbay B, et al. Stone formation in prostatic urethra after potassium-titanyl-phosphate laser ablation of the prostate for benign prostatic hyperplasia. J Endourol.2009;23:1879-1881. <https://doi.org/10.1089/end.2008.0596>

For Books:

Günalp İ. Modern Üroloji. Ankara: Yargıçoğlu Matbaası, 1975.

Chapters in books: Anderson JL, Muhlestein JB. Extra corporeal ureteric stenting during laparoscopic pyeloplasty. Philadelphia: W.B. Saunders, 2003; p. 288-307.

For website;

Gaudin S. How moon landing changed technology history [serial online]. 2009 [cited 2014 June 15]. Available from: <http://www.computerworlduk.com/in-depth/it-business/2387/how-moon-landing-changed-technology-history/>

For conference proceeding;

Anderson JC. Current status of chorion villus biopsy. Paper presented at: APSB 1986. Proceedings of the 4th Congress of the Australian Perinatal Society, Mothers and Babies; 1986 Sep 8-10; Queensland, Australian. Berlin: Springer; 1986. p. 182-191.

For Thesis;

Ercan S. Venöz yetmezlikli hastalarda kalf kası egzersizlerinin venöz fonksiyona ve kas gücüne etkisi. Süleyman Demirel Üniversitesi Tıp Fakültesi Spor Hekimliği Anabilim Dalı Uzmanlık Tezi. Isparta: Süleyman Demirel Üniversitesi; 2016.

Author Contribution&Copyright Transfer Form

The New Journal of Urology requires corresponding authors to submit a signed and scanned version of the authorship contribution form (available for download through <https://dergipark.org.tr/tr/journal/1455/file/2260/download>) during the initial submission process to act appropriately on authorship rights and to prevent ghost or honorary authorship.

Manuscript Retraction

For any other reason authors may withdraw their manuscript from the journal with a written declaration.

Revisions

When submitting a revised version of a paper, the author must submit a detailed “Response to the reviewers” that states point by point how each issue raised by the reviewers has been covered and where it can be found (each reviewer’s comment, followed by the author’s reply and line numbers where the changes have been made) as well as an annotated copy of the main document. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be canceled. If the submitting author(s) believe that additional time is required, they should request this extension before the initial period is over.

AFTER ACCEPTANCE

Accepted manuscripts are copy-edited for grammar, punctuation, and format. A PDF proof of the accepted manuscript is sent to the corresponding author and their publication approval is requested. The journal owner and the editorial board are authorized to decide in which volume of the accepted article will be printed. Authors may publish their articles on their personal or corporate websites by linking them to the appropriate cite and library rules.

THE
NEW JOURNAL
OF UROLOGY

Volume 19, Issue 3, October, 2024

İstanbul / Türkiye

Pera Publishing Services

Address: Ataköy 3-4-11 Kısım Mah. Dr Remzi Kazancıgil Cd. O-114 N:12 D:7 Bakırköy İstanbul / Türkiye

E-Mail : info@perayayincilik.com

